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Abstract: Caspasen stellen eine Familie von Cystein-Proteasen dar und sind die hauptsächlichen Effektor-
Moleküle beim programmierten Zelltod (Apoptose). Die Apotose spielt eine wichtige Rolle bei der
geordneten Elimination von Zellen in der normalen Entwicklung und bei der Zellhomeostase. Wirk-
stoffe zur Modulierung der Caspase Aktivität sind von grossem Interesse für die Therapie verschiedener
wichtiger Krankheiten wie AIDS, Schlaganfall und vieler neurodegenerativer Erkrankungen. Mehrere
irreversibel wirkende Breitspektrum-Caspase-Inhibitoren sind bekannt und deren Wirksamkeit, in- vivo
und in-vitro, ist für eine Reihe von Krankheits-Modellen beschrieben worden. Die Entwicklung von spez-
ifischen Caspase-Inhibitoren mit der gewünschten therapeutischen Wirkung stelltjedoch immer noch eine
grosse Herausforderung dar. Ein wichtiger Grund dafür sind die sich teilweise überschneidenden Substrat-
spezifitäten der verschiedenen Enzyme der Caspase-Familie. Detaillierte strukturelle Informationen über
die Substratbindungsstellen Sind eine wichtige Voraussetzung für das gezielte Design von Inhibitoren,
mit der gewüschten Spezifität für eine bestimmte Caspase. Caspase-3 ist ein zentrales Enzym in der
signaltransduktion der Apoptose und spielt daher eine wichtige Rolle beim Programmierten Zelltod. Das
primäre Ziel der vorliegenden Doktorarbeit war die strukturelle Untersuchung und Charakterisierung
der Caspase-3, im Hinblick auf ihre Spezifität und Inhibition durch peptidische, peptidomimetische und
nicht-peptidische Inhibitoren. Kapitel 1 gibt eine kurze Einleitung über die Apoptose und die Cas-
pasen. Im zweiten Kapitel wird der Aufbau des aktiven Zentrums von Caspase-3 detailliert beschrieben.
Durch die Bestimmung der Kristallstruktur von Caspase-3 im Komplex mit dem peptidischen Inhibitor
Z-DEVD-cmk bei einer maximalen Auflösung von 1.06Å konnte gezeigt werden, dass der N-terminale
loop von ￿-Untereinheit des Enzyms bei der Substrat-Erkennung eine Rolle spielt. Ausserdem führte dise
strukturelle Untersuchung zur Identifikation eines tetraedrischen Zwischenprodukts, welches eventuell
während der katalytischen Reaktion gebildet wird. Die Kapitel 3 und 4 geben einen strukturellen Ein-
blick in Aza-Peptide und Michael- Akzeptoren als eine neue Klasse von irreversiblen und hochspezifis-
chen Caspase- Inhibitoren. Aldehyde und Halogen-Methylketone sind elektrophile Gruppen, die häufig
als sogenannte ”warheads” beim Design von Caspase-Inhibitoren verwendet werden. Die unspezifische
Natur dieser ”warheads” im Hinblick auf die Inhibition von auch anderen, verwandten Proteasen, war ein
Grund für die Suche nach Caspase- spezifischen elektrophilen Gruppen. Die in der vorliegenden Arbeit
durchgeführten detaillierten strukturellen Untersuchungen dieser Inhibitoren im Komplex mit Caspase-
3 und -8 führten zur Aufklärung des struktur-basierten Inhibitions-Mechanismus, des Bindungsmodus
und der Spezifität in der ”prime site” der Substratbindungstasche. Das Verstehen der Wechselwirkun-
gen zwischen den als Inhibitoren wirkenden kleinen Molekülen und Caspasen auf atomarer Basis, bildet
eine wichtige Grundlage für die Entwicklung neuer Wirkstoffe. In-silico Screening, in-vitro Aktivität-
stests und die Strukturbestimmung von Protein:Liganden-Komplexen wurden zur Identifikation und der
sich daraus ergebenden möglichen Optimierung der gefundenen Substanzen, die entweder an das aktive
Zentrum oder an eine allosterische Bindungsstelle binden, eingesetzt. Zusätzlich zur Identifikation von
neuen, nicht-peptidischen Inhibitoren, konnten die Kristallstrukturen der Komplexe von Caspase-3 mit
drei dieser nicht- peptidischen Inhibitoren aufgeklärt warden. Die durchgeführten Versuche zur Struk-
turaufklärung einer Procaspase-3, der Caspase- 5 und der S4 subsite-Mutanten von Caspase-8 sind im
Anhang beschrieben. Caspases constitute a family of cysteine proteases and are the key effector molecules
of the programmed cell death/apoptosis. Apoptosis plays an important role in animal development and
tissue homeostasis. Agents modulating the caspase activity are of great interest for the treatment of a
wide variety of diseases, including cancer, AIDS, stroke and many neurodegenerative disorders. Several
irreversible broad-spectrum caspase inhibitors have been identified and their in-vivo and in-vitro efficacy
has been reported, in a variety of acute disease models. The design of specific caspase inhibitors with
desirable therapeutic benefit remains a challenge, mostly due to the overlapping substrate specificity
demonstrated among the caspase family members. Comprehensive structural information with respect
to the substrate binding sites is a prerequisite for the design of inhibitors with desirable selectivity for
a particular caspase. Caspase-3 is the primary executioner caspase which leads the cellular autodestruc-
tion process. This thesis work has its emphasis on the characterization of the structure, specificity and
inhibition of caspase-3 using peptidic, peptidomimetic and small molecule inhibitors. The introduction
to caspases and apoptosis are discussed in Chapter 1. In Chapter 2, the architecture of caspase-3 active
site is discussed in detail. The crystal structure of caspase-3 in complex with a peptidic inhibitor Z-
DEVD-cmk resolved at 1.06Å led to the identification of the role of the N-terminal loop and the residues
encompassing this loop in the recognition of the substrates. Additionally the study led to the identifi-
cation of a tetrahedral reaction intermediate which might be formed during the course of the catalytic
reaction. Chapters 3 and 4 provide structural insights into the azapeptide epoxide and Michael acceptor
inhibitors, two new classes of irreversible and highly specific inhibitors for caspases. The commonly used
warheads (electrophilic groups) in the design of inhibitors for caspase include aldehydes and halogen
methylketones. The unspecific nature of these warheads to inhibit other related proteases is the reason
to search for caspase specific electrophilic groups. A comprehensive structural investigation of these in-
hibitors in complex with caspase-3 and 8 were performed. The studies reveal the mechanism of inhibition
and the mode of binding especially in the prime site of caspases for these inhibitors. Understanding the
interaction between small molecules and caspases at the atomic level is imperative for the development of
novel drugs. An in silico screening followed by an in vitro functional assay coupled to the determination
of the structures of the protein ligand complexes was used to identify and optimize lead compounds that
bind either in the active site or in an allosteric site (Chapter 5). New non-peptidic inhibitors were iden-
tified and the crystal structures of three caspase: small molecule inhibitor complexes were determined.
The work performed on procaspase-3, caspase-5 and the S4 subsite mutants of caspase-8 are presented
in the appendices.
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Research summary 
 Caspases constitute a family of cysteine proteases and are the key effector molecules of 
the programmed cell death/apoptosis. Apoptosis plays an important role in animal development 
and tissue homeostasis. Agents modulating the caspase activity are of great interest for the 
treatment of a wide variety of diseases, including cancer, AIDS, stroke and many 
neurodegenerative disorders. Several irreversible broad-spectrum caspase inhibitors have been 
identified and their in vivo and in vitro efficacy has been reported, in a variety of acute disease 
models. The design of specific caspase inhibitors with desirable therapeutic benefit remains a 
challenge, mostly due to the overlapping substrate specificity demonstrated among the caspase 
family members. Comprehensive structural information with respect to the substrate binding sites 
is a prerequisite for the design of inhibitors with desirable selectivity for a particular caspase. 
Caspase-3 is the primary executioner caspase which leads the cellular autodestruction process. 
This thesis work has its emphasis on the characterization of the structure, specificity and 
inhibition of caspase-3 using peptidic, peptidomimetic and small molecule inhibitors.  
 The introduction to caspases and apoptosis are discussed in Chapter 1. In Chapter 2, the 
architecture of caspase-3 active site is discussed in detail. The crystal structure of caspase-3 in 
complex with a peptidic inhibitor Z-DEVD-cmk resolved at 1.06Å led to the identification of the 
role of the N-terminal loop and the residues encompassing this loop in the recognition of the 
substrates. Additionally the study led to the identification of a tetrahedral reaction intermediate 
which might be formed during the course of the catalytic reaction.  
 Chapters 3 and 4 provide structural insights into the azapeptide epoxide and Michael 
acceptor inhibitors, two new classes of irreversible and highly specific inhibitors for caspases. 
The commonly used warheads (electrophilic groups) in the design of inhibitors for caspase 
include aldehydes and halogen methylketones. The unspecific nature of these warheads to inhibit 
other related proteases is the reason to search for caspase specific electrophilic groups. A 
comprehensive structural investigation of these inhibitors in complex with caspase-3 and 8 were 
performed. The studies reveal the mechanism of inhibition and the mode of binding especially in 
the prime site of caspases for these inhibitors. 
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 Understanding the interaction between small molecules and caspases at the atomic level is 
imperative for the development of novel drugs. An in silico screening followed by an in vitro 
functional assay coupled to the determination of the structures of the protein ligand complexes 
was used to identify and optimize lead compounds that bind either in the active site or in an 
allosteric site (Chapter 5). New non-peptidic inhibitors were identified and the crystal structures 
of three caspase: small molecule inhibitor complexes were determined. The work performed on 
procaspase-3, caspase-5 and the S4 subsite mutants of caspase-8 are presented in the appendices.  
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Zusammenfassung 
 Caspasen stellen eine Familie von Cystein-Proteasen dar und sind die hauptsächlichen 
Effektor-Moleküle beim programmierten Zelltod (Apoptose). Die Apotose spielt eine wichtige 
Rolle bei der geordneten Elimination von Zellen in der normalen Entwicklung und bei der 
Zellhomeostase. Wirkstoffe zur Modulierung der Caspase Aktivität sind von grossem Interesse 
für die Therapie verschiedener wichtiger Krankheiten wie AIDS, Schlaganfall und vieler 
neurodegenerativer Erkrankungen. Mehrere irreversibel wirkende Breitspektrum-Caspase-
Inhibitoren sind bekannt und deren Wirksamkeit, in-vivo und in-vitro, ist für eine Reihe von 
Krankheits-Modellen beschrieben worden. Die Entwicklung von spezifischen Caspase-
Inhibitoren mit der gewünschten therapeutischen Wirkung stelltjedoch immer noch eine grosse 
Herausforderung dar. Ein wichtiger Grund dafür sind die sich teilweise überschneidenden 
Substratspezifitäten der verschiedenen Enzyme der Caspase-Familie. Detaillierte strukturelle 
Informationen über die Substratbindungsstellen Sind eine wichtige Voraussetzung für das 
gezielte Design von Inhibitoren, mit der gewüschten Spezifität für eine bestimmte Caspase. 
Caspase-3 ist ein zentrales Enzym in der signaltransduktion der Apoptose und spielt daher eine 
wichtige Rolle beim Programmierten Zelltod. Das primäre Ziel der vorliegenden Doktorarbeit 
war die strukturelle Untersuchung und Charakterisierung der Caspase-3, im Hinblick auf ihre 
Spezifität und Inhibition durch peptidische, peptidomimetische und nicht-peptidische Inhibitoren.   
 Kapitel 1 gibt eine kurze Einleitung über die Apoptose und die Caspasen. Im zweiten 
Kapitel wird der Aufbau des aktiven Zentrums von Caspase-3 detailliert beschrieben. Durch die 
Bestimmung der Kristallstruktur von Caspase-3 im Komplex mit dem peptidischen Inhibitor Z-
DEVD-cmk bei einer maximalen Auflösung von 1.06Å konnte gezeigt werden, dass der N-
terminale loop von β-Untereinheit des Enzyms bei der Substrat-Erkennung eine Rolle spielt. 
Ausserdem führte dise strukturelle Untersuchung zur Identifikation eines tetraedrischen 
Zwischenprodukts, welches eventuell während der katalytischen Reaktion gebildet wird. 
 Die Kapitel 3 und 4 geben einen strukturellen Einblick in Aza-Peptide und Michael-
Akzeptoren als eine neue Klasse von irreversiblen und hochspezifischen Caspase-Inhibitoren. 
Aldehyde und Halogen-Methylketone sind elektrophile Gruppen, die häufig als sogenannte 
„warheads„ beim Design von Caspase-Inhibitoren verwendet werden. Die unspezifische Natur 
dieser „warheads“ im Hinblick auf die Inhibition von auch anderen, verwandten Proteasen, war 
ein Grund für die Suche nach Caspase-spezifischen elektrophilen Gruppen. Die in der 
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vorliegenden Arbeit durchgeführten detaillierten strukturellen Untersuchungen dieser Inhibitoren 
im Komplex mit Caspase-3 und -8 führten zur Aufklärung des struktur-basierten  Inhibitions-
Mechanismus, des Bindungsmodus und der Spezifität in der "prime site" der 
Substratbindungstasche.  
 Das Verstehen der Wechselwirkungen zwischen den als Inhibitoren wirkenden kleinen 
Molekülen und Caspasen auf atomarer Basis, bildet eine wichtige Grundlage für die Entwicklung 
neuer Wirkstoffe. In-silico Screening, in-vitro Aktivitätstests und die Strukturbestimmung von 
Protein:Liganden-Komplexen wurden zur Identifikation und der sich daraus ergebenden 
möglichen Optimierung der gefundenen Substanzen, die entweder an das aktive Zentrum oder an 
eine allosterische Bindungsstelle binden, eingesetzt. Zusätzlich zur Identifikation von neuen, 
nicht-peptidischen Inhibitoren, konnten die Kristallstrukturen der Komplexe von Caspase-3 mit 
drei dieser nicht-peptidischen Inhibitoren aufgeklärt warden.  
 Die durchgeführten Versuche zur Strukturaufklärung einer Procaspase-3, der Caspase-5 
und der S4 subsite-Mutanten von Caspase-8 sind im Anhang beschrieben. 
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Chapter 1 Introduction 
1.1 Apoptosis and caspases 
 Programmed cell death, or apoptosis, is a physiological process of cellular autodestruction 
(1). Apoptosis plays critical roles in development, maintenance of homeostasis and host defense 
in multicellular organisms. Dysregulation of this process is implicated in various diseases ranging 
from cancer and autoimmune disorders to neurodegenerative diseases and ischemic injuries (2). 
Diverse cell types can be triggered to undergo apoptosis by various signals derived from either 
the extracellular or intracellular milieu. Cells undergoing apoptosis exhibit a series of 
characteristic morphological changes, including plasma membrane blebbing, cell body shrinkage 
and formation of membrane-bound apoptotic bodies, which in vivo are quickly engulfed by 
macrophages (3). Thus, during apoptosis, intracellular contents are not released and potentially 
harmful inflammatory responses are prevented. The mammalian caspases have evolved additional 
roles in inflammatory responses apart from apoptosis. 
 The principal molecular engines that execute apoptosis are the caspase proteases (4). The 
term caspase denotes two key characteristics of these proteases: (i) they are cysteine proteases 
and use Cysteine as the nucleophilic group for substrate cleavage and (ii) they are aspases and 
cleave the peptide bond C-terminal to aspartic acid residues (5). Synthesized as latent precursors 
or procaspases, caspases are converted to active proteases during apoptosis through an intricately 
regulated proteolytic process (6). The proteolytic processing occurs at critical aspartic acid 
residues. Consequently, caspases often function in cascades. In such a caspase cascade, upstream 
caspases (initiator caspases) are activated by interactions with caspase adapters (4, 6). This 
activation represents a key regulatory step in apoptosis and is controlled by both pro- and anti-
apoptotic proteins (7-14). Once activated, the initiator caspase processes and activates one or 
more downstream caspases (effector or executioner caspases). The activated effector caspases 
then cleave various cellular proteins, leading to apoptotic cell death.  
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1.2 Caspase structure, specificity and activation 
1.2.1 Structure of procaspases 
 Caspases were implicated in apoptosis with the discovery that CED-3, the product of a 
gene required for cell death in the nematode Caenorhabditis elegans, is related to mammalian 
interleukin-1β-converting enzyme (ICE or caspase-1) (15, 16). Since then, at least 14 mammalian 
caspases and five Drosophila caspases have been cloned. Structurally, all procaspases contain a 
highly homologous protease domain, the signature motif of this family of proteases (Fig. 1). This 
domain can be further divided into two subunits, a large subunit of approximately 20 kDa (p17) 
and a small subunit of approximately 10 kDa (p12). In some procaspases, there is a short linker 
(about 10 amino acids) between the large and small subunits. Based on the sequence similarity 
among the protease domains, caspases can be divided into three groups (17). The first group 
consists of inflammatory caspases: caspase-1, -4, -5, -11, -12, -13 and -14, the second group 
contains initiator caspase-2, -8 and -9 and the third group consists of executioner caspase-3, -6 
and -7. Each procaspase also contains a prodomain or NH2-terminal peptide of variable length. 
Initiator apoptotic caspases and inflammatory caspases contain prodomains of over 100 amino 
acids, while the prodomains in effector caspases are usually less than 30 amino acids long. The 
long prodomains contain distinct motifs, notably the death effector domain (DED) and the 
caspase recruitment domain (CARD). A novel motif termed the death-inducing domain (DID) 
was recently identified (18). Procaspase-8 and -10 each contain two tandem copies of DEDs (19-
21) whereas a single CARD domain is found in caspases-1, -2, -4, -5 and -9 as well as in CED-3 
(22). These domains mediate homophilic interaction between procaspases and their adapters and 
play important roles in procaspase activation. In contrast, the short prodomains of executioner 
caspases are unlikely to mediate protein-protein interactions. Rather, prodomains seem to inhibit 
the activation rate in vivo (23). They regulate nuclear transport in caspase-7 (24) and retain 
caspase-3 in an inactive state (25). 
 The three-dimensional structure of procaspase-7 has been determined (26, 27). The 
structures of caspase prodomains, particularly those of the DED and the CARD domains, have 
also been solved (28-30). DED, CARD and a related domain, DD (death domain, present in cell 
death adaptor proteins), all consist of six alpha-helices and have similar overall folds. 
Nonetheless, there are some major differences among them. While charge-charge interactions 
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govern CARD-CARD (30) and DD-DD association (31), hydrophobic interactions govern DED-
DED interaction (32).  
 
 
Figure 1. Mammalian caspase family and C. elegans caspase CED-3. All mammalian caspases listed 
are of human origin except for murine caspase-11 and -12, for which no human counterparts have been 
identified yet. Phylogenetic relationships are based on sequence similarity among the protease domains. 
Alternative names are listed in parentheses after each caspase. Dotted box - DED domains; wavy box - 
CARD domain. Substrate preferences at the P1 to P4 positions are indicated. Figure adapted from (33).  
 
1.2.2 Structures of active caspases 
 The three-dimensional structures of caspase-1, -2, -3, -7  and -8 each complexed with 
peptide inhibitors, have been determined (15, 34-42). These structures reveal that a mature 
caspase is a tetramer (homodimer of the p17-p12 heterodimers with a twofold symmetry), with 
the two adjacent small subunits (p12) surrounded by two large subunits (p17) (Fig. 2). Each p17-
p12 heterodimer forms a single globular domain and the core of the globular domain is a six-
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stranded beta--sheet flanked on either side by alpha-helices. These two heterodimers associate 
with each other primarily through the interaction between the p12 subunits. 
 
 
Figure 2. Structure of the caspase-3 tetramer in complex with Z-DEVD-cmk. The p17 and p12 chains 
are shown in light and dark colors. The p12 N-terminal tail is which was disordered in previous structures 
(36, 37) is given in red. The catalytic cysteine and histidine residues (yellow) and the inhibitor (grey) are 
given in stick representation. Figure adapted from (43).  
 
 Each caspase tetramer has two cavity-shaped active sites formed by amino acids from 
both the p17 and p12 subunits and these two active sites function independently (44). The 
catalytic cysteine and histidine residues of caspases are typically located at the ends of β-strands 
in a unique caspase hemoglobinase fold (45). The side chains of Arg179 (p17) and Arg341 (p12) in 
the S1 site participate in a direct charge-charge interaction with the aspartic acid of a substrate, 
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contributing to the selective recognition of Asp at the P1 position of a substrate (Fig. 3). The 
amino acids from the small subunit form the S2 and S3 sites. The side chains of P2 and P3 residues 
are mainly exposed to solvent, consistent with the less stringent requirement at these two 
positions in caspase substrates. The atomic resolution structure of caspase-3 in complex with Z-
DEVD-cmk and its implication in catalysis and substrate recognition are discussed in detail in 
Chapter 2.  
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Figure 3. Polar interactions at the active 
site of caspase-3: Ac-DVAD-cmk complex. 
(pdb code:  1CP3) 
 
 
1.2.3 Specificity 
 Caspases are among the most specific endopeptidases reported so far. An aspartic acid 
residue is absolutely required at the P1 position. For example, any substitution in this position in 
the caspase-1 substrates leads to a >100-fold decrease in cleavage activity (46, 47). The P2 to P4 
positions also show high preference for certain amino acids. Based on the substrate specificity, 
caspases are divided into three groups (Fig. 1) (17). The optimal recognition motif for the first 
group is WEHD. This group includes the inflammatory caspase-1 and its close homologues 
caspase-4 and -5. The second group prefers the sequence DEXD (where X is V, T, or H), with a 
high preference for Asp at the P4 position. This second group consists of apoptotic effector 
caspases with either long or short domains (caspase-2, -3 and -7). The inclusion of caspase-2, 
which contains a long prodomain, may imply that it can function as both an initiator and an 
effector caspase. In caspase-2, the amino acid at the P5 position also affects the cleavage 
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efficiency (38, 48). Members of the third group (caspase-6, -8, -9 and -10) preferentially 
recognize (L/V)EXD.  
 The major discriminating feature among caspases is the specificity at the S4 subsite. In 
caspase-3, the preference for a P4-Asp is of the order of 100 fold higher when compared to Asn or 
Glu in P4. There are two crystal structures for caspase-3 in complex with peptidyl inhibitors 
having a P4-Asp. The P4-Asp forms weak hydrogen bonds with Phe250, Trp214 and Asn208 (Fig. 4), 
which only partially accounts for the preference of P4-Asp. Apart from the S4 subsite, caspases 
show a considerable degree of discrimination at the prime sites. Limited structural information is 
available with regard to the specificity at the prime sites. Using internally quenched fluorescent 
peptide substrates, Stennicke HR et al (49) have found that there is a general preference for small 
amino acids at the P1` site preferences for human caspases-1, -3, -6, -7 and -8. 
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Figure 4. Polar interactions 
of P4-Asp based on 
previously determined crystal 
structures of caspase-3: 
DXXD inhibitor complexes 
(pdb code: 1PAU and 1CP3). 
 
  
1.2.4 Activation of procaspases 
 Most biochemical and structural work on caspase activation has been performed with 
human caspases-3, -7, -8, and -9. A reasonably clear picture has emerged demonstrating the 
variation and conservation with respect to the caspase activation mechanisms (10). The 
zymogens of the initiator caspases exist within the cell as inactive monomers. These monomeric 
zymogens require dimerization in order to adopt an active conformation, and this activation is 
independent of cleavage (50-52). The dimerization event occurs in multi-protein activating 
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complexes to which the caspase zymogens are recruited to by virtue of their N-terminal 
recruitment domain. The activating complex involved depends on the origin of the death stimulus: 
in the intrinsic pathway activation occurs on a molecular platform called apoptosome (53) and in 
the extrinsic pathway activation occurs within the death inducing signaling complex (DISC) (7). 
The apoptosome is composed of Apaf-1, caspase-9, caspase-3 and XIAP (X-linked inhibitor of 
apoptosis protein), while DISC is composed of Fas receptor, FADD (Fas-associating protein with 
death domain) and caspase-8. In contrast to the initiators, the executioner caspase-3 and -7 
zymogens exist within the cytosol as inactive dimers. They are activated by specific proteolytic 
cleavage in the inter-domain linker region carried out by an initiator caspase, and occasionally by 
other proteases under specific circumstances (54-56). The crystal structures of procaspase-7, 
active caspase-7, and inhibitor-bound caspase-7 provided a basis to derive a mechanism for the 
executioner caspase activation, and the dimerization mechanism for initiator caspase activation 
(26, 27, 57). Inflamatory caspases are activated through a multi-protein complex called the 
inflammasome. The inflammasome is composed of caspase-1, caspase-5, the adapter protein 
PYCARD and the infectious agent, multidomain protein NALP1(58). 
 
1.3 Regulation of caspase activity 
1.3.1 Active site inhibitors 
 A typical caspase inhibitor can be divided into three structural components: the warhead, 
the P1 aspartic acid and the P2-P4 peptidomimetic.  
Warhead     
 The warhead consists of an electrophile that reacts with the nucleophilic cysteine residue 
of the active site. Depending on the nature of the groups flanking the warhead, an inhibitor can 
either be reversible or irreversible. Reversible inhibitors are generally advantageous as they are 
often more selective towards the target protein compared to irreversible inhibitors. Despite the 
lack of specificity, a significant advantage associated with irreversible inhibitors is their greater 
potency in cellular assays of apoptosis. Commonly used warhead groups for the inhibition of 
caspases along with their chemical structure are given in Fig.5. 
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Figure 5: Commonly used "warheads" (electrophilic groups) for the inhibition of caspases. 
 
P1 Asp   
 Caspases have a strong preference for an aspartic acid as the P1 residue (17, 46, 47). 
Therefore this feature has been incorporated into almost all lead compounds (Fig. 6). There are 
however two examples of compounds lacking the P1 aspartic acid sub-structure while retaining 
binding affinity for caspases. In one case, compound-A (Fig. 6) was initially identified by high-
throughput screening. It was subsequently optimized to a potent and selective low nanomolar 
inhibitor of caspases-3 and -7 (59, 60). The warhead is a cyclic ketoamide and the crystal 
structure of this compound bound to caspase-3 revealed a tetrahedral intermediate formed 
between the active site thiolate and the ketone carbonyl group. Despite the lack of significant 
binding in the S1 subsite, this series of compounds displays potent inhibitory activity and higher 
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selectivity for caspases than for other cysteine proteases and inhibition of apoptosis in cell-based 
assays.  
 An acyl-sulfonamide (a classic carboxylic acid replacement) was substituted for the 
aspartic acid residue (compound-B) (61). In this case the crystal structure revealed that the 
methane-sulfonamino-carbonyl group in the P1 position is buried in the S1 pocket and engages in 
hydrogen bonding interactions with Arg179 and Arg341 (residues that typically form hydrogen 
bonds to the P1 Asp residue). The additional steric bulk of the methane-sulfonyl group is 
accommodated by rearrangement of the surrounding amino acids.  
 
P2-P4 Peptidomimetic  
 This is the part of caspase inhibitors for which the greatest variety has been generated. In 
most cases, inhibitor design relies on a substrate analog approach in which a tetrapeptide 
substrate sequence is the starting point. After incorporation of a suitable warhead, non-peptide 
substitutions for the P2-P4 regions are identified that improve the pharmacokinetic properties of 
the molecule. With the structural information of different caspases, structure-based design plays a 
major role in the lead optimization process. Several novel peptidomimetic inhibitors (e.g. 
Compounds-C-H) have been identified. Some of these compounds were shown to rescue mice 
from lethal experimental hepatitis, decreased circulating levels of plasma markers associated with 
fulminant hepatic failure (62), and neuroprotective effects in a rat model of transient focal 
ischemia (63). However, these inhibitors are irreversible broad spectrum inhibitors, which raise 
questions regarding their in vivo specificity and potential toxicity. Recently, two caspase 
inhibitors have entered clinical trials. Vertex Pharmaceuticals announced the completion of 
Phase-IIa clinical trials with Pralnacasan (VX-740; compound-C, a caspase-1 specific inhibitor, 
for the treatment of Rheumatoid Arthritis (RA). This compound is administered orally as an 
acetal pro-drug which undergoes in vivo hydrolysis to the active species possessing an aldehyde 
warhead (Compound D). The aldehyde version of the compound has a Ki of ∼1 nM for caspase-1 
and inhibits IL-1β secretion from human peripheral blood mononuclear cells (PBMCs) with an 
EC50 of  ∼0.6 µM. Pralnacasan was found to significantly reduce joint inflammatory symptoms in 
patients (64, 65). The Phase I clinical trials  of the second caspase inhibitor, IDN-6556 have been 
successfully completed for acute alcoholic hepatitis (IDUN pharmaceuticals, now acquired by 
Pfizer, www.idun.com). 
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Figure 6: Examples of synthetic inhibitors of the inhibition of caspase activity described in the literature. 
Figure adapted from (66). 
   
 The structure of this compound has not been disclosed, but it does possess an irreversible 
warhead (67). However, the structures of earlier compounds developed by IDUN have been 
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disclosed (e.g. compound-E) (68, 69). One of these compound (IDN-1965) was shown to 
dramatically increase survival in rats following Fas-induced liver damage (70).  
 Apoptosis and inflammatory responses are the major host defense mechanisms against 
viruses. Viruses produce inhibitors of caspases, to prolong the life of host cells for maximal viral 
replication. These viral inhibitors either directly inhibit caspases (cowpox virus protein CrmA 
(cytokine response modifier A), baculovirus proteins p35 and IAPs) or inhibit caspase-adapter 
interactions (v-FLIP (viral FLICE-inhibitory protein)). CrmA is a serpin that directly targets the 
active site of mature caspases (71). After being cleaved by a caspase, however, CrmA stays 
bound to the caspase and blocks the active site (72). p35 is a broad-spectrum caspase-specific 
inhibitor; it inhibits human caspase-1, -3, -6, -7, -8 and -10 with Kis  ranging from 0.1 nM to 9 nM 
(73). In contrast to CrmA and p35, cellular IAPs (inhibitors of apoptosis) are not active-site-
specific inhibitors and their inhibition of apoptosis does not require cleavage by caspases. The 
IAPs, originally identified in the genome of baculovirus based on their ability to suppress 
apoptosis in infected host cells, antagonize cell death by interacting with and inhibiting the 
enzymatic activity of mature caspases.  
 
1.3.2 Allosteric site inhibitors  
 An allosteric site is a remote site where a molecule that is not a substrate may bind and 
influence the ability of the enzyme to be active. The discovery of allosteric sites generates 
opportunities for the identification of novel pharmaceuticals and increases the understanding of 
biological processes. In caspases it has proven difficult to find drug-like caspase inhibitors 
possessing favorable pharmacokinetic properties, because of a strong preference for an acidic 
side chain and an electrophilic functionality to bind at the active site (17). Allosteric sites provide 
appealing alternatives for drug discovery because the chemical properties for binding are different 
from active site-directed compounds (74-77).  
 Active caspases are homo-dimers of hetero-dimers and their oligomeric state  is directly 
linked with the enzymatic activity (78). Initiator caspase-1, -8, and -9 shift from the monomeric 
to the dimeric state when active site inhibitors bind (51, 79, 80). An allosteric cavity exists at the 
dimer interface of active caspases and it was shown previously that this allosteric site can be 
utilized to modulate the caspase activity (81). The amino acids forming the interface are not 
conserved between different caspases. For example, the interface is hydrophobic in case of 
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caspase-3, -6 and -7. In contrast, hydrophilic residues are commonly found in caspase-1, 4, -5 and 
-11. The interfaces of caspase-2, -8, -9 and -11 include both hydrophobic and hydrophilic 
residues. In addition the size and shape of the dimer interface cavity is differ considerably among 
the caspase family members. Caspase-8 has the largest cavity, with an approximate volume of 
17×15×11 Å3, while the interface cavity in caspase-2 and -3 are slightly smaller. In two of the 
crystal structures of caspase-8, an oxidised DTT molecule occupies this site (40, 82). Caspase-2 
has a distinct feature for the dimer formation, as illustrated by the structural study, a disulphide 
bond between Cys419 and Cys419’ from each monomer promotes the dimerization and stabilizes 
the active caspase-2 (38). One of the aims in this thesis was the identification of specific caspase 
inhibitors that bind to this allosteric site using a structure based design approach Chapter 5. 
  
1.3.3 Caspase activators 
 Selective activation of caspases might be a valuable strategy, especially for the therapy of 
human cancers. Several strategies to trigger caspase activation specifically in tumor cells are 
currently being designed.  Inducible caspases that can be activated "on demand" have been 
engineered by fusing them to chemical dimerization domains. After delivery of these chimeric 
"death switches" by adenoviral gene transfer, caspases can be activated to trigger apoptosis in 
tumor cells by cell-permeable dimerization drugs (78, 83). Inducible caspase-9 (iCasp9) under the 
control of a prostate-specific, androgen-responsive promoter was targeted to prostate cancer cells 
(84). Another apoptosis-triggering approach is based on fusion proteins that contain effector 
caspases (85, 86).  
 Activation of caspases in vivo, using small molecules might be an effective approach to 
kill cancer cells or at least to reverse the resistance against anticancer drugs. Caspase-3 is kept in 
an inactive state by an intramolecular electrostatic interaction facilitated by a triplet of aspartic 
acid molecules termed the “safety-catch” (87). Removal of the safety catch loop resulted in 
increased autocatalytic maturation and susceptibility to caspase-9. Thus, the release of the 
caspase-3 “safety catch” may be an important feature for apoptotic competence Attempts have 
been made to design small pharmacologically active molecules capable of inducing auto-
activation in caspases. Maxim Pharmaceutical Inc. has developed a pharmacologically-active 
caspase activator MX-2060 (88).  
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 Arginine-glycine-aspartate (RGD) tripeptides are recognized by integrins in extracellular 
matrix proteins and can block integrin-mediated signalling and cell adhesion (89-91). The RGD 
motif exhibit marked proapoptotic properties and can directly induce auto-processing (auto-
activation) of procaspase-3 (92). A strategy to selectively activate caspase-3 using synthetic small 
molecules which mimic RGD peptides is followed by Merck Frosst (http://www.merckfrosst.ca). 
   
1.3.4 Compartmentalization, phosphorylation and nitrosylation 
 Different procaspases may be present at different intracellular compartments and their 
localizations may change during apoptosis (33). One of the best examples is that, during Fas-
mediated apoptosis, procaspase-8 is recruited from the cytosol to the Fas receptor complex and 
becomes activated (7). This translocation is mediated by the homotypic interaction between the 
DEDs in the prodomain region of procaspase-8 and that in a Fas-associated adapter protein named 
FADD. Procaspase-2 is also present in the nucleus as well as the cytoplasm (93). In mouse liver, 
procaspase-3 is present in both cytosol and mitochondria, while procaspase-7 is found only in the 
cytosol (94, 95). Procaspases may normally be compartmentalized away from their substrates to 
prevent accidental apoptosis; during apoptosis, the activation and coordinate translocation of 
caspases allow them to move close to their targets (33).  
 As a major form of posttranslational modification, phosphorylation is also employed to 
modulate caspase activity. One example is the phosphorylation of caspase-9 by Akt (96), a 
serine-threonine protein kinase downstream of phosphatidylinositol 3-kinase, which is implicated 
in apoptosis suppression mediated by growth factor receptors. Another way to modify caspases 
post-translationally is by S-nitrosylation. Nitric oxide (NO) and related molecules have been 
found to inhibit apoptosis. A study showed that in unstimulated human cells, the active site of 
endogenous procaspase-3 is S-nitrosylated, but during Fas-mediated apoptosis, it becomes 
denitrosylated (97). The denitrosylation enhances mature caspase-3 activity, although it does not 
affect procaspase-3 processing.   
 
1.3.5 Caspase substrates 
 To date, more than 60 proteins have been shown to be substrates of one or more caspases 
in mammalian cells and the list is still growing (98). These substrate proteins contain caspase 
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cleavage sites in inter-domain linker sequences. Substrate proteins are thus not degraded by 
caspase processing; instead, caspase cleavage may activate or inactivate the substrate protein's 
function. Because of the strict requirement for an aspartic acid residue in P1 and distinct 
preferences for P2 to P4 residues, it is relatively straightforward to identify the likely caspase 
cleavage sites within a given substrate protein and the likely group of caspases that may 
recognize them. The substrates identified so far fall into two general groups: a large group of 
proteins thought to be involved in regulation and execution of apoptosis and a small group of pro-
inflammatory cytokine precursors. For many of the identified substrates, the functional 
consequences of their cleavage have only been inferred from their normal functions. In other 
cases, the role of caspase cleavage has been experimentally assessed by expressing mutant 
substrate proteins that have altered caspase cleavage sites or by expressing protein fragments that 
represent caspase cleavage products. The evolutionary conservation of caspase substrate proteins, 
in particular their caspase cleavage sites, suggests that caspases were first employed for apoptosis 
and later co-opted for cytokine processing in mammals (33).  
Representative list of substrates are the following:  
Cell death proteins Bcl-2, Bid, CrmA, IAP, p28 Bap31, p35 and Procaspases 
Cell cycle regulation 
Cdc27, Cyclin A, MDM2, p21 (Cip1/Waf1), p27 (Kip1), PITSLRE 
kinases, Retinoblastoma protein, Wee1 phosphatase 
Cytoskeleton 
Actin, β-Catenin, Fodrin, Gas2, Gelsolin, Keratin-18 and -19, 
Lamins, Plakoglobin 
Cytokine precursors Pro-IL-1β, Pro-IL-16, Pro-IL-18 
DNA metabolism Acinus, DNA-dependent protein kinase (DNA-PK), ICAD, PARP 
Neurodegenerative 
disease proteins 
APP, Huntingtin, Presenilins 
RNA metabolism Eukaryotic initiation factor 2α, 70-kDa U1-snRNP 
Signal transduction MEKK1, Protein kinase C delta, TCR-ζ chain 
Transcription factors Heat shock factor, GATA-1, Sp1, STAT1, NRF-2 
Others Hsp90, Nedd4, Calpastatin, Rabaptin-5, Transglutaminase 
Abbreviations 
Bcl-2 
B-cell CLL (chronic lymphocytic    
leukemia)/ lymphoma 2 
ICAD Inhibitor of caspase-3-activated DNase 
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Bid 
BH3 domain-containing pro-
apoptotic Bcl-2 family 
CrmA 
Cow pox cytokine response modifier 
protein 
PARP POLY (ADP-ribose) polymerase APP Amyloid precursor protein 
Nedd 
Neural precursor cell expressed, 
developmentally down-regulated 
snRNP Small nuclear ribonucleoprotein particle 
Bap Benzo(a)pyrene MAP Mitogen-activated protein kinase 
Cdc cell division cycle MEKK murine MAP kinase kinase kinase  
Mdm Murine Double Minute GATA Globin transcription factor 
Cip Cyclin B1-interacting protein STAT 
Signal transducer and activator of 
transcription 
Kip Kinase interacting protein NRF Nuclear respiratory factor 
Gas Growth arrest-specific Hsp Heat shock protein 
IAP Inhibitor of apoptosis IL Interleukin 
 
1.3.6 Physiological functions of caspases  
 The physiological functions of caspases have been assessed by both pharmacological 
inhibition and gene knockout experiments (99). Because of the overlapping substrate specificities 
of caspase family members, both pharmacological and genetic approaches have been fruitful in 
elucidating the redundant and specific roles of caspases. To date, the genes for caspase-1,-2, -3, -
8, -9, -11 and -12 have been deleted in mice; human cell lines deficient in caspase-3, -8 and -10 
have also been described (33, 100, 101). The results from these genetic experiments reveal that 
mammalian caspases have overlapping and tissue-specific roles in controlling apoptosis in 
response to specific stimuli.  
 
1.3.7 Pathological consequences of caspases dysregulation 
 Caspases have a pivotal role in the progression of a variety of neurological disorders. 
Despite the various causes of such disorders, the mechanism of cell death is similar in a broad 
spectrum of neurological diseases (102). However, the trigger of aberrant caspase activation in 
most of these diseases is not well understood. In acute neurological diseases, both necrosis and 
caspase-mediated apoptotic cell death occur (103). In contrast, in chronic neurodegenerative 
diseases, caspase-mediated apoptotic pathways have the dominant role in mediating cell 
dysfunction and cell death (104). A primary difference between acute and chronic neurological 
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diseases is the magnitude of the stimulus causing cell death. The greater stimulus in acute 
diseases results in both necrotic and apoptotic cell death, whereas the milder stimulus results in 
chronic diseases initiate apoptotic cell death.  
 The amyloid-beta precursor protein (APP) is directly and efficiently cleaved by caspases 
during apoptosis, resulting in elevated amyloid-beta (A-β) peptide formation (105). The 
predominant site of caspase-mediated proteolysis is within the cytoplasmic tail of APP and 
cleavage at this site occurs in hippocampal neurons in vivo following acute excitotoxic or 
ischemic brain injury. Caspase-3 is the predominant caspase involved in APP cleavage, 
consistent with its marked elevation in dying neurons of Alzheimer's disease brains and co-
localization of its APP cleavage product with A-β in senile plaques (106). Caspases thus appear 
to play a dual role in proteolytic processing of APP and the resulting propensity for A-β peptide 
formation, as well as in the ultimate apoptotic death of neurons in Alzheimer's disease (107).  
 Cell and animal models of ALS (Amyotropic lateral sclerosis), along with the finding of a 
greater than 80% increase in caspase-1 activity in spinal cord samples from humans with ALS 
indicate that caspases may play an essential role in the pathology of this disease (108). A role of 
caspases in the pathogenesis of Huntington’s disease was suggested by the finding that the 
protein huntingtin is a substrate for caspases. In brains of patients with Huntington’s disease 
increased levels of DNA strand breaks are found, a process typical of apoptotic cells. 
Tetrapeptide aldehyde inhibitors Ac-DEVD-CHO and Ac-YVAD-CHO were used to 
demonstrate that caspases cleave other polyglutamine-containing proteins involved in 
neurodegenerative diseases such as spinal bulbar muscular atrophy (SBMA)(109). 
 Several experimental models of Parkinson’s disease have supported a role of caspases in 
apoptotic dopaminergic cell death (110-112). Peptide caspase inhibitors have been shown to 
protect against 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis of cultural cerebrellar 
granular neurons and increase the rate of survival (113). Additionally, administration of Z-VAD-
FMK prevented the loss of nigral dopaminergic neurons following intrastriatal administration of 
the neurotoxin 6- hydroxydopamine (6-ODHA). This prevention of dopaminergic neuron loss by 
Z-VAD-FMK suggests a role for caspases in 6-OHDA-mediated cell death (114). 
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1.3.8 Therapeutic intervention for regulation of caspase activities  
 Abnormal cell survival is a hallmark of cancer cells, both oncogenes and tumor 
suppressor genes have been shown to regulate apoptosis. p53, the most frequently mutated human 
tumor suppressor gene, functions in critical pathways to connect DNA damage to cell cycle arrest 
and apoptosis (115). Reduced apoptosis gives cancer cells a selective advantage in many steps of 
tumorigenesis. Initially, it allows cancer cells to survive dysregulated growth signals from 
oncogenes, which would normally induce apoptosis. p53 appears to be a common effector 
pathway in oncogene and DNA damage-induced apoptosis, but the exact molecular mechanisms 
connecting p53 activation to caspase activity remains poorly understood (116).   
  The critical role of caspase-mediated cell death in controlling viral infection is reflected 
by the number of virally encoded genes that interfere with caspase activation or inhibit caspase 
activity (8). Apoptosis of infected cells, either induced autonomously or instructed by CTL 
(cytotoxic T lymphocytes), can decrease viral replication or spread by limiting the pool of host 
cells for productive infection, but excessive apoptosis may also lead to tissue dysfunction. The 
rapid decline in CD4+ T cells by apoptosis in human immunodeficiency virus (HIV) infection has 
been viewed as a promising target for caspase inhibition (2). Apoptosis plays a critical role in the 
deletion of unnecessary and dangerous lymphocytes. Because the antigen receptors arise from 
random DNA recombination, autoimmune lymphocytes that recognize self-antigens are 
constantly produced. Selective depletion of auto-reactive lymphocytes by caspase activation and 
apoptosis may be a valid therapeutic strategy (117).  
 Excessive apoptosis has been blamed for several serious pathologies for which there are 
currently limited therapeutic options, including neurodegenerative diseases, ischemia-reperfusion 
injury, graft-versus-host disease and autoimmune disorders (33). Thus caspases are attractive and 
potential targets for the therapeutic treatment of these disease states (66). This thesis adopted a 
structure based design approach for the identification and X-ray crystallographic structure 
determination for the validation of the inhibitors that might be specific towards caspases. 
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1.4 Structure based design of inhibitors for caspases 
 In the past new drugs have been discovered using a conventional screening approach, 
which is a very tedious process. However, if the three dimensional structure of the target protein 
is known, a structure-based drug design strategy can be very successful. Currently, 
structure/activity relationship for a ligand/receptor interaction can be analyzed by a variety of 
techniques, like high throughput screening (HTS), NMR, X-Ray, Mass Spectrometry (MS), 
Surface plasmon resonance etc. The combination of structure-based drug design involving X-ray 
crystallography has become increasingly popular in drug discovery since it offers the means to 
identify and optimize lead compounds in terms of their binding affinities and specificities. When 
combined with in silico methods, it can speed-up drug discovery as it provides a faster and 
cheaper alternative to in vivo testing (Fig. 7). Additionally, it allows to screen a large chemical 
diversity without actually synthesizing the compounds. The process has the potential to discover 
compounds with acceptable ADME (Absorption, Distribution, Metabolism, and Elimination) and 
toxicology properties. These properties are poor for substrate based peptide inhibitors which 
prevent their widespread use in medicinal chemistry. An application of this procedure for the 
identification of new lead compounds that inhibit caspase-2, -3 and -8 is described in Chapter 5 
of this thesis. 
 
 
 
 
Figure 7.  An iterative cycle for the discovery and re-design of lead compounds 
Crystal structures 
of caspases 
In-silico selection 
In vitro selection 
Compound acquiring 
Biochemical 
evaluation 
Crystallographic 
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inhibitor complexes 
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1.4.1 Azapeptide Michael acceptors and epoxides as caspase inhibitors  
 Most of the caspase inhibitors reported so far possess either an aldehyde or halogen 
methylketone moiety as warhead (66). Such inhibitors are very unspecific, since they also inhibit 
related proteases (55, 118). Therefore the search for other potential warheads with a high 
selectivity for caspases was undertaken. Recently, azapeptide epoxides (Fig. 8a) and Michael 
acceptors (Fig. 8b) as a new class of irreversible caspase inhibitors that are highly specific for 
caspases have been identified (119-121). Several azapeptide epoxide and Michael acceptor 
inhibitors with varying prime site constituents were synthesized and their potencies for the 
inhibition of caspases were determined in an in vitro assay in the group of James C. Powers 
(Georgia institute of technology, Atlanta, USA). Chapters 3 and 4 describe the structural studies 
with caspase-3 and -8, using some of these inhibitors. These studies led to the elucidation of the 
structure based mechanism of the inhibition. In addition, the study revealed the factors 
determining the prime site specificity. 
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Figure 8. Chemical structure of a typical azapeptide epoxide (a) and Michael acceptor (b) 
inhibitor. 
 The motivation for the design of epoxides was primarily based on the observation that the 
naturally occurring E-64 (an epoxysuccinyl peptide, L-trans-epoxysuccinyl-leucylamide-(4-
guanidino)-butane) is a potent, selective and irreversible inhibitor for cysteine proteases (Fig. 9a) 
(122). E-64 was isolated from Aspergillus japonicus (122, 123) and it does not inhibit serine 
proteases, aspartic proteases, or metalloproteases (124-126). The synthetic derivatives of E-64, 
(e.g. E-64c, Fig. 9b) are also potent cysteine protease inhibitors. The design of Michael acceptor 
inhibitors for caspases was based on the finding, that the fumarate analog of E-64c (Fig.9c) was 
an inhibitor of Cathepsin-B and -L (126).  
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Figure 9. Chemical structure of E-64 (a), E-
64c (b) and the fumarate analog of E-64c, 
which are potent and selective inhibitors for 
cysteine proteases. 
 
   
1.4.2 Azapeptides 
 Azapeptides are peptidomimetic compounds in which the Cα atom of an amino acid 
residue is replaced by a nitrogen atom (127-129) (Fig. 10). This modification renders certain 
unique conformational properties to the peptide structure and dynamics because of the loss of 
chirality and reduction in the flexibility of the parent peptide by restricting the rotation around 
Cα-C bond or the Ψ angle.  
 
Figure 10. (a) Aza-amino acid and (b) L-amino acid   
 
 Azapeptides possess several advantageous features compared to the natural peptides. 
They are resistant to proteolysis and they offer enhanced stability to acyl-enzyme complex 
against nucleophilic attack by water molecules during the deacylation step. The increase in 
acidity of the NH group attached to the Nα atom improves the tendency towards the formation of 
hydrogen bond. Azapeptides therefore possess improved pharmacokinetic properties like 
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absorption, distribution, metabolism and excretion apart from the metabolic stability, and are 
widely used as an attractive peptidomimetic in drug design (130, 131).  
 The biological activity of peptides is strongly dependent on their three dimensional 
structure, because bioactive peptides must adopt a specific conformation in order to bind to an 
acceptor molecule. Exploration of a binding conformation is one of the most important aspects in 
designing a potent and selective inhibitor. Stabilisation of a particular conformation can be 
achieved by incorporating geometric constraints. The most obvious changes can be made by 
replacing a tetrahedral carbon atom with a planar nitrogen atom (122). This leads to the loss of an 
easily rotatable Cα-C bond. Due to this change, azapeptides are more rigid than their 
conventional peptide counterparts. The rotational barrier is high for Nα-N bond because of the 
repulsive interaction between the nitrogen lone pair which forces the lone pair and the 
substituents on both nitrogen atoms to be eclipsed in the planar geometry. Substitution of an Nα 
atom generates two structural elements: hydrazine and urea whose conformational properties are 
described by φ and Ψ angles respectively (129).  
 
1.4.3 Epoxysuccinyl inhibitors of caspases  
 An initial attempt to obtain epoxysuccinyl inhibitors for caspase-1 was made by selecting 
the residues of its precursor, proIL-1β (pro-Interleukin-1β) and replacing the P1-Asp with an 
epoxysuccinyl moiety. A few compounds were synthesised and tested for their inhibitory activity 
towards caspase-1, but none of the compounds were found to inhibit caspase-1 (132) possibly 
because, they all lack the critical aspartic acid residue in P1. Alternatively, the group of James C. 
Powers designed some epoxide peptide inhibitors for caspases (133) (Fig. 11). Their design 
strategy included the placement of an epoxide moiety at the N-terminus of an aspartic acid 
residue assuming a retro-substrate like binding as commonly witnessed for clan CA cysteine 
proteases. They have synthesized both D and L amino acid derivatives of this series of 
compounds. The compounds were tested in an in vitro assay, but they failed to inhibit caspase-3, 
-6 and -8, yet they had some inhibitory activity against papain and cathepsin B.  
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Figure 11. Design strategy to design α-aminoacyl 
epoxides for caspases, which failed to inhibit 
caspases. Figure adapted from (133). 
 
The study led to the following hypotheses regarding the binding mechanism of epoxide inhibitors:  
i. the binding mode of azapeptide epoxide inhibitors would be opposite to that of E-64 and E-
64 derivatives. E-64 like compounds bind to papain and cathepsin B in a manner which is 
reverse to substrate binding, while azapeptide epoxide might bind in a manner similar to 
substrate binding. 
 
ii. the epoxysuccinate derivative of azapeptides would be more reactive than simple α-
aminoacyl epoxides     
 
1.4.4 Binding mode of epoxysuccinyl inhibitors 
 More than a dozen x-ray structures of epoxysuccinate derivatives bound to cysteine 
proteases have been reported (122). Three general binding modes have been observed or 
proposed (Fig. 12). In the most often observed binding mode, the epoxysuccinate binds in the S 
subsites. However, in contrast to the substrate binding mode (N-terminal to C-terminal, Fig. 12a), 
the peptide chain of the inhibitor is oriented in the reverse direction (C-terminal to N-terminal, 
Fig. 12b). In the second binding mode, the inhibitor is located only in the S` subsites (Fig. 12c). 
Newly developed inhibitors, which extend in both directions, are proposed to bind with both the 
S and S` subsites (Fig.12d). One crystal structure is available so far for a P and P` extended 
inhibitor (papain-CLIK148, 1CVZ) (134). Nucleophilic attack by the active site cysteine residue 
is dictated by the binding mode of the peptide portion of the inhibitor. Binding in the S subsites 
leads to C-2 attack (Fig.12b), whereas binding in the S` subsites leads to C-3 attack (Fig. 12c). So 
far, the latter binding mode has been observed only with cathepsin B. As a general rule, the 
covalent bond with the cysteine residue will be formed at the oxirane carbon that possesses the 
prime site substituent. 
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Table 2.  PDB codes for X-ray crystal structures of cysteine proteases and epoxysuccinyl-based 
inhibitors. Table adapted from (122). 
 
Enzyme Inhibitor PDB code 
actinidin  E-64  1AEC  
cathepsin B  CA-030  1CSB  
cathepsin B  CA-074  1QDQ  
cathepsin B  E-64c  1ITO  
cathepsin K  E-64  1ATK  
papain  E-64c  1PE6  
papain  E-64c  1PPP  
papain  CLIK 148  1CVZ  
staphopain  E-64  1CV8  
 
Figure 12. Schematic representation of the binding modes of peptidyl epoxysuccinates: (a) 
normal binding mode with a peptide substrate; (b) binding mode of E-64 to papain; (c) binding 
mode of CA-074 to cathepsin B; (d) binding mode of MeO-GlyrGlyrLeur(2S,3S)-Eps-Leu-Pro-
OH to cathepsin B. Arrow indicates the reversed peptide chain. Cys-S- represents the side-chain 
thiolate of the active site cysteine residue. Figure adapted from (122). 
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1.5 Low barrier hydrogen bond 
 The atomic resolution structure of caspase-3 in complex with Z-DEVD-cmk inhibitor 
(Chapter 2) has revealed the formation of a low-barrier hydrogen bond (LBHB) between the P4-
aspartic acid of the inhibitor (Z-DEVD-cmk) and Asp-179 of the N-terminal loop of the β-
subunit of caspase-3. A hydrogen bond occurs when two electronegative atoms, such as nitrogen 
and oxygen, interact with the same hydrogen. The hydrogen is normally covalently attached to 
one atom, the donor, but interacts electrostatically with the other, the acceptor. This interaction is 
due to the dipole between the electronegative atoms and the proton. An enzyme may stabilize the 
transition state by forming a strong hydrogen bond or it may force the donor atoms into proximity 
and relieve the resulting destabilization of the enzyme: substrate complex by forming a hydrogen 
bond (135). In either case, this may be a LBHB with possible covalent nature. Hydrogen bond 
strength in an aprotic solvent is sensitive to change in acidity or basicity (136). The hydrogen 
bond will be strengthened when going from the enzyme: substrate complex to the transition state 
relative to aqueous solvent. This strengthening arises from the relief of destabilization associated 
with a poor solvation of the anions in aprotic solvents but this relief can then increase kcat.  
 The binding energy of a hydrogen bond ranges from very weak (∆Gformation ~ -2 kcal/mol) 
to very strong (∆Gformation < -25 kcal/mol) approaching in some cases, the energy values of 
covalent bonds (136). In weak hydrogen bonds, the proton is covalently bound to one 
electronegative atom at a distance of ~1.0Å , and electrostatically attracted to another 
electronegative atom at approximately twice the distance  (1.7 to 2.0 Å) (Fig. 13). The overall 
hydrogen bond length, given by the distance between the two electronegative or heavy atoms, is 
2.7 to 3.0Å. The proton has two alternative locations or free energy wells as it can be covalently 
bound to either A or B (Eq. 1)  
 
 
 
-A-H         :B- 
 
 
-A:      H B- 
Equation 1. Hydrogen bond between two electronegative atoms A and B.  
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 As the electronegative atoms A and B approach each other, the hydrogen bond is 
shortened to values between 2.60 and 2.50Å. The length of covalent A-H moiety increases and 
the noncovalent moiety H…B decreases. The hydrogen bond energy increases (-7 kcal/mol ≥ 
∆Gformation  ≥ -25 kcal/mol) and the energy barrier between two proton wells decreases (Fig. 13). 
When the barrier approaches the zero point vibrational energy of the hydrogen, the proton is 
delocalized between the two wells while a deuterium would remain localized. This state is 
referred to as LBHB (137).  
 
Figure 13.  Strengths of hydrogen bonds. Potential functions for weak, double-well (upper), strong-low-
barrier (middle), and very-strong-single-well hydrogen bonds (lower) in which the pKa values of A-H and 
B-H are equal. Horizontal lines give the zero-point vibrational energy levels of a proton and deuterium. 
Also indicated are the bond lengths and strengths of such hydrogen bonds. Figure adapted from (137). 
  
Hydrogen bond length (Å) 
(A               B) 
∆GFormation 
(kcal/mol) 
A H  B 
A H       B 
A H B 
2.7 - 3.0 
2.5 - 2.6 
2.3 - 2.45 
-1 to -3 
-7 to -25 
< -25 
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 Specifically, as the O-H…O hydrogen bond length decreases from 2.54 to 2.45Å its free 
energy increases rapidly from -7.8 to 32 kcal/mol, presumably due to an overlap of the proton 
and oxygen wave functions. As the heavy atoms continue to approach each other, further 
shortening the hydrogen bond 2.45-2.3 Å, the barrier between two wells disappears, and the 
proton is (or deuterium) in a single well. Single well hydrogen bonds are very strong. The proton 
is at equal distances from the two electronegative atoms.While the strength of the hydrogen 
bonds correlates with its bond length, little or no correlation is found experimentally and 
theoretically between strength and bond angle, A - H…B, over a range of 180 ± 30° (137). 
LBHBs are best studied in enzymes and have been proposed to participate in the mechanism of 
action of hydrolase's, lyases, ligases and several isomerase's (135). It is noteworthy that all 
LBHBs detected so far in enzymes involve carboxyl groups (138). 
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Abstract 
Caspases are cysteine proteases involved in the signalling cascades of programmed 
cell death in which caspase-3 plays a central role, since it propagates death signals 
from intrinsic and extrinsic stimuli to downstream targets. The atomic resolution (1.06 
Å) crystal structure of the caspase-3 DEVD-cmk complex reveals the structural basis 
for substrate selectivity in the S4 pocket. A low-barrier hydrogen bond is observed 
between the side chains of the P4 inhibitor aspartic acid and Asp179 of the N-terminal 
tail of the symmetry related p12 subunit. Site directed mutagenesis of Asp179 
confirmed the significance of this residue in substrate recognition. In the 1.06 Å 
crystal structure, a radiation damage induced rearrangement of the inhibitor 
methylketone moiety was observed. The carbon atom that in a substrate would 
represent the scissile peptide bond carbonyl carbon clearly shows a tetrahedral 
coordination and resembles the postulated tetrahedral intermediate of the acylation 
reaction. 
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Introduction 
 Programmed cell death (apoptosis) is a central process in all multi-cellular 
organisms. This process is highly regulated and involves several different classes of 
proteins. Apoptosis is triggered by external- and internal stimuli, which are 
propagated by either extrinsic- or intrinsic cell death pathways. Cysteine Asp-specific 
proteases (caspases) are common to both pathways.(1-3) In the pre-apoptotic cell 
caspases are synthesized as inactive proenzymes. Upon triggering of the cell death 
pathway caspases are activated by proteolytic cleavage on the C-terminal side of well-
conserved aspartic acids, cleaving the polypeptide chain into p12- and p17 subunits 
(4), which are in intimate contact and form one catalytic domain. Active caspases are 
dimers of two catalytic domains. So far 11 human caspases are known, they are 
classified into initiator and executioner caspases, depending on their role in the cell 
death process.(5) Caspase-3 is a key executioner caspase. It occupies a prominent 
position in the apoptotic cascade where death signals from both the intrinsic and 
extrinsic stimuli converge to activate downstream death events. 
 Since apoptosis is a dangerous process for the cell, caspases are highly 
regulated and selective towards substrates. All caspases recognize tetrapeptide 
sequence and have an absolute requirement for an aspartic acid in the P1 position. 
Caspases are subdivided into three specificity families(6), depending on their 
preference for P4 amino acid. The prototype caspases are caspase-1, -3 and -8 
requiring tryptophan, aspartatic acid and leucine residues in the P4 positions, 
respectively. The specificity of caspase-3 for a P4 aspartic acid is at least 100-fold 
higher than for a glutamate or an asparagine.(7) Thus the P4 selectivity is nearly as 
stringent as the P1 selectivity. The P4 selectivity was attributed to different 
Crystal structure of caspase-3: Z-DEVD-cmk complex                                   Chapter 2 
 50 
interactions with residues in loops flanking the P4 binding pocket.(8, 9) Several 
crystal structures of caspase-3 in complex with substrate analogues are known, which 
do not sufficiently explain the reason for the high selectivity in the P4 position.(8, 9) 
The caspase-3 heterotetramer contains two active sites, each of them is formed by 
residues belonging to one subunit. However, the existence of inhibitors, such as 2-
(2,4-Dichlorophenoxy)-N-(2-mercapto-ethyl)-acetamide, that bind outside the active 
site at the subunit interface of caspase mutants supports the hypothesis of an allosteric 
regulation of caspases.(10) 
 Caspases are very attractive drug targets as they are implicated in various 
diseases and precise structural data is of great interest to facilitate the design of 
selective inhibitors.(11) The reaction mechanism of caspases has not been studied in 
detail.(4) Site directed mutagenesis studies in caspase-1 emphasized the importance of 
residues Cys285 and His237.(12) In contrast to the classical catalytic triad described 
for many serine- and cysteine proteases, where the imidazole group of the active site 
histidine is involved in the deprotonation of the nucleophile(13-17), His237 in 
caspase-1 seems to be responsible for the protonation of the leaving group.(18) In 
papain-like cysteine proteases the interaction between the cysteine and histidine side 
chains is maintained throughout the catalytic cycle, whereas in caspases this 
interaction is disrupted by the binding of the substrate or inhibitor. Quantum 
mechanical and molecular dynamics studies of the deacylation reaction suggested that 
the active site histidine might also be responsible for the activation of a water 
molecule that hydrolyzes the thioester bond of the acylated caspase.(19) 
 Here, we report the crystal structure of the wild-type executioner caspase-3 at 
atomic resolution 1.06 Å and an Asp179Ala mutant at 1.7 Å resolution, respectively, 
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both in complex with Z-DEVD-cmk. The high resolution crystal structure of the 
wildtype caspase-3/Z-DEVD-cmk complex revealed that Asp179 of the symmetry 
related subunit forms a low-barrier hydrogen bond with the P4 aspartate of the 
inhibitor, providing experimental evidence that residues from both subunits are 
responsible for inhibitor recognition nurturing the idea of on an allosteric regulation 
of caspase-3 activity.(10) In addition, we observed a radiation damage induced 
rearrangement of the active site that is similar to the tetrahedral intermediate of the 
acylation reaction. 
Results 
Overall structure 
 The 1.06 Å resolution crystal structure of caspase-3/Z-DEVD-cmk provides 
well defined electron density for residues Ser29 to Thr174 and Ser176 to His277 of 
the p17- and p12 subunits, respectively. Only electron density for Asp175 at the C-
terminus, which is disordered, and for residues 1 to 29 at the N-terminus of the p17 
subunit, which were excluded from the expression construct, is missing in the crystal 
structure of human caspase-3 (SwissProt accession number P42574). The p12- and 
p17 subunits fold into a central six-stranded mixed β-sheet that is flanked on both 
sides by 5 α-helices (Fig. 1). This architecture, which is designated as the caspase 
hemoglobinase fold is conserved throughout all caspase structures.(20) Superposition 
of the caspase-3/Z-DEVD-cmk structure with known caspase-3 structures reveal 
rmsd's in the range of 0.32 Å (1gfw)(21) and 0.40 Å (1cp3)(8) for Cα-atoms. 
The subunit interface 
 The active caspase-3 heterotetramer is generated by applying the symmetry 
operator (1-x, y, 1-z) to all atoms in the asymmetric unit. A total area of 2788 Å2 is 
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buried upon dimerization of the catalytic domains. In previously published caspase-3 
crystal structures, a buried surface area of only 2000 Å2 was reported.(8) The increase 
in buried surface area in the caspase-3/Z-DEVD-cmk structure is attributed to residues 
176 to 184 that wind around the loop formed by residues 246* to 258* (* refers to the 
symmetry related subunit). In most caspase-3 structures determined so far, the p12 N-
terminal tail was disordered explaining the lower value for interface area. Although 
the interactions between subunits are more intense in the caspase-3/DEVD-cmk 
complex, the angle between subunits remains unchanged compared to previous 
caspase-3 structures.(8, 9) 
 Besides main chain hydrogen bonds between residues in the anti-parallel beta-
strands f and f* that were already visible in the other caspase-3 structures, several 
novel interactions are observed involving the p12 N-terminal tail (Fig. 2a and 2c.). 
The side chain of Asp179 forms a short hydrogen bond (2.35 Å) with the P4 aspartate 
side chain of the inhibitor in the symmetry related subunit. The main chain of residues 
178 to 179 forms a short parallel β-sheet with main chain of residues 247* to 248* 
including a hydrogen bond between Asp179-O and Glu248*-N (2.90 Å). The side 
chains of Asp180 and Asp181 are pointing towards the solvent. The side chain of 
Val178 stacks onto the side chain of Phe250* in the loop that restricts the S4 pocket 
and the side chain of Met182 is at Van der Waals distance to the side chain of Glu248. 
Isotropic temperature factors of the p12 N-terminal tail (for residues 176 to 184 is 
29.4 Å2) are similar to the overall average temperature factor (for all residues is 21.3 
Å2) with a pronounced minimum for Asp179. Asp179 belongs to a group of three 
aspartatic acid residues designated as "safety catch", because the mutations within this 
motif resulted in increased autocatalytic activation and susceptibility to caspase-9 
activation.(22)  
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 To investigate the impact of the interaction between Asp179 and AspP4*, the 
crystal structure of the caspase-3 Asp179-Ala mutant in complex with Z-DEVD-cmk 
was determined at 1.7 Å resolution. In the Asp179-Ala mutant structure, several well-
defined water molecules populate the space around AspP4* (Fig. 2b). The mutation 
causes a disordering of the p12 N-terminal tail confirming that the rigidity of the tail 
is a consequence of the interaction between Asp179 and AspP4*. Crystal packing 
effects can be excluded since wild type and mutant crystals are isomorphic. The lower 
resolution of the Asp179-Ala mutant also does not seem to be responsible for the lack 
of interpretable electron density since the conformation of the tail is clearly visible in 
the 1.7 Å crystal structure of the wild type. 
The active site 
The P4-site 
 The conformation of the Z-DEVD-cmk inhibitor is almost identical compared 
to the conformations seen in previous caspase/inhibitor complex structures. Although 
the structure was refined at 1.06 Å resolution, the N-terminal Cbz protection group is 
absent from the final electron density map. Some positive difference electron density 
at AspP4-N suggests the presence of a carbonyl group, but the bulky phenyl ring is 
completely disordered (lower number of ligand atoms in Table-2). Similiarly, the N-
terminal Cbz protection group is disordered in the structure of the Asp179Ala mutant. 
The AspP4-Oδ1 atom interacts with Asp179*-Oδ2 (2.35 Å) and both carboxylate 
groups are approximately coplanar. Distances between AspP4-Oδ1 and the side chain 
atoms of residues Asn208 and Trp214 are longer than 3.5 Å (Fig. 2a). Moreover, the 
angles between these side chains are not ideal for the formation of stable hydrogen 
bonds. AspP4-Oδ2 forms a hydrogen bond with Phe250-N (2.98 Å) as observed 
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previously.(8, 9) The caspase-3/DEVD-cmk complex was crystallized at pH 4.75, 
suggesting that Asp179* or AspP4 might be protonated. Therefore, bond lengths and 
angles between Cγ- and Oδ-atoms in Asp179* and AspP4 were not restrained during 
the final refinement cycle. Bond lengths between AspP4-Cγ and Oδ1 and Oδ2 are 
1.234 Å and 1.243 Å, respectively, whereas in Asp179* the equivalent bond lengths 
are 1.253 Å and 1.230 Å (Fig. 2c). Because the bond lengths of Cγ-Oδ1 in AspP4 and 
Cγ-Oδ2 in Asp179* are almost identical, it is assumed that this interaction involves a 
proton that is shared by both carboxylate groups. Hydrogen bonds between 
carboxylate groups, where the proton is located at approximately the same distance 
between oxygen atoms, are defined as low-barrier hydrogen bonds (LBHB), and it is 
assumed that they contribute a significant amount of binding energy, which is 
typically in the range between -20 and -30 kcal.mol-1.(23) The distance between 
Asp179*-Oδ2 and AspP4-Oδ1 is extremely short (2.35 Å), which is in agreement 
with the LBHB definition.(24) The hydrogen bonding pattern in the S4 pocket is 
shown in Fig. 2c. 
 To investigate the contribution of the interaction between Asp179 and AspP4, 
the kinetic parameters of the Z-DEVD-AMC and Ac-DEVD-AMC hydrolysis by 
caspase-3 wild type were compared with that of the Asp179-Ala and ∆176-181 caspase-
3 mutants, at different pH values (Table 1). The replacement of Asp179 to alanine has 
a significant effect on Km and kcat at acidic and neutral pH values, indicating that this 
interaction plays a role also at a physiological pH. At neutral pH, the Km and kcat 
values are increased approximately 2.5-fold leaving the kcat/Km-ratio unchanged, 
whereas at acidic pH the kcat/Km-ratio of the Asp179-Ala mutant is three to four times 
larger compared to the wild type. Although the interactions between Asp179 and 
AspP4 are lost in the Asp179-Ala and ∆176-181 mutants, the kinetic values of these 
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mutants are different, suggesting a more complex interaction pattern. In contrast to the 
Asp179-Ala mutant the Km and kcat values of the ∆176-181 mutant are decreased two to 
five fold compared to the wild type. The kcat/Km-ratio is decreased at neutral pH 
whereas it is approximately the same at acidic pH. Although the absolute numbers are 
not identical for the Z-DEVD-AMC and Ac-DEVD-AMC substrates, the changes on 
the kinetic parameters are independent of the N-terminal protection groups. 
The P1-site 
 The interactions seen for the side chains in the S3, S2 and S1 pockets are  
similar compared to previous caspase-3 complex crystal structures.(8, 9) The 
conformation of the covalent interaction between the methylketone and the active site 
Cys163 are similar in the 1.7 Å crystal structures. However, after extending the 
resolution to 1.06 Å significant movements of the methylene group and the Cys163-
Sγ atom have been observed. This movement is probably caused by radiation damage. 
The Fobs(1.06 Å) - Fobs(1.7 Å) · ϕcalc(1.06 Å) map reveals that major differences between the 
1.7 Å and the 1.06 Å resolution crystal structures exist in the neighborhood of the 
active site cysteine (Fig. 3). In the 1.7 Å resolution structure, the methylene group 
bridges the gap between the keto group and the sulfur atom as it has already been 
described for many caspase and cysteine protease structures in complex with halogen 
methylketone inhibitors.(8, 25) In the 1.06 Å resolution structure, the methylene 
group has moved 1.29 Å away from the active site cysteine and the Cys163-Sγ atom 
moved 0.41 Å towards AspP1-C. This conformation is closer to the conformation 
seen in caspase/aldehyde complexes(9, 12, 26)  with a tetrahedral coordination of 
AspP1-C and a short distance between AspP1-C and Cys163-Sγ (2.027 Å) than to the 
1.7 Å resolution caspase-3/Z-DEVD-cmk structure with a planar keto group. With a 
distance of 1.588 Å the bond length between AspP1-C and the methylene group 
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(AspP1-CM) is significantly longer than normal carbon-carbon single bonds (1.525-
1.530 Å) and the distance between AspP1-C and AspP1-O is longer than normal 
carbon-oxygen double bonds (1.265 Å compared to 1.231-1.249 Å). The AspP1-C 
atom is clearly tetrahedrally coordinated with all bond angles between 104° and 117°. 
To investigate the impact of radiation damage a second high resolution data set was 
collected and the diffraction quality was investigated using program XDSSTAT.(27)  
This analysis showed a constant decay of diffraction quality (Fig. 4). The Rd-values 
between subsequent frames were well below 10 % at the beginning of data collection 
and increased to more than 30 % after 220 frames. A difference Fourier map that was 
calculated between the 1.7 Å in-house data and the first 40 frames from the first 
synchrotron run (76 % completeness) gave no indication for a rearrangement of 
Cys163, whereas a difference Fourier map based on the combined last 50 frames of 
the first run and the first 40 frames of the third run showed elevated radiation damage.  
Discussion 
 The 1.06 Å crystal structure of caspase-3 in complex with Z-DEVD-cmk 
reveals novel details concerning the interactions in the P4 site and at the active site 
cysteine, both of which are important to understand substrate recognition and 
catalysis. It has been previously shown that caspase-3 has an absolute requirement for 
an aspartate in the P4 position. However previous structural data of caspase-3 
inhibitor complexes failed to explain this pronounced selectivity. The interactions 
seen in the present 1.06 Å resolution crystal structure confirm that AspP4 is 
recognized by Asp179, located at the N-terminal part of the small subunit. The 
extremely short distance and the equal distribution of Cγ-Oδ bond lengths suggest that 
this interaction resembles a low-barrier hydrogen bond (LBHB), which is 
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characterized by a low energy barrier for the exchange of the hydrogen atom between 
interacting dipoles. It is preferentially formed between groups with similar pKa 
values. Therefore, the observation of a LBHB between aspartate side chains at acidic 
pH perfectly agrees with this definition. The energy of a hydrogen bond depends very 
much on the bond distance ranging from -1 kcal·mol-1 to better than -25 kcal·mol-1 for 
distances between 3.0 Å and 2.3 Å, respectively.(24) Therefore, LBHBs with typical 
bond distances below 2.45 Å are considered to contribute a significant amount of 
binding energy. 
 Although the caspase-3 was crystallized at acidic pH, the kinetic data suggests 
that the observed LBHB contributes binding energy at acidic and physiological pH 
values. Lowering the pH causes a significant reduction of caspase-3 activity, which is 
attributed to dissociation of active caspase-3 dimers into inactive monomers and 
protonation of the active site Cys163. (28)  All kinetic values given in Table 1 support 
this trend.  At both pH values the Km values of the Asp179-Ala mutant are higher 
compared to the values of the wild type, suggesting that the LBHB increases the 
affinity of caspase-3 for peptides with an aspartate in P4. Due to the increased 
affinity, the product of the hydrolysis is released slower from the active site of the 
wild type, which correlates with the decreased kcat value of the wild type, compared to 
the Asp179-Ala mutant. At neutral pH, the effects on Km and kcat are equivalent 
whereas at acidic pH, the effect on kcat overcompensates the effect on Km, rendering 
the Asp179-Ala mutant more active than the wild type. 
 Interestingly the kinetic constants for the ∆176-181 mutant differ from the values 
obtained for the Asp179-Ala mutant. At neutral pH, the deletion of six amino acids at 
the p12 N-terminal tail decreases the kcat/Km ratio suggesting that the p12 N-terminal 
tail has additional functions besides the recognition of the AspP4 side chain. The p12 
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N-terminal tail could for example be responsible for a transient stabilization of the P4 
pocket including the loop formed by residues 246 to 258. The main chain hydrogen 
bond between Asp179*-O and Glu248-N would be present in the Asp179-Ala mutant 
but not in the ∆176-181 mutant structure. Another possible explanation for the different 
kinetic behaviors of the Asp179-Ala and the ∆176-181 mutants relies on the assumption 
that either Asp179, Asp180 or Asp181 occupy the position of the AspP4 in a caspase-
3 structure with an empty P4 pocket. Although the p12 N-terminal tail possesses a 
rigid conformation in the present structure, it can adopt different conformations 
depending on the nature of the bound ligand. In the structures of caspase-3 in complex 
with two low-molecular weight inhibitors(29) (pdb-id 1nmq and 1nms), residues 
Asp179 to Asp181 are bridging the P4 pocket but do not contribute to inhibitor 
recognition. In the caspase-3/XIAP-BIR2 complex(30) (pdb-id 1I3O) the N-terminal 
tail is involved in the recognition of the BIR2 domain but it is pointing away from the 
P4 pocket and occupies the SMAC binding pocket.  
 Another interesting detail revealed by this high resolution caspase-3 structure 
concerns the geometry of the active site cysteine. The Fobs(1.06 Å) - Fobs(1.7 Å) · ϕcalc(1.06 Å) 
map confirm the rearrangement of the methylene group of the inhibitor. This 
rearrangement is a clear consequence of radiation damage since the first part of the 
high resolution data set resembles the conformation seen in the 1.7 Å structure. 
Unfortunately the transition between both conformations is a continuous process. 
Therefore it is nearly impossible to record a high resolution data set with reasonable 
merging statistics that resembles only the rearranged active site. In the high resolution 
structure the methylene group has moved 1.29 Å away from the active site cysteine 
and its sulfur atom moves 0.41 Å towards the keto group. Unfortunately the chemical 
nature of the observed rearrangement product is uncertain. Most likely the observed 
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structure resembles a zwitterionic intermediate with a methylene cation and a 
carbonylate anion. The stretching of bond lengths supports the suggested dissipation 
of charges.  
 Different mechanisms for the inhibition of cysteine proteases by halomethyl 
ketones have been postulated. The simplest mechanism relies on a direct displacement 
of the halide by the thiolate anion (mechanism I in Fig. 5a). In the alternative 
mechanism the thiolate anion would attack directly the keto group (intermediate II) 
and the halide is released in a second step upon the formation of the zwitterionic 
sulfonium intermediate IV.(15) The present data supports mechanism II. The 
zwitterionic intermediate postulated for the present structure (V) could be a reaction 
product of the cyclic three-membered sulfonium intermediate (IV). In contrast to the 
proposed mechanism the bond between the sulfonium cation and the methylene group 
is broken yielding a zwitterionic intermediate similar to II but lacking the chloride 
atom. The interpretation that the present structure resembles a zwitterionic 
intermediate also agrees with the proposed reaction pathway. During hydrolysis of the 
peptide bond the N-terminal part of the polypeptide chain forms a thioester adduct 
with the active site cysteine (VIII in Fig. 5b). The formation of this acyl-enzyme 
travels through a tetrahedral intermediate (VII) that is expected to possess a similar 
conformation as the observed zwitterionic intermediate. In this case the methylene 
cation resembles the amino group that is released upon the formation of the acyl-
enzyme. 
 It has been reported that the inhibition of caspases by halomethyl ketones is 
reversible under certain conditions, such as high DTT (1,4-Dithio-threitol) 
concentrations(31), although this inhibitor class was regarded to inhibit caspases 
irreversibly. The observed rearrangement helps to explain this behavior. Provided that 
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the rearrangement from III to V is also possible in solution in the absence of radiation, 
the zwitterionic intermediate (V) would be hydrolyzed yielding the α-hydroxy methyl 
ketone peptide and the protonated active site cysteine. 
 The rearrangement in the active site also affects the surrounding water 
molecules Wat93 and Wat215 (Fig. 6a). These water molecules are well conserved in 
other structures of caspases inhibited by halo methylketones, (such as 1cp3)(8) and 
form hydrogen bonds with His121-ND1 and Gly122-N. After the rearrangement one 
water molecule has been squeezed out of the active site and the second water 
molecule moves into the proper position to form short hydrogen bonds with His121-
ND1 and Gly122-N (Fig. 6b). Wat238 would therefore be well positioned to stabilize 
either a negative charge at the oxygen of the keto group or a positive charge at the 
methylene cation using its lone electron pairs.  
Methods 
Protein purification   
 Human recombinant caspase-3 was produced in E.coli as inclusion bodies, 
refolded and purified as described.(32) Briefly, the cloned genes for the large p17- 
(Met-Ser29-Asp175) and the p12 subunit (Met-Ala-Ser176-His277) of caspase-3 were 
inserted in the NcoI/BamHI sites of pET11d plasmids (Novagen). Site-directed and 
deletion mutagenesis was performed using the QuikChange method (Stratagene). 
Mutants were completely sequenced to ensure that only the desired mutations were 
introduced. For separate expression of both subunits, E. coli BL21-CodonPlus (DE3)-
RIL cells (Stratagene), containing one of the two plasmids were grown to a density of 
A600 = 0.5 at 37 °C in a 0.5-liter LB medium. Expression was induced by the addition 
of IPTG (1 mM), and the culture was shaken at 37 °C for 4 hours post induction. Cells 
were harvested, washed in PBS buffer and lyzed using French press. Owing to over 
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expression the protein was localized in inclusion body portion. Refolding was 
achieved by rapid mixing of equimolar amounts of each subunit to a final 
concentration of about 100 µg of subunit/mL in the refolding buffer (100 mM HEPES 
(N-2-Hydroxyethyl)piperazine-N'-2-ethane sulfonic acid), pH 7.5, 10% sucrose, 1% 
CHAPS (3-(3-cholamidopropyl)diethyl-ammonio-1 propanesulfonate), 100 mM NaCl 
and 10 mM DTT) and was incubated overnight at room temperature with continuous 
stirring. Misfolded and aggregated protein was removed by centrifugation (5,000g, 30 
min), and the supernatant was concentrated using an Amicon-stirred cell. To reduce 
the salt concentration and to facilitate binding to an anion exchange column 
(Resource-Q, GE Healthcare),  the protein solution was dialyzed against the anion 
exchange buffer (20 mM Tris pH 8.0, 30 mM NaCl and 10 mM DTT) prior to 
chromatography. The protein was eluted using a 300mM NaCl gradient. The protein 
was further purified by size exclusion chromatography (Superdex S200, GE 
Healthcare) with buffer containing 20 mM Tris pH 8.0, 50 mM NaCl and 10 mM 
DTT. Fractions containing pure and active caspase were pooled and concentrated by 
ultrafiltration to a final concentration of 10 mg/mL and the final yield was about 5-7 
mg/L culture. Eventually, the purified caspase was subsequently inhibited with a 3-
fold molar excess of the inhibitor.  
Caspase activity assay 
 The activities of wild type caspase-3 and Asp179-Ala and ∆176-181 mutants  
were determined as described previously(33) using the fluorescent substrate Z-
DEVD-AMC and Ac-DEVD-AMC assays were performed in a buffer containing 40 
mM Pipes pH 7.2, 100 mM NaCl, 0.1% CHAPS, 10% sucrose, and 10 mM DTT, at 
37°C and in a buffer containing 40 mM sodium acetate pH 4.75, 100 mM NaCl, 0.1% 
CHAPS, 10% sucrose, and 10 mM DTT, at 37°C. The total reaction volume was 100 
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µL, and the final concentration of the enzymes was either 10 nM (for assays at pH 
7.2) or 100 nM (for assays at pH 4.75). The concentration was determined by active 
site titration using the Z-DEVD-cmk inhibitor at the desired pH value. Upon dialysis 
of caspase-3 against the pH 4.75 buffer, approximately 90 % of protein precipitated. 
The active site titration at pH 4.75 allowed to compensate for this loss of protein in 
the activity assay. Samples were excited at 360 nm, and the fluorescence emission 
was monitored at 465 nm. All fluorescence measurements were acquired using a HTS 
7000 plus Bio Assay Reader (PerkinElmer Life Sciences). The steady-state 
parameters, Km and kcat, were determined from plots of initial velocity versus 
substrate concentration (Table 1). 
Crystallization and data collection 
 Crystals of the recombinant human caspase-3 and Z-DEVD-cmk  inhibitor 
(Bachem) complex were grown in 2µL hanging drops formed by mixing equal 
volumes of protein (10 mg/mL in 20 mM Tris/HCl pH 8.0, 10 mM DTT ) and 
reservoir solution ( 5% (w/v) polyethylene glycol 6000, 100 mM Sodium citrate, pH 
4.75). Crystals (  300 · 300 · 100 µm) grew within 2-3 days. For data collection, 
crystals were frozen in the nitrogen stream after a short soak in reservoir solution 
containing 20% glycerol. The crystal space group was I222 and with unit cell 
dimensions, a = 67.2 Å, b = 83.3 Å, c = 96.0 Å. Diffraction data were collected at the 
rotating anode generator (Bruker-Nonius, FR591) at 100 K. Images were integrated 
with MOSFLM(34) and scaled with SCALA(35) (CCP4 suite of programs). 
Diffraction data for the caspase-3: Z-DEVD-cmk complex at atomic resolution were 
collected at the Swiss Light Source synchrotron (Paul Scherrer Institute, Villigen, 
Switzerland). Three data sets were collected from one crystal with maximum 
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resolutions of 1.06 Å, 2.5 Å and 1.06 Å and exposure times of 1, 0.5 and 3 seconds, 
respectively. The data were processed using the programs XDS(36) and 
XSCALE.(37) Radiation damage was analysed using the program XDSSTAT.(27)  
Structure solution and refinement 
 The structure was solved by the difference Fourier technique. Structure 
refinement and automated water addition was performed initially using the program 
CNS(38) at 1.5 Å, model building and manual adjustments with the program O(39) 
and the atomic resolution refinement (1.06 Å) with SHELXL.(40) The final 
crystallographic R and free R factors for caspase-3 complexes are 10.6% and 14.0%, 
respectively. The model is nearly complete, 249 of a total of 250 residues were 
modelled into the density map. Asp175 located at the C-terminus of the p17-subunit is 
the only disordered residue. The final model for caspase-3 complexes consisted of 
residues 29-174 (p17-fragment) and 176-277 (p12 subunit) along with 353 water 
molecules and 33 atoms of the inhibitor molecule. In case of the Asp179-Ala mutant, 
residues 176-185 (p12 subunit) were disordered and have therefore been omitted from 
the structure. Detailed data collection statistics and parameters are summarized in 
Table 2. The final models were validated using PROCHECK.(41) Figures were 
prepared using PyMOL (http://www.pymol.org) and ISIS Draw (MDL, San Leandro, 
USA). 
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Figure legends 
Figure 1. Ribbon diagram of caspase-3/Z-DEVD-cmk complex. The p12- and p17 
subunits are shown in light and dark colors. The p12 N-terminal tail is shown in red. 
The β-sheet strands are labeled.  
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Figure 2. H-bonding network in the P4 pocket. (a) Stereo diagram for the wild type 
P4 pocket. Polypeptide chains belonging to different subunits are shown in red and 
green. Hydrogen bonds and general inter-atomic distances are shown in red and grey, 
respectively. (b) P4 pocket in the Asp179Ala mutant. (c) Bond lengths and hydrogen 
bonds in the P4 pocket. 
Figure 3. Superposition of active sites in the 1.06 Å and 1.7 Å resolution structures 
with carbon atoms shown in cyan and magenta, respectively. The Fobs(1.06 Å) - Fobs(1.7 Å) 
· ϕcalc(1.06 Å) map was contoured at +5σ (green) and -5σ (red) levels.  The 2Fobs(1.06 Å) - 
Fcalc(1.06 Å) · ϕcalc(1.06 Å) map contoured at +3σ is shown in grey. 
Figure 4. Radiation damage analysis using the program XDSSTAT (27). Black, red 
and green symbols refer to data collection runs 1, 2 and 3 at the SLS. Runs 1 and 2 
were merged to prepare the final data set for structure refinement. Data from run 3 
were used to monitor progression of radiation damage but not for refinement 
purposes.  
Figure 5. (a) Mechanisms of caspase inhibition (adapted from(15)). The 1.7 Å and 
1.06 Å resolution structures represent complexes III and V, respectively. (b) Acylation 
reaction of proteases. Complexes VII and VIII represent the tetrahedral intermediate 
and the acyl-enzyme, respectively.  
Figure 6. Active site geometry of the 1.7 Å (a) and 1.06 Å (b) resolution structures. 
Putative hydrogen bonds and general distances are shown in red and grey, 
respectively. 
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Tabel 1: Kinetic parameters for caspase-3: wild type, Asp179-Ala and ∆176-181 
Z-DEVD-AMC substrate 
pH 7.2 pH 4.75  
Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
x106 (M-1s-1) 
Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
x106 (M-1s-1) 
Wild type 
9.7 ± 
0.4 
7.08 ± 
0.07 
0.72  
8.0 ± 
0.5 
0.16 ± 
0.002 
0.020  
Asp179-Ala 
25.5 ± 
3.1 
19.04 ± 
0.2 
0.74  
13.0 ± 
1.8 
1.10 ± 
0.01 
0.084 
∆176-181  
6.9 ± 
0.3 
1.43 ± 
0.01 
0.21  
2.0 ± 
0.2 
0.06 ± 
0.001 
0.033 
 
Ac-DEVD-AMC substrate 
pH 7.2 pH 4.75  
Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
x106 (M-1s-1) 
Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
x106 (M-1s-1) 
Wild type 13.8 ± 
0.9 
6.01 ± 
0.06 0.44  
12.2 ± 
0.5 
0.33 ± 
0.003 0.027  
Asp179-
Ala 
33.5 ± 
2.7 
19.56 ± 
0.2 0.58  
16.3 ± 
1.1 
1.37 ± 
0.01 0.083  
∆176-181  8.8 ± 
0.8 
1.54 ± 
0.01 0.18  
4.8 ± 
0.2 
0.08 ± 
0.0001 0.016  
 
 
 
Crystal structure of caspase-3: Z-DEVD-cmk complex                                   Chapter 2 
 70 
Table 2: Data collection and refinement statistics 
 Caspase-3: 
Z-DEVD-cmk 
Caspase-3 D179A: 
Z-DEVD-cmk 
Caspase-3:  
Z-DEVD-cmk 
Data collection   
Space group I222 I222 I222 
Cell dimensions 
a, b, c (Å) 67.7, 83.9, 96.2 68.4, 83.6, 95.8 67.6, 83.8, 96.1 
α, β, γ  (°)  90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 20-1.06 (1.15-1.06)  20-1.7 (1.8-1.7) 20-1.6 (1.75-1.66) 
Rmerge 0.055(0.37) 0.058 (0.36) 0.041 (0.17) 
I / σI 7.9 (3.06) 16.4 (3.6) 16.6 (5.7) 
Completeness (%) 92 (89) 99.5 (100) 89 (80) 
Redundancy 3.1 (2.9) 4.0 (3.9) 2.5 (2.3) 
 
   
Refinement    
Resolution (Å) 20 - 1.06 20-1.7 (1.8-1.7) 20-1.66 
No. reflections 111061 30451 28626 
Rwork / Rfree 0.142 /0.175 0.181 /0.208 0.173/0.203 
No. atoms    
    Protein 2059 1921 1996 
    Ligand/ion 33 33 43 
    Water 335 372 337 
B-factors    
    Protein 17.18 16.2 14.92 
    Ligand/ion 19.48 23.34 23.1 
    Water 35.07 35.92 32.49 
r.m.s deviations    
    Bond lengths (Å) 0.017 0.0050 0.0051 
    Bond angles (°) 2.429 1.275 1.268 
Values in parenthesis are for the highest-resolution shell. 
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Figures 
 
 
Figure 1.  
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ABSTRACT 
 
Aza-peptide Michael acceptors are a novel class of inhibitors that are potent and 
specific for caspases-2, -3, -6, -7, -8, -9 and -10.  The second order rate constants are in 
the order of 106 M-1s-1.  The aza-peptide Michael acceptor inhibitor 18t (Cbz-Asp-Glu-
Val-AAsp-trans-CH=CH-CON(CH2-1-Napth)2 is the most potent compound and it 
inhibits caspase-3 with a k2 value of 5,620,000 M-1s-1.  18t is 13707, 189.2, 6.4, 594, 
37470, and 172.9 fold more selective for caspase-3 over caspases-2, -6, -7, -8, -9, and -
10, respectively. Aza-peptide Michael acceptors designed with caspase specific 
sequences do not show any cross reactivity with clan CA cysteine proteases such as 
papain, cathepsin B, and calpains, demonstrating the selectivity of the inhibitors for clan 
CD proteases.  There is also little to no reactivity toward other clan CD cysteine proteases 
including legumain, gingipain K, and clostripain.  High resolution crystal structures of 
caspase-3 and caspase-8 in complex with aza-peptide Michael acceptor inhibitors 
demonstrate the nucleophilic attack on C3 and provide insight into the selectivity and 
potency of the inhibitors with respect to the P1' moiety.  
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INTRODUCTION 
Cysteine proteases, also known as thiol proteases have been identified in the 
biological systems of bacteria, protozoa, fungi, plant viruses, and mammals.  Cysteine 
proteases acylate the peptide bond via a nucleophilic thiol and are involved in numerous 
physiologically important processes.  Cysteine proteases have been grouped into 
evolutionary families and clans by Rawlings and Barrett.1,2  The majority of structurally 
relevant cysteine proteases belong to the well known clan CA, which includes papain, 
cathepsins, and calpains.  Several important cysteine proteases such as caspases, 
legumain, gingipain, clostripain, and separase belong to a new but smaller clan of 
cysteine proteases, which is termed as clan CD.  The tertiary structure of clan CD 
proteases shows a unique α/β fold unlike any other protein, with the catalytic residues in 
the order His, Cys in the sequence.  Clan CD cysteine proteases differ from the clan CA 
proteases also by their substrate specificity requirements.  The substrate specificity of 
clan CD proteases is determined by the S1 pocket, whereas the S2 pocket is the major 
determinant of substrate specificity with the clan CA cysteine proteases.   
Caspases, also known as cysteinyl aspartate-specific proteases, are found in 
worms to flies to humans.  Currently, > 15 members are identified, with 11 members in 
humans.3  One distinctive feature of this family of enzymes is their near absolute 
specificity for Asp residue at P1.  The only other known mammalian protease with the 
same specificity requirement is the lymphocyte serine protease granzyme B, which acts 
as a caspase activator.  Caspases have been the focus of both industrial and academic 
research since their discovery.  Over the past decade, the exact roles and functions of 
individual caspases in cellular systems have been intensely investigated.  Some caspases 
are important mediators of inflammation, whereas others are involved in apoptosis 
(programmed cell death).  Excessive neuronal apoptosis leads to a variety of diseases 
such as stroke, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, 
amyotropic lateral sclerosis (ALS), multiple sclerosis (MS), and spinal muscular 
atrophy.4  Caspases are recognized as novel therapeutic targets for central nervous 
diseases in which cell death occurs mainly by an apoptosis mechanism.5-8  Hence, potent 
and specific inhibitors of caspases could lead to the development of potential drugs, 
which can modulate the apoptotic process. 
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A number of different classes of inhibitors have been developed for cysteine 
proteases including reversible transition state inhibitors and a variety of irreversible 
inhibitors.9  Relatively few classes have been applied to clan CD cysteine proteases, 
particulary caspases.  Several substrate based caspase inhibitors have been extensively 
used to address the roles of caspases in cellular systems over the past few years.10  These 
include reversible inhibitors such as peptide aldeyhdes (Ac-YVAD-CHO, Ac-DEVD-
CHO, Ac-WEHD-CHO) and irreversible inhibitors such as fluoro- or chloromethyl 
ketones (Z-VAD-FMK, Z-YVAD-FMK/CMK, Z-DEVD-FMK/CMK).  A few of these 
inhibitors have even entered preclinical studies with animal models of human diseases.  
However, the major disadvantage of these inhibitors is their lack of selectivity.  Several 
of these caspase inhibitors have been recently shown to efficiently inactivate other 
cysteine proteases, such as cathepsins B, L, and S.11  Cathepsin B inhibition by Ac-
YVAD-CMK rescued neuronal cells against glucose/oxygen deprivation-induced 
apoptosis, suggesting that other proteases may be involved in the processes previously 
designated only to caspases.  Furthermore, several lysosomal cysteine proteases were 
shown to be involved in various apoptosis models, although the mechanisms are not yet 
clear.12,13  Thus, there is a considerable need for potent and selective caspase inhibitors to 
elucidate the roles of individual caspases in apoptosis and as potential therapeutics.   
A variety of other inhibitors with electrophilic warheads have been reported as 
irreversible inhibitors effective for clan CA cysteine proteases.9  One of the first Michael 
acceptors described in the literature is the fumarate derivative of E-64c (3, Figure 1).14  
This inhibitor contains an α,β-unsaturated carbonyl moiety and was found to be an 
irreversible inhibitor of cathepsin B, cathepsin H, and cathepsin L.  Vinyl sulfones and 
α,β-unsaturated carbonyl derivatives (4, Figure 1) have been developed as highly potent 
inhibitors for exopeptidases such as DPPI and many clan CA cysteine endopeptidases 
including papain, cathepsins B, L, S, and K, calpains, and cruzain.15,16  Michael acceptor 
inhibitors have great potential for use as drugs. One Michael acceptor CRA-3316 
developed by Celera as a cruzain inhibitor to treat Chagas’ disease is also in clinical 
trials.17  Another Michael acceptor AG7088 (Ruprintrivir®) has entered phase II clinical 
studies with humans as a potential nasally delivered antirhinoviral agent.18-21  Recently, 
Michael acceptor inhibitors based on the AG7088 structure drew considerable attention in 
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the treatment of SARS (Severe Acute Respiratory Syndrome) due to their potential as 
antiviral agents against the SARS coronavirus.22   
Our laboratory has recently reported aza-peptide Michael acceptor inhibitors (2, 
Figure 1) that are highly specific for clan CD cysteine proteases.23  The aza-peptide 
Michael acceptor structure resembles the substrate peptide sequence (1, Figure 1), where 
the carbonyl group of the double bond moiety replaces the carbonyl group of the scissile 
bond.  Replacement of the α-carbon of the P1 amino acid with a nitrogen results in the 
formation of the aza-peptide, which allows the ready synthesis of a variety of derivatives.  
In the fumarate derivative 3, the Michael acceptor is on the N-terminus of the amino acid 
residue, while in our aza-peptide design, the warhead is at the C-terminal end of the 
inhibitor.   On the other hand, the design of vinyl sulfones and α,β-unsaturated carbonyl 
derivatives was based on the optimal peptide sequence of the target enzyme, where the 
carbonyl of the scissile bond was replaced by the double bond moiety.   
In an effort to obtain greater potency and selectivity, we elaborated our aza-
peptide Michael acceptor design in the P' portion.  Although considerable effort has been 
devoted to the optimization of interactions of caspase inhibitors at the S1-S4 sites24,25, 
interactions of substrates or inhibitors at the S1´ site in the past were analyzed in only 
very few studies.26,27 Recently, a few peptidomimetic compounds binding to the groove 
located near the S1` site of caspase-3 were identified and characterized structurally.26  We 
were particularly interested in designing inhibitors for the key executioner caspases-3, -6, 
and -7 and initiator caspases-2, -8, -9, and -10.  Here we also report crystal structures of 
caspase-3 and caspase-8 in complex with aza-peptide Michael acceptors with different 
P1' substitutions to elucidate the structural determinants for the preference and 
discrimination at this site. The analysis of the crystal structures of the caspase: Michael 
acceptor inhibitor complexes also provide insights into the difference in reactivity of cis 
(18g) and trans (18h) isomers. 
 
CHEMISTRY 
We synthesized a variety of aza-peptide Michael acceptors with P1 Asp residue as 
potential inhibitors for caspases.  We previously reported the general method to prepare 
aza-peptide Michael acceptors in our preliminary communication.23  Aza-peptide Michael 
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acceptors for caspases were synthesized by coupling the appropriate substituted peptidyl 
hydrazides with P1 Asp side chain with the desired fumarate derivative.   
A variety of fumarate esters and fumarate mono- and diamides have been 
synthesized in order to couple to the substituted peptidyl hydrazides (Figure 2).  The 
monobenzyl fumarate 7 was obtained by the addition of 1 eq of benzyl alcohol to 
monoethyl fumarate 5 using EDC and NMM as coupling reagents followed by the 
hydrolysis of the ethyl ester 6 in methanol by aqueous NaOH.  Mono- and disubstituted 
amide derivatives 10 and 11 were obtained by coupling the desired primary or secondary 
amine to monoethyl fumarate 5 and subsequent hydrolysis of the ethyl ester 8 or 9 with 
1.2 eq of KOH in ethanol.  Monoethyl maleate 13 was synthesized by the alcoholysis 
reaction of maleic anhydride 12 with ethanol.   
Peptidyl hydrazides 14 were obtained by reacting mono-, di-, or tripeptidyl methyl 
esters with excess hydrazine in methanol.  The aza-Asp side chain was introduced by 
alkylation of the peptidyl hydrazide with t-butyl bromoacetate to form the substituted 
peptidyl hydrazide 15. 
The final aza-peptide Michael acceptors (16-21 (a-u), Figure 3) were synthesized 
primarily by the EDC/HOBt coupling method with the peptide sequences Cbz-Val-NH-
NH-CH2COO-tBu, Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-NH-NH-CH2COO-tBu, Cbz-Val-
Glu(O-tBu)-Val-NH-NH-CH2COO-tBu, Cbz-Ile-Glu(O-tBu)-Thr-NH-NH-CH2COO-tBu, 
and Cbz-Leu-Glu(O-tBu)-Thr-NH-NH-CH2COO-tBu using an excess of the desired 
fumarate derivative.  To simplify the purification process and maximize the yield various 
aza-peptide Michael acceptors were synthesized by the mixed anhydride method using 
the peptide sequences Cbz-Glu(O-tBu)-Val-NH-NH-CH2COO-tBu, Cbz-Ile-Glu(O-tBu)-
Thr-NH-NH-CH2COO-tBu, and Cbz-Leu-Glu(O-tBu)-Thr-NH-NH-CH2COO-tBu.  In the 
final step of the aza-peptide Michael acceptor synthesis, the t-butyl protecting groups on 
the aza-Asp, Glu, and Asp residues were deprotected using TFA in CH2Cl2 at 0 ºC. 
 
RESULTS AND DISCUSSION 
The optimal peptide sequences of the target caspases were utilized in the design of 
the aza-peptide Michael acceptors. The optimal sequences were derived either from 
natural caspase cleavage sites or from peptide mapping of caspases with libraries of AMC 
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substrates.28  Based on S4 subsite preferences, Thornberry and co-workers divided the 
caspases into three groups: group I caspases (1, 4, and 5) prefer aromatic amino acid 
residues at P4; group II caspases (6, 8, 9, and 10) have a preference for branched apolar 
residues, and group III caspases (2, 3, and 7) prefer an aspartic acid residue.  The DEVD 
and LETD sequences are optimal sequences for caspase-3 and caspase-8, respectively, as 
determined by positional scanning synthetic combinatorial library.29,30  The IETD 
sequence for caspases-6 and -8 is the cleavage sequence of a natural caspase-8 substrate, 
the caspase-3 proenzyme.28  The VEVD sequence was chosen as the optimal substrate for 
caspase-6 in accordance with the branched amino acid preference of this enzyme.  The 
EVD sequence was selected to obtain a truncated caspase-3 inhibitor. Similarly, the VD 
sequence was chosen to represent a general inhibitor for all the caspases (caspases-2, -3, -
6, -7, -8, -9, and -10).   
The aza-peptide Michael acceptors with an aza-Asp residue at P1 position and 
designed with the appropriate target sequences were tested against various caspases for 
kinetic activity.  The aza-peptide Michael acceptors exhibit excellent inhibitory potency 
against caspases-2, -3, -6, -7, -8, -9, and -10 (Table 1).  The second order inhibition rates 
are as high as 106 M-1s-1.  Generally, the DEVD sequence is the most reactive with 
caspases-2, -3 and -7.  The IETD and LETD sequences are more reactive with the 
caspases-6, -8, and -9.  The VEVD sequence is equally potent as IETD for caspases-6 and 
-8.  Interestingly, the DEVD sequence is the best sequence for caspase-10 although this 
enzyme was originally included into group II along with caspases-6,-8, and -9.  Also the 
most potent caspase-8 inhibitor has the DEVD sequence. Its favourable interaction with 
caspase-8 has been demonstgrated in a crystal structure47. Similarly, the most potent 
caspase-9 inhibitor is the one with the EVD tripeptide sequence.  This result seems to be 
an exception to the requirement of the tetrapeptide sequence of caspases for efficient 
cleavage. 
Aza-peptide Michael acceptors are easily extended at their P' site. To gain more 
insight about the potency and selectivity of the aza-peptide Michael acceptor inhibitors, 
we modified the substituents on the fumarate moiety extending into the P' site.  We 
utilized various groups like simple alkyl, alkenyl, and aryl groups, as well as halogens, 
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esters, and amides in the hopes of obtaining selectivity in the P' site among the various 
caspases. 
Caspase-2.  In contrast to the other caspases, caspase-2 requires a P5 residue for 
efficient substrate cleavage.  The optimal sequence of caspase-2 is VDVAD, but the 
caspase-3 specific DEVD sequence still worked best for caspase-2.  Because of the P5 
requirement, the second order rates of inhibition with caspase-2 remained in the range of 
102 M-1s-1, except for the inhibitors 18g and 18h.  The most potent inhibitor of caspase-2 
was the cis isomer 18g with a k2 value of 26,200 M-1s-1.  18g was 10-fold more reactive 
than the trans isomer 18h (k2 = 2,640 M-1s-1).  This result was interesting since for the 
other caspases (3, 6, 7, 8, 9, and 10) 18g was less potent when compared to its trans 
isomer 18h.  The order of reactivity of the inhibitors with the DEVD sequence according 
to the substituent Y is as follows: COOEt (cis) > COOEt (trans) > CON(CH3)CH2Ph > 
CON(CH2-1-Napth)2 > CON-tetrahydroquinoline > CON(CH3)CH2CH2Ph > COPh > 
CONHCH2Ph > CONHCH2-4-F-Ph > CONHCH2CH2Ph > CON(CH2Ph)2.  It seems that 
the esters are the best substitutents and the disubstituted amides are more preferred over 
the monosubstituted amides.   
Caspase-3.  Considerably high rates were obtained for the inhibitors with the 
caspase-3 specific DEVD sequence against caspase-3.  The most potent caspase-3 
inhibitor was 18t (Cbz-Asp-Glu-Val-AAsp-trans-CH=CH-CON(CH2-1-Napth)2) with a 
second order inhibition rate of 5,620,000 M-1s-1.  With caspase-3, the order of reactivity 
of the inhibitors with various substituents on the double bond moiety is CON(CH2-1-
Napth)2 >  CON(CH2Ph)2 > CON(CH3)CH2Ph > CON-tetrahydroquinoline > CO2Et 
(trans) > CONHCH2-4-F-Ph > CONHCH2CH2Ph > CONHCH2Ph > CO2CH2Ph > 
CON(CH3)CH2CH2Ph > CO2Et (cis) > COPh.  Generally, the bulky aromatic groups 
were preferred in the prime site of this enzyme.  The disubstituted amide derivatives 
worked better than the monosubstituted ones and the ester derivatives.  Replacement of 
the amide or the ester group by a carbonyl group caused a decrease in potency by 10-fold.  
18f (Cbz-Asp-Glu-Val-AAsp-trans-CH=CH-COPh) inhibits caspase-3 with a k2 value of 
122,000 M-1s-1.  18g, the inhibitor with the cis configuration of the double bond moiety is 
a potent inhibitor of caspase-3 (k2 = 1,060,000 M-1s-1).  However, the trans ethyl ester 
derivative 18h is twice as potent against caspase-3 (k2 = 2,130,000 M-1s-1).  Considerable 
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decrease in potency was observed with the EVD sequence based inhibitor 17h (k2 = 
38,600 M-1s-1) with caspase-3, which emphasizes the importance of an acidic P4 residue 
for increased potency.  In addition, our caspase-3 inhibitors are equally if not more potent 
than chloromethyl ketone inhibitors such as Cbz-DEVD-CMK which has a k2/KI value of 
1,000,000 M-1s-1.11  More importantly, the aza-peptide Michael acceptors are much more 
selective (See the Cross-reactivity Section). 
Caspase-7.  The DEVD sequence worked also best with caspase-7.  The second 
order rate constants were in the range of 105 M-1s-1.  Cbz-Asp-Glu-Val-AAsp-trans-
CH=CH-CON(CH2-1-Napth)2 (18t) is the most potent inhibitor with a second order rate 
constant of 875,000 M-1s-1.  The order of reactivity with the substituted Y group among 
the DEVD series is as follows: CON(CH2-1-Napth)2 >  CON(CH2Ph)2 > CONHCH2-4-F-
Ph > CON(CH3)CH2Ph > CONHCH2CH2Ph > CONHCH2Ph > CO2Et (trans) > 
CON(CH3)CH2CH2Ph > CO2Et (cis) > CON-tetrahydroquinoline > CO2CH2Ph > COPh.  
Similar to caspase-3, bulky aromatic groups such as benzyl or napthyl groups which 
extend deep into the pocket are preferred at the caspase-7 S' subsite.  There is no distinct 
preference for disubstituted amide group preference like in the case of caspase-3.  
However, amide substituents still work generally better than the ester ones.  18m (Cbz-
Asp-Glu-Val-AAsp-trans-CH=CH-CONHCH2-4-F-Ph) is still the best monosubstituted 
amide inhibitor for both caspase-3 and caspase-7.  The rate of inhibition is 10 fold lower 
(18f ,k2 = 10,8000 M-1s-1), where only a carbonyl group is present instead of an amide or 
ester group in the substituent structure.  There is also a decrease in potency with the 
tripeptide inhibitor 17h (k2 = 52,400 M-1s-1) indicating that the P4 amino acid is an 
important factor in potency with caspase-7. 
Caspases-6 and -8.  The IETD sequence works best with caspase-6, whereas the 
LETD sequence is ideal for caspase-8.  Caspase-8 prefers leucine > valine > aspartic acid 
at its P4 position. This preference offers some room for the selectivity of caspase-8 over 
caspase-6, where caspase-6 prefers valine > threonine > leucine at the same position 
(P4).27  The best caspase-6 inhibitor is 20k (Cbz-Ile-Glu-Thr-AAsp-CH=CH-CONPh) 
with a k2 value of 99,200 M-1s-1.  Unfortunately, this inhibitor also potently inactivates 
caspase-8 (k2 = 245,000 M-1s-1).  The order of reactivity with differing Y groups for 
caspase-6 within the IETD sequence is as follows: CONHPh > CO2Et (trans) > 
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CON(CH2Ph)2 > CON(CH3)CH2Ph > CO2CH2Ph > CONHCH2CH2Ph > CONHCH2Ph.  
There is no distinct preference for any substitution pattern at the caspase-6 S' subsite.  
Monosubstituted amide derivative 20k is the most preferred, but the disubstituted amide 
derivatives 20o, 20p, and 20r are also potent inhibitors.  The other caspase-6 specific 
sequence (VEVD) also yielded very potent inhibition. The inhibitor 19h (Cbz-Val-Glu-
Val-AAsp-CH=CH-COOEt) inhibits caspase-6 with a k2 value of 83,600 M-1s-1.  
However, the VEVD sequence seems to be less selective.  Not only it inhibits caspase-8 
potently (k2 = 175,800 M-1s-1), it also inhibits caspase-3 with a k2 of 41,200 M-1s-1. 
Although the LETD sequence is determined to be the best one for caspase-8, other 
caspase-specific sequences are also preferred by this enzyme.  The most potent caspase-8 
inhibitor is the one that is actually designed for caspase-3 with the DEVD sequence.  
Hence, 18h (Cbz-Asp-Glu-Val-AAsp-trans-CH=CH-COOEt) has a second order rate 
constant of 272,960 M-1s-1 with caspase-8.  Also, the inhibitor 20k with the IETD 
sequence is a very potent caspase-8 inhibitor (k2 = 245,000 M-1s-1).  The same Y group 
(CONHPh) when attached to a LETD sequence (21k) makes a less potent inhibitor with 
caspase-8 (k2 = 176,000 M-1s-1).  For the inhibitors with the LETD sequence the order of 
reactivity with caspase-8 with differing Y groups is as follows: COOEt (trans) > CON-
tetrahydroquinoline > CON(CH3)CH2-1-Napth > CONHPh > CONHCH2-4-F-Ph > 
CON(CH3)CH2Ph > CON(CH2Ph)2 > CONHCH2CH2Ph > COOCH2Ph > 
CON(CH3)CH2CH2Ph > CONHCH2Ph.  The inhibitor 21h (Cbz-Leu-Glu-Thr-AAsp-
trans-CH=CH-COOEt) is the best one among this series with a k2 value of 237,000 M-1s-
1
.  The tetrahydroquinoline derivative 21u (Cbz-Leu-Glu-Thr-AAsp-trans-CH=CH-
CON-tetrahydroquinoline) is less potent than the ethyl ester derivative 21h, but it is more 
selective over caspase-6.   Interestingly, one of the most potent caspase-8 inhibitors is the 
tripeptide derivative 17h (Cbz-Glu-Val-AAsp-trans-CH=CH-COOEt) with a k2 value of 
244,000 M-1s-1.  In general, higher rates were obtained with caspase-8 where Y is a small 
sized group such as ethyl and when Y is not extending deeply into the S' subsite. 
Caspase-9.  The rates of inhibition of caspase-9 by the aza-peptide Michael 
acceptors are not as high as the other members of the caspase family we have tested.  
However, the LETD is still the best sequence with rates in the range of 10-103 M-1s-1.  
The best inhibitors are 21s and 21o with k2 values of 5,030 M-1s-1 and 4,320 M-1s-1, 
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respectively.  However, the most potent caspase-9 inhibitor is the tripeptide derivative 
17h (Cbz-Glu-Val-AAsp-trans-CH=CH-COOEt) with a k2 value of 32,900 M-1s-1.  
Surprisingly, a considerable decrease in potency is observed with the same Y group 
(ethyl) when attached to a tetrapeptide sequence.  The inhibitor 21h (Cbz-Leu-Glu-Thr-
AAsp-trans-CH=CH-COOEt) inhibits caspase-9 very weakly (k2 = 37 M-1s-1).   
Caspase-10.  The best inhibitors of caspase-10 have the caspase-3 optimal 
sequence DEVD.  The rates of inhibition are in the range of 103-104 M-1s-1 and the best 
inhibitor is Cbz-Asp-Glu-Val-AAsp-trans-CH=CH-COOEt (18h, k2 = 49,900 M-1s-1).  
The order of reactivity with differing Y groups with the DEVD sequence is as follows: 
COOEt (trans) > CONHCH2-4-F-Ph > CON(CH2-1-Napth)2 >  CONHCH2CH2Ph > 
CON(CH3)CH2Ph > COOCH2Ph > CONHCH2Ph > COOEt (cis) > 
CON(CH3)CH2CH2Ph > CON-tetrahydroquinoline > CON(CH2Ph)2.  The tripeptide 
inhibitor 17h works equally well as some of the tetrapeptide inhibitors with caspase-10 
(k2 = 8,940 M-1s-1).  Once again, this result indicates that with group II caspases (6, 8, 9, 
10) the absence of the P4 residue is not as crucial as for group III caspases (2, 3, 7) for 
potency and selectivity. 
Caspase Selectivity.  In general, the most potent inhibitors of a target caspase 
were the ones that were designed with its ideal sequence, although in some cases 
caspases-8, -9, and -10 exhibited exceptions.  Interestingly, the most specific inhibitors 
were still very potent but they were not the most potent ones.  The most specific inhibitor 
for caspase-3 was Cbz-Asp-Glu-Val-AAsp-trans-CH=CH-CON(CH2Ph)2 (18r, k2 = 
3,000,000 M-1s-1), which is 27 300, 588, 8.4, 348, 6670, and 476 fold more selective for 
caspase-3 over caspases-2, -6, -7, -8, -9, and -10, respectively.  The most specific 
caspase-6 inhibitor was Cbz-Ile-Glu-Thr-AAsp-trans-CH=CH-COOEt (20h, k2 = 88,700 
M-1s-1).  It is 295.6, 13.2, 167.4, 1.6, and 12.9 fold more selective for caspase-6 over 
caspases-2, -3, -7, -8, and -10, respectively.  The most selective caspase-8 inhibitor was  
Cbz-Leu-Glu-Thr-AAsp-trans-CH=CH-COOEt (21h, k2 = 237,000 M-1s-1), which is 
42.6, 12.6, and 6405 fold more selective for caspase-8 over caspases-3, -6, and -9, 
respectively.   
The selectivity of the aza-peptide Michael acceptor inhibitors with the DEVD 
sequence for caspase-3 over caspase-7 is 6.9-16.8 fold.  Selectivity between caspase-3 
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and caspase-7 was hard to achieve, since the DEVD sequence is the ideal one for both 
enzymes.  The selectivity of caspase-3 over caspase-2 is as high as 105 fold, because of 
the P5 requirement of caspase-2.  The selectivity for caspase-3 over caspase-6 is usually 
around 500 fold.  However, when one obtained selectivity over caspase-6, it was difficult 
to obtain selectivity also for caspase-8.  The range of selectivity for caspase-3 over 
caspase-8 was only up to 37-fold, except in the case of the inhibitor 18r.  It has been 
previously shown that the prime site of caspase-8 differs from that of the other caspases 
by the presence of a helix-turn-helix insertion ranging from residues 245-253, which is 
unique to caspase-8.31  Clearly, we have taken advantage of this structural difference by 
designing an inhibitor with a dibenzyl amide substituent on the double bond moiety, 
which resulted in optimal selectivity.  Generally, caspase-10 behaved similarly to 
caspase-8, however it yielded less potent inhibitors.   Lastly, the rates of inhibition of 
caspase-9 were quite low when compared to the other caspases (3, 6, 7, 8, and 10). 
In addition to the tri- and tetrapeptidyl aza-peptide Michael acceptors we also 
made several dipeptidyl derivatives with the VD sequence in the hopes of obtaining a 
potent and broad spectrum inhibitor for caspases. Due to enhanced aqueous solubility, it 
has been previously shown that the inhibitor Z-VD-fmk was more active than the tri- and 
tetrapeptide based inhibitors such as Z-VAD-fmk in certain cell culture models of 
apoptosis.32  Unfortunately, our dipeptide inhibitor Cbz-Val-AAsp-trans-CH=CH-COOEt  
(16h) weakly  inactivated caspase-3 (k2 = 8,000 M-1s-1), caspase-7 (k2 = 2,680 M-1s-1), 
caspase-9 (k2 = 5,260 M-1s-1) and caspase-10 (k2 = 389 M-1s-1).  It did not show any 
inhibition of caspases-2, -6 or -8.  The two amide derivatives 16j and 16l showed little 
potency toward caspase-3 (k2 values are 184 M-1s-1 and 185 M-1s-1, respectively), caspase-
7 (k2 values are 55 M-1s-1 and 60 M-1s-1, respectively),  caspase-9 (k2 values are 32 M-1s-1 
and 20 M-1s-1, respectively), but no activity against caspases-2, -6, -8 or -10.  The 
dipeptide aza-peptide Michael acceptors with simple alkyl, alkenyl or halogen 
substituents remained unreactive toward all the caspases (2, 3, 6, 7, 8, 9, and 10).  The 
decreased potency of the dipeptide derivatives toward caspases is in accordance with the 
previous observation of the requirement of at least tripeptides for binding and 
recognition.   
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Cross Reactivity with Clan CA and Other Clan CD Proteases.  The aza-
peptide Michael acceptors designed for caspases show little to no inhibition of the clan 
CA cysteine proteases papain, cathepsin B, and calpain, where the specificity is 
determined primarily by the S2 subsite.  The inhibitors 18h, 18i, 18l, and 21i showed 
essentially no inhibition against papain, cathepsin B, and calpain after an incubation 
period of one hour (Table 2).   
We also tested the cross reactivity of our inhibitors with other members of clan 
CD proteases such as legumain, clostripain, and gingipain K.  Legumain has a strict 
requirement for Asn at P1, whereas clostripain and gingipain K prefer Orn and Lys at the 
same position.  Aza-peptide Michael acceptors designed for caspases did not show any 
activity against those enzymes after being incubated for one hour.  Likewise, the aza-
peptide Michael acceptor inhibitors with legumain, clostripain, and gingipain K specific 
sequences did not show any cross reactivity with clan CA enzymes or between each 
other.23  Clearly, the aza-peptide Michael acceptor design is specific for clan CD 
enzymes.  
Stability Studies.  We tested the stability of the aza-peptide Michael acceptors 
toward simple thiol nucleophiles such as thiol DTT contained in the caspase assay buffer.  
A representative group of inhibitors (2.5-4 mM) were treated with 10 mM DTT in the 
caspase assay buffer with a pH of 7.2 at 25 °C.  The reactivity of the Michael acceptor 
double bond was monitored by UV spectrum at 250 nm for a period of 15 hours.  The 
half-lives were obtained from first order rate plots of ln(At/A0) versus time.   
We observed that the ester derivative 18h (Cbz-Asp-Glu-Val-AAsp-CH=CH-
COOEt) had a half-life of 10 minutes.  The amide substituted Michael acceptors appeared 
to be less reactive toward DTT under the same conditions. The monosubstituted amide 
derivative 18l (Cbz-Asp-Glu-Val-AAsp-CH=CH-CONHCH2Ph) had a half life of 58 
minutes, where the disubstituted amide derivative 18o (Cbz-Asp-Glu-Val-AAsp-
CH=CH-CON(CH3)CH2Ph) was twice as long stable with a half-life of 116 minutes.  The 
dienyl derivative 16b (Cbz-Val-AAsp-CH=CH-CH=CH-CH3) was essentially stable over 
the period of 15 hours of monitoring.   
Aza-peptide Michael acceptors designed for other clan CD proteases such as 
legumain, gingipain and clostripain specific sequences were also tested for stability 
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against DTT.23  The half-life of the legumain inhibitor Cbz-Ala-Ala-AAsn-CH=CH-
COOEt in the legumain assay buffer (pH = 5.8) with excess DTT was 19 minutes.  When 
tested at a higher pH (6.8) the half-life of the same inhibitor shortened to 3.7 minutes.   
It should be noted that the pH of the assay buffer has a considerable effect on the 
stability of the inhibitors against DTT.  The DTT thiol has a pKa value of 9.2.  The lower 
the pH, the lower is the concentration of the deprotonated thiol group of DTT. Hence, a 
nucleophilic attack on the Michael acceptor double bond is more favored at higher pH 
values.   
We also anticipate that the nature of the P' substituent on the double bond 
contributes significantly to the overall stability of the inhibitor.  In general, the order of 
stability of our inhibitors is as follows: alkyl > amide > ester.  It has been previously 
demonstrated by Freidig and coworkers that simple acrylates are more reactive than 
simple acrylamides to thiol nucleophiles such as glutathione.33  Ethyl acrylate reacts with 
glutathione 85 times faster than ethyl acrylamide with second order rate constants of 0.66 
M-1s-1 and 7.8 x 10-3 M-1s-1, respectively.  Our results of the reactivity of the ester and 
amide substituted inhibitors indicate a strong correlation with the observed reactivity of 
acrylates and acrylamides with glutathione.  
Mechanism of Inhibition.  In general, the inactivation of cysteine proteases by 
Michael acceptor inhibitors proceeds through the nucleophilic attack of the active site 
cysteine thiol group on the C3-carbon of the Michael acceptor double bond.  The 
mechanism of inhibition of caspases by aza-peptide Michael acceptors could involve 
irreversible thioalkylation of the active site Cys by the two pathways shown in Figure 4.  
Theoretically, if the substituent on the double bond is an acyl derivative such as ester or 
amide, the formation of both thioether adducts 22 and 23 is possible upon a nucleophilic 
attack taking place either at the C-2 or C-3 carbon on the double bond moiety.  If the 
substituent is a simple alkyl or halogen, only the C-3 carbon is the possible site for the 
Michael addition reaction. 
Based on the results of the NMR study and the stability studies of our inhibitors 
with DTT, we previously hypothesized that a nucleophilic attack of the active site thiol 
group at the C-2 would be more favorable.23  However, to determine conclusively the 
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point of attack, crystal structures of five caspase-double bond complexes were 
determined. 
X-ray structure analysis of Caspase Inhibitor Complexes.  We have 
determined four crystal structures of caspase-3-inhibitor complexes and the structure of 
one caspase-8 inhibitor complex.  The Michael acceptors used for the structural studies 
with caspase-3 are two stereo isomers (cis and trans) of the ethyl ester derivatives 18g 
and 18h respectively, a benzyl ester derivative (18i) and a N-methyl-benzyl amide 
derivative (18o). We have determined the structure of caspase-8 complexed with 21t 
which is a tetrahydroisoquinoline derivative.  These inhibitor complexes are unique since 
they have inhibitor moieties which interact with S’ subsites of enzyme unlike most 
caspase-inhibitor complex structures published to date. 
The overall structures of the polypeptide chain in the complexes are quite similar 
to the other known crystal structures of the caspase family34-37. The superposition of the 
Cα atoms of the subunits result in a root mean square deviation of 0.2 Å for caspase-8 
and 0.35 Å for caspase-3 inhibitor complexes. This indicates that large scale 
conformational transitions do not occur upon binding of the P` portion of the inhibitor 
structure, however conformational changes do occur in parts of the enzyme directly 
interacting with the inhibitor to improve the fit.  The interactions of the P1-P4 moieties of 
the Michael acceptor inhibitors bind to the substrate binding cleft of the caspase active 
site similarly as already previously observed in the peptidyl aldehyde or halogen methyl 
ketone inhibitor complexes34-37 closely mimicking substrate binding from P1 to P4. 
The high resolution crystal structures clearly demonstrate that the nucleophilic 
attack takes place at the C-2 carbon more precisely on the re face. This results in a 
covalent thioether bond between the C-2 carbon and the sulfur atom of the active site Cys 
residue.  As a result of the nucleophilic attack, the hybridization of both the C-2 and C-3 
carbons change from sp2 to sp3 yielding a tetrahedral C-2 carbon and a chiral tetrahedral 
C-3 carbon with the R–configuration (Fig 6a-b).  
Caspase-3 Inhibitor Complexes.  As observed in the crystal structures of 
caspases complexed with halo methyl ketones26,36, the P1 azapeptide carbonyl points 
towards the “oxyanion hole” and it is stabilized by the amide protons of Gly122 and 
Azapeptide Michael acceptors as caspase inhibitors   Chapter 3 
 92 
Cys163.  A unique feature of all the crystal structures of caspase-3 Michael acceptor 
complexes is the rotation of the catalytic His121 about Chi2 by approximately 20 
degrees.  In this new orientation the imidazole ring is ideally placed to form a hydrogen 
bond to the carboxylate of P1-Asp (Fig 6c).  The distance of this hydrogen bond ranges 
from 3.3-3.6 Å in our complexes.  This interaction between the catalytic His121 and P1-
Asp is not observed in any other caspase crystal structure reported so far.  Apart from this 
interaction, His121 also forms a hydrogen bond to the azapeptide P1` carbonyl.  The 
interactions of the P2 and P3 residues are similar to those reported in other caspase-3 
structures34,36.  
The P1` site in caspase-3 is predominantly hydrophobic and it is defined by four 
loop regions.  The 179-loop (between strand β1 and helix α2), the 240-loop (between 
strand β3 and helix α3) and the C-terminal loop belong to the alpha subunit, whereas the 
fourth loop (between strand β4 and helix α3) is from the β subunit.  The approximate 
solvent accessible volume of the prime site cavity is 900 Å3.  In the Michael acceptor 
18o, the P1` moiety is a N-methyl-benzyl amide derivative.  The phenyl ring points 
towards the one side of the S1` pocket and stabilized by hydrophobic contacts with 
Thr166 and Tyr204 while the N-methyl group is stabilized by Phe128 (Fig. 7b).  This is 
most reactive caspase-3 inhibitor of those studied crystallographically.  In the case of the 
benzyl derivative 18i, the electron density for the phenyl ring is not well defined as 
indicated by high B values.  In the ethyl ester derivative formed from 18h and 18g, the 
ethyl group interacts with the side chains of Phe128 and His121.  To avoid steric 
hindrance and in tandem to maintain the hydrophobic contact with the ethyl group of the 
inhibitor, the side chain of Met61 of the 179-loop adopts a different conformation.  This 
conformation is quite different from that observed in all other known caspase-3 
structures.  As expected, the atoms of the products formed from the two stereoisomers 
(18g and 18h) of the ethyl ester overlay well on superposition. Additionally, in both 
structures , the C-3 carbon adopts a R-configuration indicating the attack is on the re face 
of the inhibitor (Fig 7a).  
 
Caspase-8.  Unlike in caspase-3: Michael acceptor inhibitor complexes, in the 
caspase-8 complex the P1` carbonyl is stabilized by the side chain of P2-Thr instead of 
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the catalytic His317.  The P4-Leu is stabilized in the manner similar to the P4-Ile as 
exemplified in the crystal structure of caspase-8:Ac-IETD-CHO complex35. The phenyl 
ring of the capping residue Cbz in 21t stacks favorably on top of Pro415, subsequently 
the puckering of this Pro is different from the one which is observed in other caspase-8 
inhibitor complex structures35,37,38. 
The S1` site of caspase-8 is different from all other caspases due to the helix-turn-
helix insertion in the 179-loop37. We have determined the structure of caspase-8 in 
complex with 21t. This compound is a tetrahydroisoquinoline derivative in which the 
tetrahydroisoquinoline occupies the hydrophobic S1' pocket defined by the residues 
Leu254, Ile257 and Tyr324 (Fig. 8). As a consequence this bulky hydrophobic moiety 
displaces the 179-loop by about 1.0 Å when compared to other caspase-8 inhibitor 
complexes. More importantly, significant changes in the side chain conformation of 
Arg258 are observed. Arg258 recognizes P3-Glu and its backbone carbonyl is critical for 
maintaining a hydrogen bond with Nε1 of the catalytic His317. In the complex with 21t 
the side chain of Arg258 is pointing towards Ser175 and in addition is involved in a 
hydrogen bond with the backbone carbonyl of Ser175. Such conformational changes 
might cost binding energy, which in turn is compensated by the formation of favourable 
hydrogen bonds or by hydrophobic interactions. Such differences are particularly 
observed in caspase-8 as it has a unique helix-turn-helix insertion loop at that site37. 
 
Stereochemistry. In our design of the aza-peptide Michael acceptors the double bond 
moiety has two different substitutents. One is the peptide chain and the other is the 
differing Y group, which consists of various groups such as alkyl, alkenyl, aryl, halogen, 
ester or amide.  Therefore, the double bond in aza-peptide Michael acceptors has two 
isomers: the cis isomer and the trans isomer.  We focused our attention of making mainly 
fumarate analogs.  However, we made one inhibitor with the cis configuration on the 
double bond moiety (18g).  This inhibitor turned out to be the most potent inhibitor of 
caspase-2 (k2 = 26,200 M-1s-1), when compared to the fumarate analogs. 18g was also 
quite potent with the other caspases as well (Table 1).  It was less potent than the trans 
isomer 18h, but overall it was more reactive than some of the fumarate analogs.  The 
weaker inhibition by the cis isomer (18g) compared to the trans isomer (18h) could be 
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due to an inherent difference in chemical reactivity of the two isomers and/or to weaker 
binding of the cis isomer to the enzyme. In an attempt to search for some structural 
reasons for this behavior, we have co-crystallized both the isomers with caspase-3. The 
crystal structure of the cis and trans isomer complexes were determined at 1.76 Å and 
1.86 Å resolution, respectively. In the cis complex the B-factor values of the inhibitor in 
general and P1' atoms in particular are higher than the trans complex, indicating higher 
mobility and/or lower occupancy in the active site. Consequently, the difference electron 
density for the bound inhibitor in the active sites of the caspase-3 cis complex is weaker 
than for the trans isomer. Nonetheless the electron density maps were good enough to fit 
the inhibitor model into the active site. The superposition of the cis and the trans 
complexes reveals that the bound covalent adducts overlap well with similar side chain 
rearrangements in the two complex structures. From structural considerations alone one 
would argue that both compounds bind with equal potency which is confirmed by kinetic 
data (give here precise values). 
 
CONCLUSION 
 Aza-peptide Michael acceptors with the Asp residue at P1 are a novel class of 
inhibitors for caspases-2, -3, -6, -7, -8, -9, and -10.  The inhibitors have excellent 
inhibitory potency and selectivity for clan CD cysteine proteases, where the second order 
rate constants are as high as 5,620,000 M-1s-1.  Aza-peptide Michael acceptors designed 
for caspases have been tested with a variety of other cysteine proteases for cross 
reactivity.  They do not show cross reactivity with the clan CA proteases such as papain, 
cathepsin B and calpain.  Aza-peptide Michael acceptors designed for caspases show 
little to no cross reactivity with legumain which has a specifity for Asn at P1.  They do 
not react with other clan CD proteases gingipain K and clostripain with specificities Lys 
and Orn at P1, respectively.    
 Analysis of our crystal structures reveals that the nucleophilic attack takes place 
on the C3-carbon of the double bond, thus additional substitution might be tolerated in 
the C2-carbon.  In an effort to obtain greater selectivity among caspases-2, -3, -6, -7, -8, -
9, and -10, we modified the P' substituent on the double bond for each appropriate 
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caspase sequence.  Our results indicate that caspases-3 and -7 can tolerate bulky and 
aromatic residues in the prime site.  Caspases-6 and -10 can accommodate a variety of 
different substituents at the same position, whereas caspase-8 prefers smaller P' 
substituents such as the ethyl group.  Currently, we are continuing to refine our design on 
the P' site, where we would like exploit the further possibilities for some polar 
interactions in the prime site.  By introducing substituents on the double bond with a 
variety of different electron-withdrawing characters, we are also hoping to improve the 
stability of aza-peptide Michael acceptors toward thiol nucleophiles such as the thiol 
DTT.Aza-peptide Michael acceptors’ potency and selectivity for caspases make them 
great candidates for potential use as probes in cellular function studies and as drugs.  Due 
to the strict requirement of the negatively charged Asp residue at P1 and the peptide chain 
itself, the hydrophobic character of our inhibitors is significantly low.  By introducing 
non-peptide moieties to replace the peptide backbone and shielding the side chain 
carboxylic acid group with certain isosteres, one can increase the hydrophobicity and 
hence the bioavailability of our caspase inhibitors.   
 
EXPERIMENTAL SECTION 
Enzyme Assays 
Caspase-2, -3, -6, -7, -8, -9 and -10.  Caspases-2, -3, -6, -7, -8, -9 and -10 were 
expressed in E. coli and purified in Guy Salvesen’s laboratory at the Burnham Institute, 
La Jolla, CA, according to the methods previously described by Stennicke and Salvesen. 
40
  Inhibition rates were determined by the progress curve method described by Tian and 
Tsou. 41  This method is suitable for measuring irreversible inhibition rates with fast 
inhibitors, where the inhibitor, the substrate and the enzyme are incubated together and 
the rate of substrate hydrolysis is measured continuously.  The rate of substrate 
hydrolysis in the presence of the inhibitor was monitored for 20 minutes.  The progress 
curve of inhibition, where the product formation approaches an asymptote is described in 
the equation 
ln ([P∞]-[P]) = ln [P∞] – A[I]t 
where [P] and [P∞] are the product concentrations at t and t = ∞ respectively, A is 
the apparent rate constant in the presence of the substrate.  The apparent rate constants 
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were determined from the slopes of plots of ln ([P∞]-[P]) versus time (t) in seconds as 
previously described, where A = slope / [I].   
For competitive and irreversible inhibition, the apparent rate constant is converted 
to the second order rate constant k2 by taking into consideration the effect of the substrate 
concentration on the apparent rate constant.  The second order rate constant is described 
as in the equation: 
k2 = A * (1 + [S] / KM)  
Assays using the fluorogenic substrates Ac-DEVD-AMC (λex = 360 nm, λem = 
465 nm), Z-VDVAD-AFC (λex = 430 nm, λem = 535 nm), and Ac-LEHD-AFC were 
carried out on a Tecan Spectra Fluor microplate reader at 37 oC.  The KM values for Ac-
DEVD-AMC with caspase-3 (KM = 9.7 µM), caspase-6 (KM = 236.35 µM), caspase-7 
(KM = 23.0 µM), caspase-8 (KM = 6.79 µM), and caspase-10 (KM = 20.2 µM) were 
determined in the laboratory of Guy Salvesen.  The KM value for Ac-LEHD-AFC with 
caspase-9 (KM = 114 µM) was also determined in the laboratory of Guy Salvesen.  The 
KM value for Z-VDVAD-AFC with caspase-2 was found to be 80.5 µM.  The k2 values 
are 2.24-fold higher than the apparent rate for caspase-2 because of the 100 mM [S] and 
KM = 80.5 µM.  The k2 values are 11.31-fold higher than the apparent rate for caspase-3 
because of the 100 mM [S] and KM = 9.7 µM.  The k2 values are 1.42-fold higher than the 
apparent rate for caspase-6 because of the 100 mM [S] and KM = 236.35 µM.  The k2 
values are 5.35-fold higher than the apparent rate for caspase-7 because of the 100 mM 
[S] and KM = 23.0 µM.  The k2 values are 15.73-fold higher than the apparent rate for 
caspase-8 because of the 100 mM [S] and KM = 6.79 µM.  The k2 values are 2.32-fold 
higher than the apparent rate for caspase-9 because of the 150 mM [S] and KM = 114 µM.  
The k2 values are 8.43-fold higher than the apparent rate for caspase-10 because of the 
150 mM [S] and KM = 20.2 µM. 
The concentration of the caspase-3 stock solution was 2 nM in the assay buffer.  
Assay buffer is a 1:1 mixture of caspase buffer (40 mM Pipes, 200 mM NaCl, 0.2% (w/v) 
CHAPS, sucrose 20% (w/v)) and 20 mM DTT solution in H2O at pH 7.2.  The 
concentration of the substrate stock solution was 2 mM in DMSO.  The enzyme was pre-
activated for 10 min at 37 oC in the assay buffer. The standard 100 µL reaction was 
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started by adding 40 µL of assay buffer, 5 µL of various amounts of inhibitor (stock 
solution concentrations varied from 5 x 10-3 M to 4.84 x 10-7 M in DMSO), and 5 µL of 
substrate in DMSO (100 µM final concentration) at 37 oC.  50 µL of 2 nM enzyme stock 
solution (final concentration: 1 nM) was added to the mixture after 1 min and reading 
started immediately for 20 min at 37 oC.  Inhibition experiments were repeated in 
duplicate and standard deviations determined.   
Caspase-2 kinetic assays were performed using Z-VDVAD-AFC as the substrate 
(2 mM stock solution in DMSO) and with the same conditions as caspase-3.  The 
concentration of the caspase-2 stock solution was 86.7 nM in the assay buffer (final 
concentration in the well:  43.3 nM).  The inhibitor stock solution concentrations varied 
from 5 x 10-3 M to 1 x 10-4 M in DMSO. Caspase-6 kinetic assays were performed using 
the same conditions and the same substrate (Ac-DEVD-AMC, 2 mM stock solution in 
DMSO). The enzyme stock solution was 10 nM (final concentration in the well: 5 nM) in 
the assay buffer.  The inhibitor stock solution concentrations varied from 5 x 10-3 M to 
2.42 x 10-6 M in DMSO. Caspase-7 kinetic assays were performed using the same 
conditions and the same substrate (Ac-DEVD-AMC, 2 mM stock solution in DMSO). 
The enzyme stock solution was 10 nM (final concentration in the well: 5 nM) in the assay 
buffer.  The inhibitor stock solution concentrations varied from 5 x 10-3 M to 2.5 x 10-6 M 
in DMSO. 
Caspase-8 kinetic assays were performed using the same conditions and the same 
substrate (Ac-DEVD-AMC, 2mM stock solution in DMSO). The enzyme stock solution 
was 100 nM (final concentration in the well: 50 nM) in the assay buffer.  The inhibitor 
stock solution concentrations varied from 5 x 10-3 M to 2.42 x 10-6 M in DMSO.   
Caspase-9 kinetic assays were performed using Ac-LEHD-AFC as the substrate 
(3 mM stock solution in DMSO) and with the following conditions.  The concentration of 
the caspase-9 stock solution was 150 nM in the assay buffer (final concentration in the 
well:  75 nM).  Assay buffer is a 1:1 mixture of buffer (200 mM Hepes, 100 mM NaCl, 
0.01% (w/v) CHAPS, sucrose 20% (w/v)) and 20 mM DTT solution in H2O at pH 7.0.  
The assay buffer was supplemented with 0.7 M sodium citrate.  The enzyme was pre-
activated for 10 min at 37 oC in the assay buffer.  The inhibitor stock solution 
concentrations varied from 5 x 10-3 M to 2.5 x 10-5 M in DMSO. 
Azapeptide Michael acceptors as caspase inhibitors   Chapter 3 
 98 
Caspase-10 kinetic assays were performed using the same substrate as caspase-3 
(Ac-DEVD-AMC, 3 mM stock solution in DMSO) and with the following conditions.  
The concentration of the caspase-10 stock solution was 50 nM in the assay buffer (final 
concentration in the well:  25 nM).  Assay buffer is a 1:1 mixture of buffer (200 mM 
Hepes, 0.2% (w/v) CHAPS, PEG 20% (w/v)) and 20 mM DTT solution in H2O at pH 7.0.  
The enzyme was pre-activated for 10 min at 25 oC in the assay buffer.  The inhibitor 
stock solution concentrations varied from 5 x 10-3 M to 2.5 x 10-5 M in DMSO. 
S. mansoni Legumain.  Conor R. Caffrey in James McKerrow’s laboratory 
performed the S. mansoni legumain kinetic assays at the Sandler Center for Basic 
Research in Parasitic Diseases, University of California at San Francisco, San Francisco, 
CA.  The zymogen form of schistosome legumain SmAE was expressed in Pichia.  The 
lyophilized enzyme (50-100 mg) was reconstituted in 1.5 mL 0.5 M sodium acetate, pH 
4.5 containing 4 mM DTT, and left to stand at 37 °C for 3-4 hours to allow for auto-
activation of the zymogen.  In a black 96-well microtiter plate, 50 µL of activated enzyme 
was added to an equal volume of 0.1 M citrate-phosphate buffer pH 6.8 containing 4 mM 
DTT.  The inhibitors, added as 1 µL aliquots (serial water dilutions of DMSO stock 
solutions, 2 to 0.00002 µM [final]), were preincubated with the protease at room 
temperature for 20 min.  After incubation, 100 uL of the same buffer containing 20 µM 
substrate (Cbz-Ala-Ala-Asn-AMC) was added to the wells and the reaction monitored for 
20 minutes.  A plot of the RFU/min versus the inhibitor concentration [µM] permitted 
calculation of an IC50 value. 
Pichia cell culture medium containing recombinant S. mansoni pro-legumain was 
incubated overnight at room temperature in 0.3 M sodium acetate, pH 4.5, 2 mM DTT to 
allow autoactivation of the endogenous zymogen.  Inhibitor (1 µl) at 6 concentrations (to 
yield 0 to 1 µM [final]) was spotted into a 96-well black microtiter plate.  To this was 
added 180 µl 0.1 M citrate-phosphate buffer, pH 6.8, containing 2 mM DTT and 20 µM 
Cbz-AAN-AMC substrate.  Activated legumain (20 µl) was added to the mix and the 
progress of inhibition followed every 2 seconds for 30 minutes at 25 °C (Molecular 
Devices Flex Station fluorometer in the injection mode; ex 355/em 460).   
Clostripain.  Clostripain was purchased from Sigma Chemical Co. (St. Louis, 
MO) as a solid which was dissolved in an activation solution of 8 mM DTT at a 
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concentration of 5.962 µM and stored at -20 °C prior to use.  The inhibition of clostripain 
began with the addition of 25 µl of stock inhibitor solution (concentration varies by 
inhibitor) in DMSO to a solution of 250 µl of 20 mM Tris/HCl, 10 mM CaCl2, 0.005% 
Brij 35, 2 mM DTT buffer at pH 7.6 (clostripain buffer) and 5 µl of the stock enzyme 
solution.  Aliquots (25 µl) of this incubation mixture were taken at various time points 
and added to a solution containing 100 µl of the clostripain buffer and 5 µl of Z-Phe-Arg-
AMC substrate solution (0.139 mM) in DMSO.  The enzymatic activity was monitored 
by following the change in fluorescence at 465 nm.  All data obtained was processed by 
pseudo-first order kinetics. 
Gingipain K.  Gingipain K stock solution was obtained from Jan Potempa's lab 
(University of Georgia, Athens, GA) in a buffer containing 20 mM Bis-Tris, 150 mM 
NaCl, 5 mM CaCl2, 0.02% NaN3, at pH 8.0 at a concentration of 9 µM, which was stored 
at -20 °C prior to use.  Before using the enzyme, an aliquot (1 µl) of the stock enzyme 
was diluted to a concentration of 4.61 nM in 1.951 ml of a solution of 0.2 M Tris/HCl, 
0.1 M NaCl, 5 mM CaCl2, 2 mM DTT at pH 8.0 (gingipain K buffer) and kept at 0 °C.  
This solution was used only for one day, as freezing the enzyme at this concentration 
destroyed all activity.  The inhibition of gingipain K began with the addition of 25 µl of 
stock inhibitor solution (concentration varies by inhibitor) in DMSO to 244 µl of the 
diluted enzyme solution (4.61 nM) in gingipain K buffer warmed to rt.  Aliquots (20 µl) 
of this were taken at various time points and added to a solution containing 100 µl of the 
gingipain K buffer and 5 µl of Suc-Ala-Phe-Lys-AMC • TFA as the substrate (0.910 mM 
stock) in DMSO.  The enzymatic activity was monitored by following the change in 
fluorescence at 465 nm.  The data for gingipain K was processed by pseudo-first order 
kinetics. 
Cathepsin B.  Irreversible kinetic assays were performed by the incubation 
method with human liver cathepsin B.  Enzymatic activities of cathepsin B were 
measured in 0.1 M KHPO4, 1.25 mM EDTA, 0.01% Brij, pH 6.0 buffer and at 23 °C 
using Cbz-Arg-Arg-AMC as the substrate.  To a freshly prepared enzyme stock solution 
of cathepsin B (approximately 6.98 x 10-3 µg/µL) in enzyme buffer containing DTT (0.1 
mM) was added an additional 300 µL of enzyme buffer and 30 µL of a stock inhibitor 
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solution in DMSO.  At various time intervals 50 µL aliquots were withdrawn from the 
incubation mixture and added to 200 µL enzyme buffer containing Cbz-Arg-Arg-AMC 
(500 µM).  Substrate hydrolysis was monitored using a Tecan Spectra Fluor microplate 
reader (λex = 360 nm, λem = 465 nm).  Pseudo first-order rate constants (kobs) were 
obtained from plots of ln vt/v0 versus time.   
 Papain.  Irreversible kinetic assays were performed by the incubation method 
with papaya latex papain.  An enzyme stock solution for the papain assays was freshly 
prepared from 330 µL of enzyme storage solution (1.19 mg/ml) diluted with 645 µL 
papain buffer (50 mM Hepes, and 2.5 mM EDTA at pH 7.5) and 25 µL of DTT (0.1 M).  
The incubation mixture was prepared from 300 µL buffer, 30 µL of inhibitor stock 
solution (DMSO), and 30 µL of enzyme stock solution.  At various times aliquots (50 µL) 
were withdrawn and added to 200 µL of Cbz-Phe-Arg-pNA substrate in buffer (53.7 
µM).  The absorbance of released p-nitroaniline was monitored at 405 nm on a Molecular 
Devices Thermomax plate reader. 
 Calpain I.  Irreversible kinetic assays were performed by the incubation method 
with calpain I from porcine erythrocytes.  Enzymatic activities of calpain I were 
measured at 23 °C in 50 mM Hepes buffer (pH 7.5) containing 10 mM cysteine and 5 
mM CaCl2, using Suc-Leu-Tyr-AMC as the substrate.  To 30 µL of an enzyme stock 
solution (1 mg/ml) of calpain I was added 300 µL of incubation buffer and 30 µL of a 
stock inhibitor solution in DMSO.  At various time intervals 50 µL aliquots were 
withdrawn from the incubation mixture and added to 200 µL enzyme buffer containing 
Suc-Leu-Tyr-AMC (1.6 mM).  Substrate hydrolysis was monitored using a Tecan Spectra 
Fluor microplate reader (λex = 360 nm, λem = 465 nm).  Pseudo first-order rate constants 
(kobs) were obtained from plots of ln vt/v0 versus time.   
Determination of the Stability of the Inhibitors in Buffer and in the Presence 
of DTT.  The stability of a representative group of inhibitors was studied by monitoring 
the UV spectrum of solutions at 250 nm, at 25 ºC.  The concentrations of the inhibitors 
were 2.5-4.0 mM and of DTT was 10 mM.  The pH of the buffer solution was 7.2 and it 
contained about 50 % (v/v) DTT.  The half-lives (t1/2) were obtained from first-order rate 
plots of ln(At/A0) versus time (15 hours) and the correlation coefficients were greater 
than 0.99. 
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 An aliquot (50 µL) of 4 mM Cbz-Asp-Glu-Val-AAsp-CH=CH-COOEt was added 
to 450 µL of assay buffer, and the stability of the inhibitor was monitored 
spectrophotometrically at 250 nm for every 30 minutes for 4 hours.  A half-life of 10 min 
was obtained from the first order rate plot from absorbance (250 nm) versus time (15 
hours).   
An aliquot (50 µL) of 2.5 mM Cbz-Asp-Glu-Val-AAsp-CH=CH-CONHCH2Ph 
was added to 450 µL of assay buffer, and the stability of the inhibitor was monitored 
spectrophotometrically at 250 nm for every 30 minutes for 4 hours.  A half-life of 58 min 
was obtained from the first order rate plot from absorbance (250 nm) versus time (15 
hours). 
An aliquot (50 µL) of 2.5 mM Cbz-Asp-Glu-Val-AAsp-CH=CH-CON(CH3) 
CH2Ph was added to 450 µL of assay buffer, and the stability of the inhibitor was 
monitored spectrophotometrically at 250 nm for every 30 minutes for 4 hours.  A half-life 
of 116 min was obtained from the first order rate plot from absorbance (250 nm) versus 
time (15 hours). 
An aliquot (50 µL) of 2.5 mM Cbz-Val-AAsp-CH=CH-CH=CH-CH3 was added 
to 450 µL of assay buffer, and the stability of the inhibitor was monitored 
spectrophotometrically at 250 nm for every 30 minutes for 4 hours.  The inhibitor was 
essentially stable over the course of the study. 
Crystal Structures-Caspase purification.  Human recombinant caspase-3 and 
caspase-8 were produced in E.coli as inclusion bodies, refolded and purified. Briefly, for 
caspase-3, the cloned genes for the large p17 subunit (Met-Ser29-Asp175) and the small 
p12 subunit (Met-Ala-Ser176-His277) were inserted in the NcoI/BamHI sites of pET11d 
plasmids (Novagen). For caspase-8, the cloned genes for the large p18 subunit (Met-Gly-
Glu218-Asp374) and the small p12 subunit (Met-Ala-Glu376-Asp479) were inserted in the 
NcoI/BamHI sites of pET11d plasmids (Novagen). For separate expression of both 
subunits, E. coli BL21-CodonPlus (DE3)-RIL cells (Stratagene), containing one of the 
two plasmids were grown to a density of A600 = 0.5 at 37 °C in a 0.5-liter LB medium. 
Expression was induced by the addition of IPTG (1 mM), and the culture was shaken at 
37 °C for 4 hours post induction. Cells were harvested, washed in PBS buffer and lyzed 
using a French press. Owing to over expression the protein was localised in inclusion 
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body portion. Refolding was achieved by rapid mixing of equimolar amounts of each 
subunit to a final concentration of about 100 µg of subunit/ml in the refolding buffer (100 
mM HEPES, pH 7.5, 10% sucrose, 1% CHAPS, 100 mM NaCl and 10 mM DTT) and 
was incubated overnight at room temperature with continuous stirring.  Misfolded and 
aggregated protein was removed by centrifugation (5,000 x g, 30 min), and the 
supernatant was concentrated using an Amicon-stirred cell. To reduce the salt 
concentration and to facilitate binding to an anion exchange column (ResQ 1mL, 
Amersham Biosciences),  the protein solution was dialyzed against the anion exchange 
buffer (20 mM Tris pH 8.0, 30 mM NaCl and 10 mM DTT) prior to chromatography.  
The protein was eluted using a 300 mM NaCl gradient. The pure and active caspase-3 
and caspase-8 were further purified by size exclusion chromatography on an analytical 
S200 column with buffer containing 20 mM Tris pH 8.0, 50 mM NaCl and 10mM DTT.  
Fractions containing pure and active caspase were pooled and concentrated by 
ultrafiltration (centricon, NMWL 10,000 Da) to a final concentration of 10 mg/ml and the 
final yield was about 5-7 mg/litre culture.  Eventually, the purified caspases were 
subsequently inhibited with a 3-fold molar excess of the inhibitor in a buffer containing 
20 mM Tris pH 8.0 and 10mM DTT.  
Crystallization and Data Collection.  Co-crystals of the complex between 
recombinant human caspase and the Michael acceptor inhibitors were grown from 2µl 
hanging drops formed by mixing equal volumes of protein (10 mg/ml in 20 mM Tris/HCl 
pH 8.0, 10 mM DTT ) and reservoir solution. The reservoir solution consists of 15% 
(w/v) polyethylene glycol 6000, 100 mM sodium citrate, pH 5.0 in case of caspase-3 and 
1.4 M sodium citrate, 100 mM HEPES/NaOH pH 8.0 in case of caspase-8.  Crystals (
100 x 100 x 50 µm) grew within 2-3 days.  For data collection, crystals were frozen in the 
nitrogen stream after a short soak in reservoir solution containing 20% glycerol for 
caspase-3.  The crystals of caspase-3 complexes belong to the space group I222 and the 
typical unit cell dimensions were, a = 67.2 Å, b = 83.3 Å, c = 96.0 Å.  Diffraction data 
were collected at the rotating anode generator (Bruker-Nonius, FR591) at 100 K. Images 
were integrated with MOSFLM 42 and scaled with SCALA 43 from the CCP4 suite of 
programs.  
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Diffraction data for caspase-8:inhibitor complex was collected at the Swiss Light 
Source synchrotron (Paul Sherrer Institute, Villigen, Switzerland).  The x-ray data was 
collected without utilising any cryo protectant.  The crystals of caspase-8 complex 
belongs to P3121 space group and the unit cell dimensions are a = 67.2 Å, b = 83.3 Å, 
c = 96.0 Å. The data reduction were done with program XDS44 and scaled with 
XSCALE45.  
Structure Solution and Refinement.  The structure was solved by the difference 
Fourier technique. Structure refinement and automated water addition were performed 
using the program CNS46 and the model building was done with program O. Iterative 
cycles of refinement and model building was performed. Manual adjustments were done 
with program O. The final crystallographic R and free R factors for caspase-3 complexes 
are in the range of 16-19 % and 19-22% respectively. The final model for caspase-3 
complexes consisted of residues 29-174 of α subunit and 176-277 of β subunit. For the 
caspase-8 complex the final R and free R factors are 16.8% and 20.1%, respectively. The 
final model shows residues 223-371 of α subunit and 390-479 of β subunit, 326 water 
molecules and 1 DTT molecule.  
Coordinates.  The atomic coordinates for caspase inhibitor complexes have been 
deposited with the Protein Data Bank. The accession codes are listed under Table 4. 
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Fig 6: Stereo view of the atomic model of (a) Caspase-3 in complex with 18h and (b) Caspase-8 
in complex with 21t overlaid with an electron density map contoured at 1.0 σ. Potential 
hyrdogen bond interactions are drawn in brown dashed lines. The residues involved in 
interaction with the inhibitor and catalytic dyad Cys163/His121 are highlighted.  
(c) Stereo view of the active site residues of caspase-3 in complex with 18h (blue) overlaid on 
top of structure of caspase-3:Ac-DEVD-CHO complex (green pdb code : 1PAU).  The atoms of 
the inhibitor (18h) are highlighted in yellow. The catalytic His121 of 18h complex  is rotated 
approximately 20° about its Chi2 angle, which enables it to form a hydrogen bond with P1-Asp 
and P1` carbonyl groups.  
Azapeptide Michael acceptors as caspase inhibitors   Chapter 3 
 107 
 
a 
 
 
 
b 
 
 
Fig. 7 Surface representation of the active site of caspase-3 with the active site and prime site 
residues are highlighted (a) Superposition of atoms of the inhibitor 18g (cis isomer in yellow) and 
18h (trans isomer is green). (b) Superposition of atoms of the inhibitor 18i (Benzyl ester 
derivative in yellow) and 18o (N-methyl, benzyl amide derivative is green).  The 18i inhibitor is 
able to form a hydrogen bond with the catalytic His121 while 18o is not involved in such an 
interaction. 
 
 
 
Fig. 8. Superposition of the crystal structure of caspase-8:21t complex (in blue) with the crystal 
structure of caspase-8: Ac-IETD-CHO (in green, pdb code 1QTN). Large scale movement of the 
179-loop apart from the different conformation of Arg258 are depicted. The hydrogen bond 
between the P1` carbonyl and the side chain of P2-Thr are given in brown dashed line. 
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Table 1.  Inhibition of Caspases by Aza-Peptide Michael Acceptors 
 k2 a(M-1s-1) 
Inhibitor Caspase-2 Caspase-3 Caspase-6 Caspase-7 Caspase-8 Caspase-9 Caspase-10 
16a    Cbz-Val-AAsp-CH=CH-CH3 ND NI NI ND NI ND ND 
16b    Cbz-Val-AAsp-CH=CH-CH=CH-CH3 NI NI NI NI NI NI NI 
16c    Cbz-Val-AAsp-CH=CH-CH2CH2Ph ND NI NI ND NI ND ND 
16d    Cbz-Val-AAsp-CH=CH-Cl NI NI NI NI NI NI NI 
16e    Cbz-Val-AAsp-CH=CH-4-Cl-Ph NI NI NI NI NI      NI NI 
16h    Cbz-Val-AAsp-CH=CH-COOEt NI 8,000 NI 2,680 ± 60 NI 5,240 ±  380    389 ±  87 
16j    Cbz-Val-AAsp-CH=CH-CONH-nBu NI 184 ± 9 NI 55 ±  5 NI    32 ±  13 NI 
16l    Cbz-Val-AAsp-CH=CH-CONHCH2Ph NI 185 NI 60 ±  1 NI     20 ±  2 NI 
17h    Cbz-Glu-Val-AAsp-CH=CH-COOEt 90 ± 10 38,600 ± 4,200 3,540 ± 4,200 
52,400 ±  
10,600 
244,000 ± 
30,000 
32,900 ± 
10,250 
    8,940 ± 
5,250 
18f    Cbz-Asp-Glu-Val-AAsp-CH=CH-COPh 165 ±           85 122,000 1,800 ± 13 
10,800 ± 
2,000 
  9,720 ± 
500 ND 
       930 ± 
80 
18g    Cbz-Asp-Glu-Val-AAsp-CH=CH-COOEt 
(cis) 
26,200 ± 
6,000 
1,060,000 ± 
92,500 
11,000 ± 
515 
139,000 ± 
4,500 
181,000 ± 
13,700 ND 
  13,500 ± 
2,300 
18h    Cbz-Asp-Glu-Val-AAsp-CH=CH-COOEt 
(trans) 2,640 ± 10 
2,130,000 ± 
99,130 35,575 ± 0 
239,000 ± 
55,600 
272,960 ± 
18,370 ND 
49,900 ± 
7,000 
18i    Cbz-Asp-Glu-Val-AAsp-CH=CH-
COOCH2Ph ND 
1,700,000 ± 
106,000 8,470 
114,000 ± 
15,900 
121,000 ± 
13,700 ND 
28,300 ± 
7,700 
18l    Cbz-Asp-Glu-Val-AAsp-CH=CH-
CONHCH2Ph 130 ± 20 
1,750,000 ± 
18,500 
3,210 ± 
105 
249,000 ± 
52,500 
78,235 ± 
8,000 
  2,010 ± 
150 
19,400 ± 
400 
18m  Cbz-Asp-Glu-Val-AAsp-CH=CH-
CONHCH2-4-F-Ph 130 ± 20 
2,100,000 ± 
26,400 
4,400 ± 
361 
329,000 ± 
53,300 
85,100 ± 
9,700   900 ± 70 
37,700 ± 
2,550 
18n    Cbz-Asp-Glu-Val-AAsp-CH=CH-
CONHCH2CH2Ph     120 ± 10 
1,950,000 ± 
53,000 3,470 ± 52 
267,000 ± 
15,000 
129,000 ± 
27,400   655 ± 50 
31,400 ± 
3,600 
18o    Cbz-Asp-Glu-Val-AAsp-CH=CH-
CON(CH3)CH2Ph    660 ± 240 
2,640,000 ± 
397,000 
9,500 ± 
210 
275,000 ± 
11,300 
90,300 ± 
18,250 820 ± 215 
29,400 ± 
830 
18p    Cbz-Asp-Glu-Val-AAsp-CH=CH-
CON(CH3)CH2CH2Ph    320 ± 25 
1,180,000 ± 
264,000 
4,000 ± 
413 
172,000 ± 
72,000 
31,900 ± 
2,800   425 ± 10 
9,570 ± 
5,240 
18r    Cbz-Asp-Glu-Val-AAsp-CH=CH-
CON(CH2Ph)2     110 ± 25 
3,000,000 ± 
80,000  5,100 ± 0 
359,000 ± 
8,400 
8,600 ± 
1,600   450 ± 30 6,300 ± 50 
18t    Cbz-Asp-Glu-Val-AAsp-CH=CH-CON(CH2-    410 ± 60 5,620,000 ± 29,700 ± 875,000 ± 9,460 ± 880      150 ± 32,500 ± 
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1-Napth)2 1,120,000 540 106,000 10 5,250 
18u    Cbz-Asp-Glu-Val-AAsp-CH=CH-CON-
tetrahydroquinoline    390 ± 90 
2,300,000 ± 
26,500  5,700 ± 0 
137,000 ± 
25,000 
118,000 ± 
14,800 340 ± 120 
8,330 ± 
1,400 
19h    Cbz-Val-Glu-Val-AAsp-CH=CH-COOEt     115 ± 20 41,200 ± 8,600 83,600 ± 8,400 
    3,650 ± 
1,330 
175,800 ± 
6,800 340 ± 120 6,600 ± 690 
20h    Cbz-Ile-Glu-Thr-AAsp-CH=CH-COOEt   300 ± 160 6,740 ± 1,650  88,700 ± 33,700 
       530 ± 
10 
56,500 ± 
3,800 ND 6,900 ± 250 
20i     Cbz-Ile-Glu-Thr-AAsp-CH=CH-COOCH2Ph    110 ± 40        2,300 ± 77 23,350 ± 1,650 
       660 ± 
210 148,400  ND 
15,200 ± 
2,500 
20k    Cbz-Ile-Glu-Thr-AAsp-CH=CH-CONHPh    365 ± 20    7,030 ± 720 99,200 ± 10,800 
       920 ± 
60 
245,000 ± 
22,800 940 ± 275 
  9,210 ± 
377 
20l     Cbz-Ile-Glu-Thr-AAsp-CH=CH-
CONHCH2Ph         15 ± 3    2,250 ± 560 
16,800 ± 
1,030 
       100 ± 
20 
61,300 ± 
2,300 440 ± 160   503 ± 209 
20n   Cbz-Ile-Glu-Thr-AAsp-CH=CH-
CONHCH2CH2Ph        30 ± 0    4,750 ± 565 
18,700 ± 
1,250 
       440 ± 
95 
71,000 ± 
13,700 615 ± 160 
8,290 ± 
1,560 
20o    Cbz-Ile-Glu-Thr-AAsp-CH=CH-
CON(CH3)CH2Ph        95 ± 8    6,000 ± 100 
45,900 ± 
5,000 
       390 ± 
90 
59,700 ± 
4,500 845 ± 190 8,500 ± 300 
20p    Cbz-Ile-Glu-Thr-AAsp-CH=CH-
CON(CH3)CH2CH2Ph         38 ± 1      5,480 ± 26 ND 
    1,020 ± 
440 
60,500 ± 
8,000 760 ± 335 
8,770 ± 
1,780 
20r    Cbz-Ile-Glu-Thr-AAsp-CH=CH-
CON(CH2Ph)2        76 ± 1 9,570 ± 1,230 
83,900 ± 
29,000 
    1,140 ± 
210    39,500 ± 0 1,930 ± 35 
7,930 ± 
2,510 
21h    Cbz-Leu-Glu-Thr-AAsp-CH=CH-COOEt NI    5,560 ± 290 18,700 ± 1,040 NI 
237,000 ± 
52,700      37 ± 0 NI 
21i     Cbz-Leu-Glu-Thr-AAsp-CH=CH-
COOCH2Ph    480 ± 170    4,600 ± 330 
47,600 ± 
2,500 
    1,570 ± 
135 
98,400 ± 
9,130 ND 
18,900 ± 
1,580 
21k    Cbz-Leu-Glu-Thr-AAsp-CH=CH-CONHPh  290 ± 150     4,700 ± 308 11,400 ± 2,060 
       730 ± 
200 
176,000 ± 
2,280 
1,190 ± 
230 
6,050 ± 
1,380 
21l     Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CONHCH2Ph      66 ± 25 1,120  1,550 ± 50 
       340 ± 
15 
70,170 ± 
13,700 
1,400 ± 
260 
14,400 ± 
1,900 
21m   Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CONHCH2-4-F-Ph        70 ± 1    4,490 ± 410 
3,100 ± 
465 
       410 ± 
60 
171,000 ± 
36,500 1,695 ± 30 
9,380 ± 
1,560 
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21n    Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CONHCH2CH2Ph     110 ± 40      5,400 ± 51 2,150 ± 52 
       440 ± 
60 
121,000 ± 
2,300 
1,760 ± 
190 
17,900 ± 
2,300 
21o    Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CON(CH3)CH2Ph    140 ± 25     6,000 ± 100 
10,800 ± 
410 
       520 ± 
60 169,000  
4,320 ± 
930 8,430 ± 710 
21p    Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CON(CH3)CH2CH2Ph      50 ± 10      2,620 ± 26 
2,550 ± 
413 
       290 ± 
170 
65,300 ± 
5,700   960 ± 30 6,190 ± 820 
21r    Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CON(CH2Ph)2    110 ± 10 8,630 ± 1,330 
14,100 ± 
1,440 
       760 ± 
100 
129,000 ± 
13,700 
1,105 ± 
460 
8,080 ± 
1,660 
21t    Cbz-Leu-Glu-Thr-AAsp-CH=CH-CON-
tetrahydroquinoline      92 ± 51   12,100 ± 720 
13,000 ± 
1,850     540 ± 30 
216,000 ± 
4,600 
1,660 ± 
710 9,000 ± 500 
21s    Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CON(CH3)CH2-1-Napth   290 ± 110 11,200 ± 1,130 
21,700 ± 
206 1,100 ± 35 
179,000 ± 
38,800 
5,030 ± 
555 
13,600 ± 
970 
NI = no inhibition, ND = not determined, Cbz = PhCH2-OCO-; a Assay buffer was 40 mM Pipes, 200 mM NaCl, 0.2% (w/v) CHAPS, sucrose 
20% (w/v) and 10 mM DTT, at pH 7.2, with Ac-DEVD-AMC as the substrate. 
 
 Table 2.  Cros Reactivity of Caspase Inhibitors with Clan CA and Other Clan CD Enzymes 
     k2 (M-1s-1)   
 Inhibitor Cathepsin B   Papain Calpain  Legumain Clostripain Gingipain K 
18h Cbz-Asp-Glu-Val-AAsp-CH=CH-COOEt NI NI NI NI NI NI 
18i Cbz-Asp-Glu-Val-AAsp-CH=CH-COOCH2Ph NI ND ND ND NI NI 
18l Cbz-Asp-Glu-Val-AAsp-CH=CH-CONHCH2Ph NI ND ND ND NI NI 
21i Cbz-Leu-Glu-Thr-AAsp-CH=CH-COOCH2Ph <10 NI <10 NI NI NI 
 NI = No inhibition, ND = not determined. 
 
 
 
 
 
Azapeptide Michael acceptors as caspase inhibitors   Chapter 3 
 111 
Table 3. X-ray data collection statistics of caspase: Michael acceptor complex crystals 
 
Table 4. Refinement statistics of caspase: Michael acceptor crystal structures 
 
Caspase-3 : 
Cbz-DEVaD-
CH=CH -
CO2Et (trans) 
18h 
Caspase-3 : 
Cbz-DEVaD-
CH=CH -
CO2Et (cis) 
18g 
Caspase-3 : 
Cbz-DEVaD-   
CH=CH -
CO2Bzl 
18i 
Caspase-3 : 
Cbz-DEVaD-   
CH=CH-
CON(CH3) 
Bzl  18o 
Caspase-8 : 
Cbz-LETaD-
CH=CH-CO 
tetrahydro-
quinoline  21t 
Resolution (Å) 20 - 1.76 20 - 1.86 20 - 1.93 20 - 2.45 10 - 1.95 
Rcryst 15.9 18.4 16.1 16.8 16.8 
Rfree  18.4 21.5 19.7 21.0 20.1 
Number of atoms 
Protein 1996 1996 1996 1996 1912 
Ligand 49 49 54 55 56 
Water 419 303 363 303 411 
Average B-factors 
Protein (Å2) 11.94 15.47 13.4 19.73 17.3 
Ligand (Å2) 18.98 30.7 29.5 42.5 23.1 
Water (Å2) 33.61 31.8 33.3 27.0 37.0 
PDB accession 
code 2C1E 2C2K 2C2M 2C2O 2C2Z 
 
 
 
 
Caspase-3 : 
Cbz-
DEVaD-
CH=CH -
CO2Et 
(trans) 18h 
Caspase-3 : 
Cbz-
DEVaD-
CH=CH -
CO2Et (cis) 
18g 
Caspase-3 : 
Cbz-
DEVaD-   
CH=CH -
CO2Bzl 
18i 
Caspase-3 : 
Cbz-
DEVaD-   
CH=CH-
CON(CH3) 
Bzl  18o 
Caspase-8 : 
Cbz-LETaD-
CH=CH-CO 
tetrahydro-
quinoline  21t 
Resolution range (Å) 
(last shell) 
20 - 1.76 
(1.86 - 1.76) 
20 - 1.86 
(1.96 - 1.86) 
20 - 1.93 
(2.03 - 1.93) 
20 - 2.45 
(2.58 - 2.45) 
10 - 1.95 
(2.05 – 1.95) 
Unique reflections 
25781 
(3441) 
22830 
(2606) 
19537 
(2531) 
10094 
(1402) 
21841 (1561) 
Redundancy 4.3 (4.0) 5.0 (4.7) 3.3 (3.1) 5.8 (5.4) 12 (13) 
Rmerge (%) 5.4 (20.8) 7.6 (43.9) 7.8 (26.2) 7.9 (24.3) 5.2 (9.0) 
Completeness (%) 95.3 (87.8) 97.8 (84.1) 94.3 (85) 99.2 (95.8) 98.5 (99.5) 
Average I/σ 19.1 (6.6) 17.3 (4.5) 12.8 (4.2) 19.6 (7.0) 36.4 (24.7) 
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Footnotes 
Abbreviation: AAsp: Aza-aspartic acid, AMC: 7−amino−4−methyl coumarin, LBHB: Low−barrier 
hydrogen bond, Z/Cbz: Benzyloxycarbonyl, E−64: 
L−trans−epoxysuccinyl−leucylamide−(4−guanidino)−butane 
Coordinates 
The atomic coordinates and structure factures for caspase−3 aza−peptide epoxide inhibitor complexes 
have been deposited with the Protein Data Bank and the accession codes are 2CDR, 2CNK, 2CNL, 
2CNO and 2CNN.  
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ABSTRACT  
Caspase−3 is a prototypic executioner caspase which plays a central role in apoptosis. Aza−peptide 
epoxides are a novel class of irreversible inhibitors that are highly specific for clan CD cysteine 
proteases. The five crystal structures of caspase−3: aza−peptide epoxide inhibitor complexes reported 
here reveal the structural basis for the mechanism of inhibition and the specificities at the S1' and the S4 
subsites. Unlike the clan CA cysteine proteases, the catalytic histidine in caspase−3 plays a critical role 
during protonation and subsequent ring opening of the epoxide moiety and facilitates nucleophilic attack 
by the active site cysteine. The nucleophilic attack takes place on the C−3 carbon atom of the epoxide 
and results in an irreversible alkylation of the active site cysteine residue. A favorable network of 
hydrogen bonds involving the oxyanion hole, catalytic histidine and the atoms in the prime site of the 
inhibitor enhance the binding affinity and specificity of the aza−peptide epoxide inhibitors towards 
caspase−3. The studies also reveal that subtle movements of the N−terminal loop of the β−subunit 
occur, when the P4 Asp is replaced by a P4 Ile, whereas the N−terminal loop and the "safety catch" 
Asp179 are completely disordered when the P4 Asp is replaced by P4 Cbz group. 
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Introduction 
Caspases are a family of cysteine aspartate specific proteases which have essential functions in 
apoptosis and cytokine activation (1, 2). Based on their biological functions, they are classified as 
initiators (caspase−8, -9 and -2) and executioners (caspase−3, -6 and -7). Caspase−3 is the most 
abundant caspase in vivo (3-5) and it is the best characterized family member. Apart from its established 
role as a prototypic executioner caspase, several non−apoptotic roles of caspase−3 are emerging (6-8). 
Currently, many industrial and academic laboratories are engaged in the design of specific inhibitors for 
caspase−3 to regulate its activity for therapeutic intervention of diseases like myocardial infarction, 
Alzheimer's, stroke, Parkinson's, sepsis and Huntington's disease (9). Even though the executioner 
caspases-3 and -7 share high sequence similarity and substrate specificity, they have distinct roles in 
apoptosis (10). Thus specific inhibitors for caspases would assist in deciphering the precise role of each 
caspase in the execution phase of apoptosis. Caspases demonstrate stringent specificity for an aspartic 
acid residue in P1 position of a substrate. Within the caspase family the substrate selectivity is highest 
for the P4 residue (11). Apart from P4, the prime site could also be utilized to gain specificity among 
caspases. Although considerable effort has been devoted to the optimization of interactions of caspase 
inhibitors in the S1−S4 subsites (9, 12), only a few studies exist that analyze the interactions of substrates 
or inhibitors at the prime site (13-16).  
Initial studies using fluorescent peptidyl substrates indicated a preference for small residues (Gly, Ala, 
Ser) at position P1' for caspase−1, −3, −6 and −8. A few peptido−mimetic compounds that bind to the 
prime site were identified for caspase−3 and were characterized structurally (13). The halogen methyl 
ketones and aldehydes are the most commonly used electrophilic groups (warheads) which were coupled 
with the preferred tetra/penta peptide recognition sequence of caspases (9). Since these warheads are 
highly reactive and tend to inhibit other clan CA cysteine proteases (17-20), the search for potential 
warheads which are highly selective for caspases becomes increasingly important. To overcome the 
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problem of lack of selectivity, we have recently reported the identification and characterization of 
aza−peptide epoxide and Michael acceptors as a new class of irreversible caspase inhibitors that are 
highly specific for clan CD cysteine proteases (21-23). In this paper, we report the crystal structures of 
caspase−3 in complex with five of the aza−peptide epoxides inhibitors, containing modifications at the 
P1' and P4 positions, to understand the specificity, binding mode and the mechanism of inhibition in 
these regions of the active site. The modifications at the prime site were intended to gain selectivity for 
caspase−3, while the study with a tripeptide (−EVD−) derivative and a tetrapeptide (−IETD−) derivative, 
was aimed at understanding the influence of the P4−residue interaction and ordering of the N−terminal 
loop of the β−subunit. The C-3 carbon atom of the epoxide moiety binds covalently to the thiol group of 
the active site cysteine of caspase-3. This observation is in contrast to the previous proposal where the 
covalent bond was reported to occur between the C-2 carbon atom of the epoxide inhibitor and thiol 
group of active site cysteine in caspase-1 (23).  
 
Experimental procedures 
Materials and methods: 
Caspase purification. Human recombinant caspase−3 was produced in Escherichia coli as inclusion 
bodies, refolded and purified. Briefly, the cloned genes for the α−subunit (Met−Ser29−Asp175) and the 
β−subunit (Met−Ala−Ser176−His277) were inserted in the NcoI/BamHI sites of pET11d plasmids 
(Novagen). For separate expression of both subunits, Escherichia coli BL21−CodonPlus (DE3)−RIL 
cells (Stratagene), containing one of the two plasmids were grown to a density of A600 = 0.5 at 37°C in 
0.5−liter Luria−Bertani medium. Expression was induced by the addition of IPTG (1 mM), and the 
culture was shaken at 37°C for 4 hours post induction. Cells were harvested, washed in PBS buffer and 
lyzed using a French press. Owing to overexpression the protein was localized in the inclusion body 
portion. Refolding was achieved by rapid mixing of equimolar amounts of each subunit to a final 
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concentration of about 100 µg of subunit/L in the refolding buffer (100 mM HEPES, pH 7.5, 10% 
sucrose, 1% CHAPS, 100 mM NaCl and 10 mM DTT) and was incubated overnight at room 
temperature with continuous stirring. Misfolded and aggregated protein was removed by centrifugation 
(5,000 x g, 30 min), and the supernatant was concentrated using an Amicon−stirred cell. To reduce the 
salt concentration and to facilitate binding to an anion exchange column (Resource−Q, GE Healthcare),  
the protein solution was dialyzed against the anion exchange buffer (20 mM Tris pH 8.0, 30 mM NaCl 
and 10 mM DTT) prior to chromatography. The protein was eluted using a 300 mM NaCl gradient. The 
pure and active caspase−3 was further purified by size exclusion chromatography (Superdex S200, GE 
Healthcare) with buffer containing 20 mM Tris pH 8.0, 50 mM NaCl and 10 mM DTT. Fractions 
containing pure and active caspase were pooled and concentrated by ultrafiltration to a final 
concentration of 10 mg/mL and the final yield was about 5−7 mg/L culture. The purified caspase was 
subsequently inhibited with a 3−fold molar excess of the inhibitor.  
Crystallization and Data Collection. Co−crystals of the complex between recombinant human 
caspase−3 and aza−peptide epoxide inhibitors were grown from 2−4 µL hanging drops formed by 
mixing equal volumes of protein (10 mg/mL in 20 mM Tris/HCl pH 8.0, 10 mM DTT ) and reservoir 
solution. The reservoir solution consisted of 15% (w/v) polyethylene glycol 6000, 100 mM Sodium 
citrate, pH 5.0. Crystals (~300 x 200 x 100 µm) grew within 2−3 days. For data collection, crystals were 
frozen in the nitrogen stream after a short soak in reservoir solution containing 20% glycerol. The 
crystals belong to the space group I222 and the typical unit cell dimensions were a = 67.2 Å, b = 83.3 Å 
and c = 96.0 Å. Diffraction data for the inhibitors (1), (2), (3), and (5) were collected using a rotating 
anode generator (Bruker−Nonius, FR591) at 100 K. Images were integrated with MOSFLM (24) and 
scaled with SCALA (25) from the CCP4 suite of programs. Diffraction data for the inhibitor (4) were 
collected at the Swiss Light Source synchrotron (Paul Scherrer Institute, Villigen, Switzerland). The data 
processing was done with the program XDS (26). 
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Structure Solution and Refinement. The structure was solved by the difference Fourier technique. 
Structure refinement and automated water addition were performed using the program CNS (27) and 
model building was done with the program O (28). Iterative cycles of refinement and model building 
were performed. To simplify the dictionary of restraints for aza−peptide epoxide inhibitors, the molecule 
was treated as three parts, the N−terminal blocking group (Cbz), tripeptide portion (DEV) and the 
P1−AAsp along with P1' peptidomimetic. The final crystallographic R and free R factors were in the 
range of 16−19% and 19−22%, respectively. The final model consisted of residues 29−174 of α−subunit 
and 176−277 of β−subunit in case of (1), (2), (3) and (5) and the residues 176−185 of the β−subunit 
were disordered in case (4). A summary of the crystallographic data processing and refinement statistics 
for the caspase−3: aza−peptide epoxide inhibitor complexes are given in Table 1 and 2 respectively. 
 
RESULTS 
Inhibitor design. The inhibitor potency critically depends on the structure of the peptide moiety and 
the chemical reactivity of the warheads. Inhibitors like E−64 and their synthetic analogs containing an 
epoxysuccinyl moiety as the warhead, are specific inhibitors for clan CA cysteine proteases (29).  
Epoxysuccinyl dipeptides without an aspartic acid residue  do not inhibit caspase-1 (30) and a variety of 
epoxysuccinyl peptides containing aspartate do not inhibit other caspases (J. C. Powers and Özlem 
Dogan Ekici, unpublished results). The reason for the inertness of E−64 derivatives against caspases 
might be the unparalleled selectivity for an aspartic acid residue in the S1 subsite or the location of the 
warhead. The design strategy for the inhibitors presented here was to place an epoxide group at the 
C−terminus of a P1 aza aspartate and also to retain an additional carbonyl group at the prime site by 
using the epoxysuccinyl moiety (Fig. 1).  
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Structure based mechanism of inhibition. Epoxides are weak electrophiles but they tend to become 
highly electrophilic upon protonation. Protonation is critical for the ring opening and subsequent 
alkylation of the active site thiol group of Cys163. When the epoxides are flanked by carbonyl groups on 
either side, they are pre−activated and referred to as epoxysuccinyl inhibitors. This strategy has led to 
the identification of compounds that are potent inhibitors of caspases (21, 23). These inhibitors possess a 
dual advantage as a result of the combination of the high reactivity of the activated epoxides coupled 
with enhanced binding properties of regular substrate like peptides.  
 
In general, the inactivation of cysteine proteases by epoxide inhibitors proceeds through the 
nucleophilic attack of the active site thiol group on either the C−2 or C−3 carbon atom of the oxirane 
ring.  This irreversible thioalkylation could follow two different pathways (Fig. 2). In a previously study, 
it was proposed that the nucleophilic active site thiol group of caspase−1 reacts  on the C−2 carbon atom 
of an aza−peptide epoxide inhibitor (23). In contrast, the high resolution crystal structures of caspase−3 
complexes presented here clearly demonstrate that the nucleophilic attack is on the re face of the C−3 
carbon atom, creating a covalent thioether bond (typically C−Sγ = 1.8Å) between the C−3−carbon and 
the sulfur atom of the active site cysteine (Cys163) (Fig. 3a).  Aza-peptides with good leaving groups will 
inhibit both serine and cysteine proteases with formation of stable acyl enzyme derivatives (30, 31). The 
acyl enzyme complexes formed by reaction of aza−peptides with cysteine proteases are thiocarbamates 
and are generally more stable when compared to the thioesters formed from normal peptide substrates. 
The reason is the inability of a water molecule to nucleophilically attack the thiocarbamyl group of the 
acyl enyzme complex (32). The increased stability of thiocarbamates is a consequence of the unique 
conformational and electronic properties of the aza-amino acid residue containing an α−nitrogen atom.  
As a consequence of the nucleophilic attack by the active site thiolate following a SN2 reaction 
mechanism, the stereochemistry of the enzyme inhibitor adduct undergoes an inversion in configuration. 
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The configuration changes from 2S,3S to 2R,3R (Fig. 3a). The change at the C−2 carbon atom is due to 
the nucleophilic attack, while the change at the C−3 carbon atom is due to the alteration in the ranking 
order of the substituents. The high resolution and well defined electron density map allowed us to make 
an unambiguous interpretation of the chiralities at the C−2 and C−3 atoms. The stereochemical changes 
observed in our structural studies are similar to those observed in other cysteine protease:epoxysuccinyl 
inhibitor complexes (29, 31, 33). 
 In the case of clan CA cysteine proteases, the critical protonation event of the epoxide ring is driven 
by water molecules (34). The enzyme−inhibitor structures with compounds (1−5) show that the nascent 
hydroxyl group formed as a result of the epoxide ring opening, is oriented towards the active site His121 
forming a hydrogen bond (hydrogen bond distance ranging from 2.7−2.9Å) (Fig. 4). This indicates 
strongly that in caspases (or at least caspase−3), unlike in clan CA cysteine proteases, the catalytic His121 
plays a key role in the protonation and subsequent ring opening of the epoxide ring.  
 
Structure and binding mode of caspase−3: aza−peptide epoxide inhibitors. We have determined 
five crystal structures of caspase−3: aza−peptide epoxide inhibitor complexes. The interactions of the 
P1−P4 moieties of the aza−peptide epoxide inhibitors in the substrate binding cleft of caspase−3 are 
similar to those observed for peptidyl aldehyde or halogen methyl ketone inhibitors (35, 36), thus closely 
mimicking substrate−like binding. The inhibitors used for the structural studies were all trans (2S,3S) 
stereoisomers. The tetrapeptide (−DEVD−) based inhibitors are: the N,N−dibenzyl amide derivative (1), 
the N−benzyl amide derivative (2) and the benzyl ester derivative (3). The tripeptide (−EVD−) based 
inhibitor is a N−phenethyl amide derivative (4) and compound (5) is a tetrapeptide (−IETD−) based 
inhibitor containing an alanine residue blocked by an N−benzyloxycarbonyl group at the C−terminus. 
The chemical structures along with the key hydrogen bond interactions in the prime site of the 
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caspase−3: aza−peptide epoxide inhibitor complexes are illustrated in Fig. 4a−e. A hydrogen bond 
between the prime site carbonyl group and a water molecule is conserved in all the complexes (Fig. 4). 
The overall structure of the enzyme in the complexes analyzed here is similar to other known crystal 
structures of caspase−3 (35, 36). The α− and β−subunits fold into a central six−stranded mixed β−sheet 
that is flanked on both sides by 5 α−helices. This architecture, which is designated as the caspase 
hemoglobinase fold is conserved throughout all caspase structures. Superposition of the Cα atoms of 
different caspase−3 inhibitor complexes resulted in a root mean square deviation of 0.3Å (35, 36). This 
indicates that large scale conformational changes do not occur upon binding of the prime site 
substituents. However rearrangements occur in residues that directly interact with the inhibitor. The 
geometries of the epoxide inhibitors bound to caspase−3 were well−defined in the electron density 
maps, allowing an unambiguous interpretation of the atoms of the inhibitor located in the prime site 
(Fig. 3a).  
 
Influence of inhibitor structure on binding and rate of inactivation. Aza−peptides are analogs of 
peptides in which the α−CH group is exchanged by a nitrogen atom (37-39). This substitution has a 
profound effect on the reactivity and results in the loss of the chiral centre. The presence of the free 
electron pair on the aza−nitrogen atom leads to an extension of the area of planarity in comparison to a 
normal peptide linkage (40). The additional limitation of free rotation seems to allow the side chains to 
adopt a configuration which is in−between the D− and L−configuration (37, 38). As a consequence, 
there is an increase in acidity of the NH group attached to the aza−nitrogen atom, which strengthens the 
P1−amide hydrogen bond to the backbone carbonyl group of Ser205 (Fig 3c). The importance of the 
backbone intermolecular hydrogen bond interaction was studied previously (41). A dramatic decrease in 
potency was observed for caspase−1 when the P1−amide proton was replaced by a methyl group 
underscoring the significance of this interaction for binding and potency. In the current structures, the 
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inhibitor moiety extends along the primed and non−primed subsites of the enzyme and it is stabilized by 
a series of hydrogen bonds and hydrophobic interactions (Fig. 4).  
 
Interactions at the prime site of caspase−3. The structural and chemical properties of the prime site 
region of caspase−3 indicate a preference to bind hydrophobic moieties of an inhibitor. Inhibitors 
containing such prime site residues might bind with higher affinity and would offer higher selectivity for 
caspase−3. The prime site in caspase−3 is predominantly hydrophobic and is delineated by four loop 
regions: the 179−loop (between strand β1 and helix α2), the 240−loop (between strand β3 and helix 
α3), the C−terminal loop from the α subunit, and by a loop (between helix α3 and strand β4) from the β 
subunit. The interactions of the P2 and P3 residues of the inhibitor are similar to the ones reported in 
other caspase−3 structures (35, 36). In all crystal structures reported here, the P1 carbonyl group which is 
a part of the aza−aspartic acid, is extending towards the oxyanion hole and is stabilized by hydrogen 
bonds to the backbone amide nitrogen's of Gly122 and Cys163 (Fig. 4). These interactions are similar to 
those observed in the crystal structures of caspases in complex with halo methyl ketones (35, 42). These 
interactions contribute to the stabilization of the enzyme inhibitor complex and also help to orient the 
inhibitor ideally for the subsequent nucleophilic attack by the active site Cys163 Sγ atom.  
A unique feature of all crystal structures of caspase−3 aza−peptide epoxide complexes is the rotation 
of the catalytic His121 around χ1 and χ2 by approximately 15°. During this rotation, the hydrogen bond 
between the His121 Nε atom and the backbone carbonyl of Thr62 (putative third residue of the catalytic 
triad) stays intact because the geometry of this hydrogen bond is nearly collinear with the Cα−Cβ bond 
(Fig. 3c). The movement of His121 is required because otherwise a steric clash with the newly formed 
hydroxyl group at the C−2 carbon atom would occur. This movement results in the formation of a 
hydrogen bond with P1 AAsp residue in case of the structure of caspase−3 in complex with (5). The 
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interaction between the catalytic His121 and P1 AAsp would implies that His121, apart from its 
implications in catalysis, plays a role in substrate binding.  
Inhibitor (1) is the most potent inhibitor used in this structural study. It possesses a bulky dibenzyl 
moiety which best fits the large cavity in the prime site and effectively buries altogether about 740 Å2 of 
the enzyme accessible surface on binding. The order of reactivity correlates well with the calculated 
buried surface area upon the binding of the inhibitor (Table 3). While one of the phenyl rings is involved 
in hydrophobic interaction with Tyr204, Thr166 and Glu123, the other phenyl ring fits the hydrophobic 
pocket formed by Met61 and Phe128 of the prime site (Fig. 5a). The monobenzyl derivative (3), unlike its 
dibenzyl counterpart, has a proton donating amide group and forms a hydrogen bond with the backbone 
carbonyl group of Gly122. Despite this additional hydrogen bond, the absence of the second phenyl ring 
resulted in a 50% decrease in the observed k2 value (Table 3). Moreover, the phenyl ring is not placed 
ideally in the hydrophobic pocket, rather it is oriented in an unfavorable position towards the carboxyl 
group of Glu123 (Fig. 5a). A superposition of the benzyl ester derivative (2) with (1) shows, that its 
phenyl ring occupies the same pocket as one of the phenyl rings of compound (1). Compound (2) is as 
potent as compound (1) as it effectively buries the residues Tyr204, Thr166 and Glu123 delineating this 
pocket (Fig. 5a).  The decreased affinity for compounds (4) and (5) is predominantly due to the 
non−optimal residues in P4 position. In addition, the extension of the aliphatic chain by one carbon in 
compound (4) does not seem to improve the affinity in the prime site. The terminal phenyl ring is very 
flexible as it is destabilized due to the presence of a charged side chain of Glu123. On the other hand, 
the presence of an alanine residue in the prime site in case of compound (5) appears to be favorable as 
its methyl group is stabilized by the side chain of P2 threonine residue (Fig. 5b).  
 
Specificity of caspase−3 in the S4 pocket. Caspase−3 and caspase−7 are highly selective for an 
aspartic acid as the P4 residue (11). In case of caspase−3, the affinity for an Asp in P4 is 100−fold higher 
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than for a Glu/Asn at this position (16). The structural basis for this observation was revealed recently 
(43). The N−terminal loop consisting of residues 176−185 of the β−subunit plays a vital role in the 
substrate recognition, particularly at the subsites S4 and S5. The predominant factors contributing to 
binding affinity of an inhibitor are (i) a “Low−barrier hydrogen bond” (LBHB) between the P4 Asp (in 
the case of (1), (2) and (3)) and the “safety catch” Asp179, and (ii) a cluster of hydrophobic interactions 
between the Val178, Phe250, Phe248 and P5−Cbz group. In contrast to the former observation (43), the 
P5−Cbz group is well ordered in all the crystal structures reported here (Fig. 3b). The electron density 
map is well defined and the B−factor values for the atoms of P5−Cbz are comparable to the rest of the 
inhibitor moiety. The P5−Cbz group is stabilized by the hydrophobic cluster formed by Val178, Phe250, 
Phe252 and Lys229.  
 In order to study the influence of the P4 residue on the ordering of the N−terminal loop and in 
particular the interaction which prevailed between the P4 aspartate and the “safety catch” Asp179, we 
have determined two crystal structures of caspase−3 with suboptimal inhibitors containing an isoleucine 
residue in P4 (IETD) and a tripeptide (EVD) based inhibitor. Procaspase−3 exists as an inactive 
zymogen and it is activated through proteolytic cleavage by the initiator caspase−8/−9 during apoptosis 
to separate the α− and the β−subunits. The subunits then rearrange to produce an active caspase−3 
molecule. Autocatalytic activation of procaspase−3 by an active caspase−3 is a way to amplify the 
apoptotic signal and the cleavage occurs at Asp175 located at the inter−subunit linker region. The 
cleavage sequence (172−IETD−175) matches the peptide sequence of the compound (5), thus the structure 
is a representation of the interactions of a substrate and the enzyme during the autocatalytic activation. 
In case of compound (5), the lower value for the second order inactivation rate constant (k2) emphasizes 
the importance of the P4 Asp in comparison to the sub−optimal P4 Ile residue (23). The P4 Ile in 
compound (5) topologically occupies the same place as a P4 Asp. It is stabilized through hydrophobic 
contacts to Trp206, Trp214 and Phe250 (Fig. 6b). Large scale movements of the residues shaping the 
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substrate binding site are observed. The most dramatic change occurs with Trp206, which rotates 15° 
around χ1 and is thus displaced by about 1.3 Å. The movement of Trp206 is necessary to prevent steric 
clashes with the P4 Ile residue. This also influences the neighboring hydrophobic residues like Leu168, 
Phe256, Tyr204 and Trp214, all of which adapt to the needs of accommodating the sub−optimal P4 Ile. 
These structural observations are in good agreement with the initial hypothesis concerning the 
reorganization of tryptophan residues during caspase−3 activation. The placement of an isoleucine 
residue in the S4 subsite, results in drastic decrease in the affinity, due to non−productive binding. As a 
consequence, the main chain atoms of the N−terminal loop of the β−subunit (residues 176−185) are 
displaced by about 0.5 Å in comparison to the other crystal structures in complex with compounds (1), 
(2) and (3). No change in the side chain conformations of residues 176−185 in the N−terminal loop is 
observed. In case of the tripeptidic inhibitor (4), the blocking group Cbz occupies the S4 pocket and it is 
stabilized by hydrophobic contacts with residues Trp206, Trp214 and Phe250 (Fig 6a). An interesting 
feature of the structure in complex with compound (4) is that the N−terminal loop of the β−subunit, in 
particular residues 176−185, is completely disordered. No interpretable electron density for the 
N−terminal loop residues was observed.  This is a consequence of the removal of both the anchor points 
which prevailed in the crystal structure complexes of compounds (1), (2) and (3).       
 
DISCUSSION 
Strategies to specifically target caspase−3 for therapeutic intervention could be fruitful in the 
treatment of variety of diseases. A large number of caspase:inhibitor complexes have been studied by 
X−ray crystallography (12, 35, 36, 42, 44, 45). The caspase structures increased the understanding of 
their important role in apoptosis and have revealed a wide variety of binding modes and geometries. 
Most of the inhibitors bind to the S1−S4 subsites of the active site, while less is known about the binding 
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at the S1' subsite. In this paper, we describe the structural basis for the mechanism of inhibition and the 
binding mode of aza−peptide epoxides by caspase−3. Analysis of the crystal structures reveals that the 
nucleophilic attack takes place on the C−3 carbon of the epoxide ring, thus additional substitution might 
be tolerated at the C−2 carbon. The binding of the aza−peptides mimics substrate like binding in the 
S1−S4 subsites. In sharp contrast to clan CA cysteine proteases, the epoxide ring is protonated by the 
catalytic His121 in caspases. Our aza−peptide epoxide inhibitors demonstrate very high selectivity 
towards caspases. The prominent reasons for this is the design strategy of placing the epoxide moiety at 
the C−terminus of an aza aspartic acid residue resulting in the overall stabilization of the charged groups 
like the oxyanion hole, catalytic histidine and P1 AAsp of the inhibitor. The other plausible reasons for 
selectivity might arise from the mechanistic differences between clan CA and CD cysteine proteases. 
The capability to recognize both D− and L−configurations of the substrates with similar reactivity is a 
unique feature of caspases (46). The P1 aza manipulation to form aza−peptide results in the change in 
the configuration of the P1 residue from L to intermediate planar D/L geometry. The difference in 
geometry prevents the nucleophilic attack on the warhead group by other proteases while caspases 
recognize compounds with this geometry as normal peptidic substrates with similar efficiency. Serine 
protease like granzyme B, having a preference for aspartic acid at the P1 position, might lack the 
nucleophilicity required for the epoxide ring opening in a SN2−like displacement.   
Selective inhibition of a particular caspase can be achieved by exploiting the specificity at the prime 
site. The highly homologous executioner caspases−3 and −7 possess slightly different size and shape of 
the prime site. While the prime site in caspase−7 is a deep and narrow pocket, the prime site in 
caspase−3 is more open and broad. We wanted to capitalize on the affinity of hydrophobic residues at 
the prime site to design some potent and specific inhibitors. Our inhibitors show reasonable selectivity 
towards caspase−3 due to the presence of the prime site constituent. The structural studies with non-
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ideal P4 substituents revealed that the ordering of the N−terminal loop of the β-subunit is dictated by 
two key interactions: (i) the LBHB and (ii) the hydrophobic cluster discussed above. A dramatic shift 
occurs in the observed k2 value, if a P4 Asp is replaced by a P4 Ile which can be explained by the large 
scale movements of the residues shaping the substrate binding site. The N−terminal loop of the β-
subunit is completely disordered in the crystal structure if both key interactions are missing. This leads 
to insufficient charge compensation and a conformational change that decreases the binding surface, 
implying a drop in the binding affinity. Therefore, the S4 subsite in capsase−3 has a strong preference for 
an aspartic acid. In conclusion, we have highlighted the structural basis for achieving selective inhibition 
of caspase−3 by utilizing the variations and subtle differences, particularly in the S4 and S1' subsites.  
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Table 1. X−ray data collection statistics of caspase−3: aza−peptide epoxide complex crystalsa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) 
Caspase−3:  
Cbz−DEVaD
−(S,S) 
EP−CO−N(C
H2Ph)2 
(2) 
Caspase−3 :  
Cbz−DEVaD
−(S,S) 
EP−COO−CH
2Ph 
(3) 
Caspase−3 :  
Cbz−DEVaD
−(S,S) 
EP−CO−NH−
CH2Ph 
(4) 
Caspase−3 :  
Cbz−EVaD−(
S,S) 
EP−CO−NH−
CH2CH2Ph 
(5) 
Caspase−3: 
Cbz−LETaD−
(S,S) 
EP−CO−Ala−
NHCH2 Ph 
Space group I222 
Unit cell 
dimensions (Å) 
a = 65.9  
b = 83.4    
c = 96.4   
a = 66.8  
b = 83.8    
c = 96.5   
a = 67.7  
b = 84.0    
c = 96.2   
a = 69.1  
b = 83.5    
c = 95.8   
a = 67.9  
b = 83.7    
c = 96.2   
Resolution range 
(Å) 
20.0−1.70 
(1.79−1.70) 
20.0−1.75 
(1.84−1.75) 
20.0−1.67 
(1.76−1.67) 
20.0−2.05 
(2.15−2.05) 
20.0−1.69    
(1.78−1.69) 
Unique 
reflections 
28860 (3974) 27485 (3983) 31449 (4313) 16966 (2257) 30129 (3591) 
Redundancy 4.1 (3.8) 3.8 (3.6) 4.4 (4.3) 4.5 (5.9) 4.6 (4.3) 
Rmerge (%) 4.8 (29.9) 5.6 (24.6) 6.4 (32.6) 2.5 (3.6) 6.6 (28.1) 
Completeness 
(%) 
97.7 (93.0) 99.7 (100) 98.1(93.4) 95.4 (97.7) 97.8 (85.5) 
Average I/σ 18.8 (3.9) 17.0 (5.5) 17.3(3.8) 31.9 (25.3) 19.3 (4.3) 
aThe values in the parentheses refer to that of the highest resolution shell 
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Table 2. Refinement statistics of caspase−3: aza−peptide epoxide crystal structures 
 
(1) 
Caspase−3 :  
Cbz−DEVaD−(
S,S) 
EP−CO−N(CH2
Ph)2 
(2) 
Caspase−3 :  
Cbz−DEVaD−(
S,S) 
EP−COO−CH2P
h 
(3) 
Caspase−3 :  
Cbz−DEVaD−(
S,S) 
EP−CO−NH−C
H2Ph 
(4) 
Caspase−3 :  
Cbz−EVaD−(S,
S) 
EP−CO−NH−C
H2CH2Ph 
(5) 
Caspase−3: 
Cbz−IETaD−(S
,S) 
EP−CO−Ala−N
H−CH2Ph 
Resolution (Å) 20.0 − 1.70 20.0 − 1.75 20.0 − 1.67 20.0 − 2.05 20.0 − 1.69 
R 17.4 16.2 18.5 16.4 18.0 
Rfree  20.1 18.9 21.4 19.4 20.4 
Number of atoms 
Protein 2004 1996 2004 1931 1996 
Ligand 62 55 55 48 60 
Water 363 403 361 299 348 
Average B−factors 
Protein (Å2) 18.2 13.1 18.8 14.2 16.9 
Ligand (Å2) 31.6 22.5 30 41.0 35.6 
Water (Å2) 38 34.3 37.7 31.1 36.0 
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Table 3. The second order inactivation rate constants (k2) and buried surface area for aza−peptide 
epoxide inhibitors against caspase−3.   
 Aza−peptide epoxide inhibitorsa k2 (M−1s−1)b   Buried accessible 
surface area (Å2) 
(1) Cbz−DEVaD−(S,S) EP−CO−N(CH2Ph)2 2,170,000 742 
(2) Cbz−DEVaD−(S,S) EP−COO−CH2Ph 1,910,000 682 
(3) Cbz−DEVaD−(S,S) EP−CO−NHCH2Ph 1,090,000 619 
(4) Cbz−EVaD−(S,S) EP−CO−NH−CH2CH2Ph 27,300 614 
(5) Cbz−LETaD−(S,S) EP−CO−Ala−NH−CH2Ph 1,280 618 
 
aaza-aspartic acid residue is represented by aD 
bk2 values were compiled from (23). 
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FIGURE LEGENDS 
Figure 1: The design of aza−peptide epoxide inhibitors was based on the structure of caspase substrates. 
Selectivity was achieved by the introduction of an epoxide moiety at the C−terminus of the P1−aza aspartic acid 
residue. 
 
Figure 2: Two possible pathways for the mechanism of inhibition caspase by aza−peptide epoxides involving 
either a C−2 attack or a C−3 attack resulting in the epoxide ring opening and formation of a thio−ether adduct. 
 
Figure 3: Close-up view of the active site of caspase−3. (a) The nucleophilic attack resulted in the formation of a 
covalent bond between Sγ and C−3 carbon and the stereochemistry of the enzyme inhibitor (2) adduct underwent 
an inversion in configuration from 2S,3S to 2R,3R. The prominent hydrogen bond interactions include the P1 
carbonyl with the oxyanion hole, and the catalytic His121 with the prime site hydroxyl group (C−2 carbon). (see 
Fig.4a-e) (b) A low barrier hydrogen bond (bond length 2.4 Å) is observed between the P4−Asp of the inhibitor 
(2) and the "safety catch" Asp179 from the N−terminal loop of the β−subunit. (c) The superposition of the active 
site residues of caspase−3 in complex with compound (5) and Ac−DEVD−CHO complex (green, pdb code: 
1PAU).  The catalytic His121 of compound (5) complex is rotated approximately 15° about its χ1 and χ2 angles, 
resulting in a hydrogen bond formation with P1-AAsp while retaining its interaction with Thr62. The electron 
density map was contoured at 1.0 σ and the hydrogen bond interactions are drawn as red dashed lines. The 
residues belonging to the other monomer are indicated by an asterisk. 
 
Figure 4: Chemical structures and hydrogen bond networks at the prime site for caspase−3 in complex with 
aza−peptide inhibitors (1)−(5). The nascent hydroxyl group at the C2−carbon atom formed as a result of 
nucleophilic attack is involved in a hydrogen bond formation with the catalytic His121. The P1−carbonyl group is 
stabilized with hydrogen bond interaction of the "oxyanion hole" while the P1 prime carbonyl group is stabilized 
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with a conserved water molecule. The interaction between the P1−Asp and His121 in case of the structure of 
caspase−3 in complex with compound (5) implies apart, from its implications in catalysis, that His121 plays a role 
in substrate binding. 
 
Figure 5: Surface representation of the active site of caspase−3. The active site and prime site residues are 
shown in stick representation. (a) Superposition of compounds (1) (blue), (2) (green), and compound (3) 
(yellow). The biphenyl derivative effectively buries the residues Tyr204, Thr166, Glu123, Phe128 and Met61 in the 
prime site.  (b) Superposition of the compound (4) (green) and compound (5) (yellow). The methyl group of the 
alanine residue of compound (5) in the prime site is stabilized through hydrophobic contacts with the P2 Thr 
residue.   
 
Figure 6: (a) Superposition of compound (4) and compound (2). The Cbz group of compound (4) occupies the S4 
binding pocket resulting in the disordering of the N−terminal loop (residues 176-185) of the β−subunit. (b) 
Superposition of compound (5) and compound (2). The isoleucine residue in compound (5) occupies the S4 
binding pocket resulting in the displacement of the N−terminal loop of the β−subunit by about 0.5 Å. Large scale 
deviations of main chain atoms as well as side chain conformations of the residues, Trp206, Phe256, Leu168, and 
Trp214 in the selectivity loop are observed in both the crystal structures. 
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ABSTRACT 
A significant interest persists towards the identification of non-peptidic inhibitors for 
regulating caspase activity leading to the therapeutic intervention of variety of diseases 
like myocardial infarction, Alzheimer's, stroke, Parkinson's, sepsis and Huntington's 
disease. We report the identification of several small molecule inhibitors through a 
structure based design approach involving an in silico selection, in vitro high throughput 
screening for the inhibition of caspase activity and further validation by X-ray structure 
determination of three caspase-3:inhibitor complexes. Inhibitors targeting either the 
active site of caspase-3 or the allosteric site of caspase-8 were identified. Insights from 
the crystal structures of caspase-3 in complex with two of the active site inhibitors 
revealed that these compounds bind only to the prime site of caspase-3 thus leaving the 
subsites S1-S4 unoccupied. Conformation of residues shaping the S1-S4 subsites support 
an induced fit mechanism for the binding of the substrates at the active site. Size 
exclusion chromatographic experiments indicated that the inhibition of caspase-8 activity 
by two of our allosteric inhibitors was achieved through the modulation of the 
oligomerization state. 
KEYWORDS Caspases, in silico screening, X-ray structure, allosteric inhibitors. 
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INTRODUCTION 
 Caspases represent a unique class of cysteine aspartate-specific proteases because 
of their substrate specificity and biological functions [1, 2]. Inhibition of caspase 
represents a highly promising avenue for intervention in a number of conditions involving 
apoptosis-mediated cell and tissue damage [3]. Many potent caspase inhibitors have been 
prepared based on structures of the caspase peptide substrates. However, due to their 
peptidyl structure, most of these inhibitors do not possess good cell permeability to be 
considered as candidates for drug development [3]. So far 11 human caspases are known, 
they are classified into initiator or executioner caspases, depending on their hierarchy in 
the cell death process. Caspases demonstrate stringent specificity for an aspartic acid 
residue in P1 position and they use their active site thiol to cleave peptide/protein targets 
exclusively at the C−terminus to an aspartic acid residue. Within the caspase family, a 
certain degree of selectivity for substrates resides in S4 and S1 prime subsites. Caspases 
have been subdivided into three main specificity families, the caspase-1, -3 and -8 family 
require a tryptophan, aspartic acid and leucine residue respectively in the P4 positions of a 
substrate. Caspase inhibitors typically contain an electrophilic group termed ‘warhead’ 
which reacts with the nucleophilic active site cysteine residue. The most commonly used 
warheads are halogen methyl ketones and aldehydes, which were coupled with the 
preferred tetra/penta peptide recognition sequence of caspases to produce potent 
inhibitors. 
 Caspases are homo-dimers of hetero-dimers with the active site in close proximity 
of the dimer interface [4]. Structure-based thermodynamic analysis indicates that residues 
from the dimer interface of caspase-3 are critical for stabilizing the active site loops [5]. 
The dimer interface of caspase-3, a prototypic executioner comprises about 2500 Å2 of 
hydrophobic surface area, mainly contributed by residues that belong to the small subunit 
[6]. At the interface between the hetero-dimers, a cavity is formed [1, 6-12]  and the 
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largest cavity is formed by caspase-8 with an approximate volume of 17 × 15 × 11 Å3, 
while the cavities formed by the caspase-2 and -3 are smaller. Due to the differences in 
shape and chemical properties of the surface of the cavity in different caspases, specific 
inhibition by compounds binding in the cavity through this allosteric mode of inhibition 
can be envisaged [12].  
 Here we present the identification and structural characterization of small 
molecule inhibitors either binding to the substrate binding site of caspase-3 or to the 
interface cavity of caspase-8, using an in silico screening approach combined with 
enzyme assays and structure determination. Initially, an in silico docking approach was 
carried out using the fragment-based docking suite DAIM-SEED-FFLD [13-16] to 
compounds carrying an aldehyde or halogen methyl ketone warhead binding best to the 
active site of caspase-3. The same docking approach was also carried out for the 
identification of compounds that might bind to the dimer interface cavity. Enzyme in 
vitro inhibition assays and structure determination of a selected subset of the newly 
identified inhibitors showed its potential to find low-molecular weight inhibitors. The 
combined profile of the compounds analyzed provides a starting point for the 
optimization of new chemically different caspase-3 inhibitors.  
 
EXPERIMENTAL PROCEDURES 
 In this work we used in silico screening for identifying compounds containing a 
halogen methyl ketone or aldehyde group, which can form a covalent bond with the 
catalytic cysteine residue of caspases. Screening the Available Chemical Directory 
database (ACD about 240’000 compounds), the National Cancer Institute 3D database 
(NCI-3D 140’000 compounds) and the Cambridge Crystallographic Data Centre database 
(250’000 compounds) yielded a total of about 7200 molecules containing a halogen 
methyl ketone or aldehyde group. In order to search for inhibitors which bind to the 
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cavity at the dimer interface and thereby could influence the activity, we used the NCI 
diversity set of compounds for screening against three different caspase targets. The NCI 
diversity set covers a wide range of structural space and is a library of compounds with 
non-redundant pharmacophore profiles [17].  
 For docking of the molecules into the active site used a fragment-based docking 
procedure consisting of the three programs DAIM [13], SEED [14, 15] and FFLD [16, 
18]. The used computational approach presumes three fragments for the placement of a 
flexible ligand in the binding site. DAIM decomposes a larger ligand into fragments and 
also determines the anchor fragments used in an initial rigid docking procedure [13]. 
Optimal positions and orientations for the small to medium-sized fragments generated by 
DAIM are determined by SEED [14, 15]. This program places polar fragments into a 
predefined binding pocket on condition that at least one hydrogen bond is formed to the 
protein whereas apolar fragments are docked into hydrophobic regions. The fragments are 
then being docked exhaustively.  Binding energies are calculated as the sum of van der 
Waals and electrostatic terms taking into account the interaction energies between the 
fragment and the protein, as well as desolvation energies [16, 18]. In the last step of the 
docking procedure, the whole molecule is being docked flexibly into the binding pocket 
by the program FFLD. This program uses a genetic algorithm for the modification of the 
torsion angles and applies an efficient scoring function [19, 20]. The placement of the 
ligand in the binding site is defined by the anchor points defined by SEED, therefore only 
the conformation of the ligand is being altered. For efficiency reasons, the scoring 
function used in FFLD does not explicitly include solvation and is based solely on van 
der Waals and hydrogen bond energy terms. Nevertheless, the solvation effects are being 
indirectly considered by utilizing the best binding modes previously determined by 
SEED.  
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 The crystal structures of caspase-3 (PDB accession codes 1CP3, 1NME, 1NMQ, 
1NMS) of caspase-8 (PDB accession code 1QTN) and caspase-2 (PDB accession code 
1PYO) were used as the basis of the docking experiments [6, 8, 9, 21, 22]. For caspase-3 
we used multiple structures as templates in order to partially take into account protein 
flexibility induced by ligand binding. Coordinates of caspase-8 structure in complex with 
Ac-IETD-CHO was chosen due to the high resolution 1.20 Å (pdb accession code 
1QTN). Prior to docking the binding sites were defined by analysis of the residues 
involved in the formation of the active site pocket or the cavity at the dimer interface, 
respectively. All crystallographic water molecules were removed from the protein 
structures. The 2D structures from the NCI diversity set were converted to 3D coordinates 
by using the program Corina [23]. Hydrogen atoms, considering appropriate ionization 
states, atom types and partial charges were assigned to the protein targets and the ligands 
using the programs Babel [24] and WITNOTP [25]. 
 A docking protocol was established by docking of known inhibitors in the active 
sites of different caspase-3 structures. Different ligand poses obtained from the docking 
procedure were energy minimized, while keeping protein atoms rigid, using the 
CHARMM force field [26]. After inspection of the best scored poses in the active sites of 
the four different protein structures used as templates for the docking, implausible poses 
were discarded. This selection was based on criteria as eventual clashes with the protein 
and other unfavorable interactions. The docked binding modes of the energetically most 
favorable compounds were analyzed by visual inspection. Compounds with plausible 
poses, including the 1990 compounds of the NCI diversity set, were either obtained from 
the Drug Synthesis and Chemistry Branch, the Developmental Therapeutics Program, 
NCI or purchased from external suppliers and tested in an in vitro activity assay for their 
inhibition potency. The "structural diversity set" is a publicly available set of structurally 
diverse chemical compounds (about 2000) from the National Cancer Institute (NCI). The 
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compounds are prepared as a 10 mM solution in DMSO and are available in 96-well 
microtitre plate.  
Caspase purification. The human recombinant caspases were produced in Escherichia 
coli as inclusion bodies, refolded and purified as described previously [27]. Briefly, for 
separate expression of both subunits, E. coli BL21−CodonPlus (DE3)−RIL cells 
(Stratagene), containing one of the two plasmids were grown to a density of A600 = 0.5 at 
37 °C in 0.5−liter Luria−Bertani medium. Expression was induced by the addition of 
IPTG (1 mM), and the culture was shaken at 37 °C for 4 hours post induction. Cells were 
harvested, washed in PBS buffer and lyzed using a French press to retrieve the protein 
localized in the inclusion body portion. Refolding was achieved by rapid dilution of 
equimolar amounts of each subunit to a final concentration of about 100 µg of 
subunit/mL. The protein was purified by anion exchange chromatography (Resource−Q, 
GE Healthcare). As a last step, the active caspase was further purified by size exclusion 
chromatography (Superdex S200, GE Healthcare).  
In vitro caspase assay based screening. The screening process consisted of measuring 
the inhibitory activity of the compound under test against a defined concentration of 
recombinant caspases. Typically, the enzyme (10 nM) was incubated with 100 µM of the 
compounds for 30 min at 37°C. The remaining caspase activity was assayed 
fluorometrically using the fluorogenic substrates Ac-DEVD-AMC. The caspase activity 
was determined from the initial rate of hydrolysis of substrate by measuring the accumu-
lation of the fluorogenic product 7-amino-4-methylcoumarin. The increase in sample 
fluorescence was measured at an excitation wavelength of 360 nm and an emission wave-
length of 460 nm for 15-30 min at 37°C using an HTS 7000 Plus Bio Assay plate reader 
(Perkin Elmer). Both, the enzymes and the substrates were diluted in the assay buffer 
consisting of 20 mM piperazine-N,N`-bis (2-ethanesulfonic acid) (PIPES) pH 7.2, 100 
mM  NaCl, 10 mM 1,4-dithiothreitol (DTT), 1 mM EDTA, 0.1% (w/v) 3-((3-
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cholamidopropyl)-dimethyl-ammonio)-1-propane sulfonate (CHAPS) and 10% (w/v) 
sucrose. The active caspase concentration was determined by active site titration using a 
covalently binding inhibitor Ac-DEVD-cmk. As a pre-requisite for the assay, the 
concentration of DMSO was less than 2% and the substrate to enzyme ratio was at least 
50. The typical assay volume was 100 µL in a 96-well microtitre plate.  
Crystallization and structure determination. For the crystallization studies, the 
purified caspase-3 was subsequently inhibited with a 3-fold molar excess of the inhibitor. 
Co-crystals of the complex between caspase-3 and small molecule inhibitors were grown 
from hanging drops formed by mixing equal volumes of protein (10 mg/mL in 20 mM 
Tris/HCl pH 8.0, 10 mM DTT ) and reservoir solution. The reservoir solution consisted of 
0-15% (w/v) polyethylene glycol 6000, 100 mM sodium citrate pH 5.0. Prior to data 
collection, crystals were frozen in the nitrogen stream after a short soak in reservoir 
solution containing 20% glycerol. The crystals belong to the space group I222 and the 
unit cell dimensions are as listed in Table 3. X-ray data for the inhibitor (1) was collected 
at the Swiss Light Source synchrotron (Paul Sherrer Institute, Villigen, Switzerland). The 
data processing was done with program XDS [28]. Diffraction data for the inhibitors (5) 
and (8) were collected with the rotating anode generator (Bruker-Nonius, FR591) at 100 
K. Images were integrated with MOSFLM [29] and scaled with SCALA [30] from the 
CCP4 suite of programs. The structure was solved by the difference Fourier technique. 
The model building was done with program O [31] and structure refinement was 
performed using the program CNS [32]. The topology and parameter files for the energy 
minimized inhibitor were generated using the program XPLO2D [33]. The final 
crystallographic R and free R factors were in the range of 18-20% and 19-22% 
respectively. The final models consisted of residues 29-174 of the α-subunit and residues 
186-277 of the β−subunit for the all three caspase-3:inhibitor complexes described here. 
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RESULTS 
 The results of the re-docking experiments are shown in Figure 1. The predicted 
binding modes for the inhibitors (1), (5), and (8) were very similar to the experimental 
binding modes. The observed rmsd values to the crystallographic coordinates were in the 
range of 0.5-1.1 Å (Table 1). In order to facilitate crystallization and subsequent structure 
determination, we focused our docking efforts towards the irreversible warhead 
possessing a halogen methyl ketone moiety rather than the reversible aldehyde group. 
Visual inspection of the best scored poses of our docking results, led to the subset of 27 
compounds which were ordered either at the NCI open chemicals repository or with the 
commercial suppliers. 21 of these compounds could be obtained and were subsequently 
assayed for the inhibitory activity against caspase-3. At least 8 of these compounds 
showed more than 50% inhibition in the caspase activity assay. The relative inhibition 
data for these compounds along with their chemical structures are given in Table-2. The 
structure-based design approach as described above was also employed for the 
identification of allosteric inhibitors for caspases. In silico pre-selection followed by an in 
vitro HTS screening yielded a series of compounds, the relative inhibitory activity values 
for these inhibitors and their chemical structures are summarized in Table 4. 
 
Crystallographic studies for the active site directed inhibitors of caspase-3 
 All the identified inhibitors listed in Table 2 were screened for co-crystallization 
with caspase-3. The three compounds (1), (5), and (8) yielded suitable crystals for 
collecting diffraction data. A summary of the crystallographic data processing and 
refinement statistics is given in Table 3. Additionally, we obtained co-crystals of caspase-
3 in complex with the compounds (3), (4), (6), and (7). Unfortunately, these crystals were 
either too small or were not diffracting to reasonable resolution despite several 
optimization attempts.  
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 The overall conformation of caspase-3 is similar in all of the three inhibitor 
complexes reported here and is also similar to the other known crystal structures of 
caspase-3:inhibitor complexes [6, 7]. The halogen methyl ketone warhead groups are 
covalently bonded to the thiol group of the active site cysteine through a thio-ether bond.  
 The compound (5) mimics an aspartic acid coupled to a methylene chloride 
moiety at the C-terminus. The binding mode is very similar to that of the inhibitors 
possessing a P1-aspartate moiety [6, 7]. The compound (5) occupies the S1 subsite and is 
stabilized by ionic interactions with Arg64 and Arg207 apart from the hydrogen bond 
interaction with Gln161 (Fig. 2b and 4b). In the other known structures, caspases 
typically form two critical mainchain-mainchain interactions with the peptidic inhibitors. 
One of the interactions is between the P1-amide protons of the inhibitor and the backbone 
carbonyl of the conserved Ser205, the other interaction is between the P3-carbonyl group 
with the amide proton of the conserved Arg207. The lack of the amide group in the 
compound (5) and thus the missing hydrogen bond interaction renders methylene carbons 
very flexible. The carbonyl group of the inhibitor is stabilized by the "oxyanion hole" 
formed by the amide protons of cysteine Cys163 and Gly122. Being the smallest 
inhibitor, it just occupies the S1 subsite thus leaving the subsites S2-S4 unoccupied. As a 
consequence, the residues involved in shaping these sites have different orientations 
compared to the ones observed in other known structures [6, 7]. One significant change is 
observed in the case of Tyr204, which rotates about 90° and occupies the P2-pocket where 
it is stabilized by hydrophobic contacts with Cys163, Trp206 and Phe256 (Fig. 2b).  
 
 In contrast to the mode of binding observed in the caspase-3:compound (5) 
complex, compound (1) binds only in the prime site of caspase-3. Due to this unusual 
binding along the prime site, the substrate binding subsites S1-S4 are unoccupied. Apart 
from some movements of the side chain conformation of residues forming these subsites, 
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a similar conformational change of Tyr204 as observed in case of caspase-3: compound 
(5) complex was also observed in this structure.  Given the lack of the critical P1-Asp 
residue, the S1 subsite is occupied by a cluster of water molecules. As a consequence, the 
active site Arg207 is displaced by about 0.5 Å in comparison to caspase-3: compound (5) 
complex and it also adopts a different side chain conformation. The inhibitor is covalently 
bound to the active site cysteine residue and the P1-carbonyl group of the inhibitor is 
stabilized partly by the "oxyanion hole" (the amide protons of Gly122) (Fig 2a, 3a and 
4a). One of the phenyl rings of the inhibitor covers the S1 subsite and is involved in 
hydrophobic contacts with Tyr204 and His121, while the p-toluyl group is stabilized by 
the side chains of Thr166 and Glu123. Furthermore, it is evident from the crystal 
structure that the sulfone amide group is not involved in direct interactions to the protein 
and instead forms water-mediated interactions with the main chain carbonyl groups of 
Gly122 and Gly165. Therefore, the sulfone amide presumably could be replaced by other 
groups linking the p-toluyl and the benzyl groups of the inhibitor. Since the amide group 
is not involved in any contacts, it might be advantageous to replace the sulfone amide 
group by a sulfone group.  
 
 Although the binding of the carbamic acid group in the structure of the caspase-3: 
compound (8) complex is reminiscent of the binding of the sulfone amide group of 
compound (1), the two aromatic rings of compound (8) bind to completely different 
regions to the active site. One of the phenyl ring is well placed in a deep hydrophobic 
cavity delineated by cluster of residues Thr166, Leu168, Tyr204 and Phe256, while the 
other phenyl ring is stabilised by hydrophobic contacts with Met61 and Phe128 (Fig 2c, 
3b and 4c). The carbonyl group of the inhibitor is stabilized by hydrogen bond interaction 
with the amide proton of Gly122. An additional stabilizing interaction is observed 
between the carbonyl group of the inhibitor and the catalytic His121. As already observed 
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for the compounds (1) and (5), a similar conformational change of Tyr204 is observed 
here as well. Therefore, the conformation reported for most of the caspase-3 peptidic 
inhibitor complexes [6, 7] is due to displacement of the Tyr204 by the P2-Val residue of 
the inhibitor. Thus the observed conformational changes of the active site residues like 
Tyr204 and Arg207 provide a glimpse of adaptability and plasticity of the active site 
residues. Additionally, these observations also support an induced-fit mechanism in a 
concerted fashion involving both the enzyme and substrate amino acid residues. 
 
Size exclusion chromatography 
 In an attempt to assess whether the modulation of caspase activity by allosteric 
inhibitors is due to the altering of the monomer-dimer equilibrium, we have performed 
size exclusion chromatography experiments for caspase-8 in complex with two of the 
identified allosteric inhibitors. The uninhibited caspase-8 exists in monomer-dimer 
equilibrium with 80-85% of the protein in the dimeric form (Fig. 5). This equilibrium can 
be shifted to higher degree of dimer formation, by the addition of potent inhibitors [34]. 
Two of the identified allosteric inhibitors showed varying degree of shift in the monomer-
dimer equilibrium. This observation indicated that apart from weakening of the dimer 
interface and subsequently shifting the equilibrium towards the formation of monomers, 
these inhibitors also seem to induce some conformational changes which propagate from 
the dimer interface to the active site  and thereby results in decreased activity. 
Accordingly, the results from the size exclusion chromatographic experiments indicate 
that the inhibition of caspase-8 activity by the allosteric inhibitors (9) and (10) is achieved 
through the modulation of the oligomerization state. Nevertheless, the precise mechanism 
by which they achive this modulation awaits further structural and biochemical 
characterization.  
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DISCUSSION 
 From experimental observations at the atomic level of how inhibitors bind to their 
macromolecular targets, specific interactions that are important in molecular recognition 
can be inferred. Apart from the de novo design of novel lead compounds, the structural 
information obtained in this study could aid in the improvement of existing inhibitors. We 
have shown that our fragment-based docking procedure is capable of reproducing the 
binding modes of known caspase-3 inhibitors and that the in silico screening approach 
identifies novel compounds in compound databases exhibiting caspase-3 inhibitory 
activity. The observed mode of binding was different in all our three caspase-3:inhibitor 
complexes determined. The high-resolution crystal structures reported here provides 
insights into the architecture of the active site, which might be useful for the design of 
more potent caspase-inhibitors by considering not only the S1-S4 pockets but also the S1 
prime subsite. Moreover, the replacement of some fragments of the crystallographically 
determined compounds in complex with caspase-3 by more favorable moieties could 
eventually be utilized for the optimization of the compounds.  Preliminary tests using the 
NCI diversity set of approximately 2000 compounds also showed that the combination of 
in silico docking and high-throughput screening might be implemented for the 
identification of allosteric inhibitors for caspases without the need for an electrophilic 
warhead group. Size exclusion chromatography experiments indicated that the inhibition 
of caspase-8 activity by two of the found allosteric inhibitors was achieved through the 
modulation of the oligomerization state shifting the equilibrium towards the formation of 
monomeric caspases. Thus this strategy capitalizes on the feature that caspases activity 
would be attenuated when its oligomerization state is perturbed. The detailed 
investigation of allosteric regulation of caspases which includes the determination of the 
stoichiometry, affinity and critical residues involved in the interaction with the ligand 
moiety has to be established in the near future. In conclusion, we have showed that our 
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fragment-based docking procedure is capable of reproducing the binding modes of known 
caspase-3 inhibitors and that our in silico screening approach could be used for screening 
of databases for compounds exhibiting caspase inhibition activity. 
 
Coordinates. Crystallographic coordinates and structure factors for the three caspase-
3:inhibitor complex structures have been deposited to the Protein Data Bank with 
accession ID PDB1, PDB2 and PDB3.  
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Table 1. Redocking and cross docking of halogen methyl ketone inhibitors 
 iCP3 iNME iNMS 
1CP3 0.5 3.8 3.7 
1NME 1.0 1.1 1.4 
1NMS 4.0 1.5 0.9 
 
 
 
 
 
 
 
 
Table 2. List of active site directed inhibitors with their relative inhibitory 
activities for caspase-3a.  
 
H
N Cl
O
SO
O
 
(1) 
NSC-89167  
CAS: 329-30-6 
71% 
 
Br
O
Br
-O
O
 
(2) 
NSC-24873 
CAS:1775-46-8 
69% 
 
Br
O
N
H
O O-
 
(3) 
NSC-107152 
CAS:10161-88-3 
68% 
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Cl
O
N
N
N
NH2
H2N
 
(4) 
NSC-211621 
CAS:19159-87-6 
66% 
-O Cl
O
O
 
(5) 
NSC-18508 
CAS: 60254-71-9 
59% 
 
Cl
O
N
H
O O-
 
(6) 
NSC-106024 
CAS: 10161-89-4 
53% 
 
Br
O
N
O
O O
 
(7) 
NSC-107443 
CAS:37660-62-1 
53% 
 
Cl
OH
NO
O
 
(8) 
NSC-251810 
CAS: 26049-94-5 
50% 
a The relative inhibitory activities against caspase-3 are indicated below the 
chemical structures. 
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Table 3. X-ray data collection and refinement statisticsa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) 
NSC 89167 
(2) 
NSC 251810 
(3) 
NSC 18508 
Space group I222 
a (Å) 68.7 69.5 68.5 
b (Å) 83.5 83.7 83.5 
c (Å) 96.1 95.8 95.8 
Resolution range 
(Å) 
20 - 1.57  
(1.65-1.57) 
20 – 1.86 
(1.95 - 1.86) 
20 – 1.89 
(2.0-1.89) 
No. of unique 
reflections 
28900 (5491) 23676 (3379) 21385 (3029) 
I/σI 30.5 (4.3) 27.8 (13.8) 21.1 (8.2) 
Rmerge (%) 9.8 (22.0) 4.2 (10.6) 5.0 (16.9) 
Completeness (%) 96.9 (88.4) 99.3 (98.5) 96.1 (94.5) 
R 18.6 19.9 18.5 
Rfree 19.6 22.6 21.9 
rmsd bond (Å) 0.0081 0.0068 0.0051 
rmsd angles(deg) 1.559 1.4831 1.2441 
Average B (Å2) 
Protein 11.5 11.5 13.3 
Ligand atoms 34.6 44.5 32.8 
Water molecules 30.5 31.1 28.9 
No of atoms 
Protein 1931 1931 1931 
Ligand atoms 22 22 8 
Water molecules 399 393 289 
aThe values in the parentheses refer to that of the highest resolution shell 
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Table 4: Influence on the activity and oligomerization state of caspase-8 due to the inhibitor binding 
 
Modulation of 
oligomerization state 
 
Relative 
inhibitory 
activity  
(%) 
% Monomer % Dimer 
Chemical structure 
Caspase-8 
(uninhibited) 0 17 83  
Caspase-8 + 
NSC-50352 
90 57 43 OO O O
O
N
O
O
N N
O
 
(9) 
 
 
Caspase-8 + 
NSC-117274 
85 91 9 
O
O
O
O
O
O
 
 
(10) 
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FIGURE LEGENDS 
 
Figure 1: Comparison of the docking poses with the corresponding conformations observed in 
the known caspase-3:inhibitor structures from PDB entries (a) 1CP3, (b) 1NME, and (c) 1NME. 
The rmsd between the modeled and the crystallographically observed conformations are in the 
range 0.5 – 1.1 Å. 
 
 
Figure 2: Cartoon representation of the crystal structure of caspase-3 in complex with active site 
directed inhibitors (a) compound (1) (b) compound (5) and (c) compound (8), superimposed with 
the structure of caspase-3/DEVD complex (grey). The atoms of the inhibitor are in yellow and the 
residues of caspase-3 involved in the interaction are in blue. The conformational change of 
Tyr204 is observed in the all the three caspase-3:inhibitor complexes reported here. 
 
Figure 3: Surface representation illustrating the differences in the binding mode of the structure 
of caspase-3 in complex with compound (1) and (8), (a) and (b) respectively. Even though both 
the compounds bind to the S1 prime subsite, the orientations of the aromatic rings are different to 
one another. 
 
Figure 4: Network of polar interactions in the structure of caspase-3 in complex with compounds 
(1), (5) and (8), (a-c) respectively. Compound (5) is involved in an extensive network of polar 
interactions, while compounds (1) and (8) are stabilized predominantly by hydrophobic contacts. 
 
Figure 5: Size exclusion chromatographic profiles reflecting the modulation of oligomerization 
state induced by allosteric inhibitor binding to caspase-8. The uninhibited caspase-8 exists 
predominantly in the dimeric form. The allosteric inhibitors, compounds (9) and (10), inactivate 
caspase-8 by shifting the equilibrium towards the formation of monomer.  
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Appendix A An attempt towards the structure determination of  
   procaspase-3  
A.1 Introduction 
 Caspase activation is an important event as it defines a cellular response to the onset of 
apoptosis [1]. Like the other caspases, caspase-3 exists in normal cells as an inactive zymogen 
and must be activated by proteolytic processing. Procaspase-3 is organized with an amino-
terminal pro-domain followed by the large (p17) subunit and the small (p12) subunit, as shown 
in Fig. 1. There are two amino acid sequences, ESMD S (residues 25-29) and IETD S 
(residues 172-176) in the 32-kDa procaspase-3 that have been found to be the cleavage sites for 
the production of the p17 and p12 subunits [2]. At both sites, the cleavage occurs between the 
aspartic and serine residues. The first cleavage event is after Asp175 to produce partly active 
caspase-3 which subsequently cleaves itself after Asp29 to generate a fully active and 
functional caspase-3. 
 
Figure 1. Schematic representation of full-length procaspase-3, showing the pro-domain sequence and 
the cleavage sites, D9, D28 and D175.  
 While the longer prodomains of the initiator caspases associate with factors required for 
enzyme activation through specific folded domains [3], the function of the smaller prodomains 
of effector caspases is unclear. For all effector caspases studied to date, the N terminus is 
disordered and not visible in the crystal structures. Even in the crystal structure of procaspase-
7, the prodomain (residues 1-23) and adjacent residues (residues 24-55) are disordered [4, 5]. 
Nonetheless, several studies suggest that the prodomain of effector caspases have specific roles. 
Proteolytic removal of the prodomain of human effector caspase-6 contributes to cleavage and 
activation of human caspase-8 [6], and the prodomain of Xenopus caspase-7 regulates nuclear 
transport [7]. The prodomain in human effector caspase-7 regulates both the activation rate and 
enzyme activity in vivo [8]. Finally, the prodomain of human caspase-3 may act as a silencing 
element by retaining the caspase in an inactive state [9].  
P r o  L a r g e  s u b u n i t  S m a l l  s u b u n i t  
MENTENSVD9 S KSIKNLEPKI IHGSESMD28 SG 
D175 
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A.2 Cloning, expression and purification 
 The protease domain of procaspase-3 (∆proC3) consisting of the α subunit and the β 
subunit along with the N-terminal 6xHis tag were cloned into a pET28 plasmid (Novagen) 
using the restriction sites BamH I and Xho I. The active site C163A (catalytic cysteine mutated 
to alanine) mutation was introduced using the Stratagene quick change mutagenesis kit 
(Strategene). The oligonucleotide primers used for the PCR based cloning strategy are listed in 
Table-1. Clones having correct sequence directionality were identified through DNA 
sequencing. The cloned gene (Met-6xHis-GSM-S29-His277) was expressed in E. coli BL21 
(DE3) Codon plus RIL (Stratagene). The cells were grown to a density of A600 = 0.5 at 30°C in 
a 0.5-litre Luria-Bertani culture. Expression was induced by the addition of IPTG (1 mM), and 
the culture was shaken at 25 °C for 4 hours post induction. Cells were harvested by 
centrifugation at 5000 g for 30 minutes. Bacterial pellets were resuspended in buffer A (50 mM 
NaH2PO4 pH 8.0, 300 mM NaCl, 2 mM β-mercapto-ethanol and 10 mM Imidazole) and lyzed 
on ice using a French press. The supernatant was separated from cell debris by centrifugation at 
20,000 g for 30 min.  
Table-1: List of primers for ∆proC3 cloning 
# Primer_name Oligonucleotide sequence 
1 pC3p17_fwd GCGGGATCCATGAGCGGTATCTCCCTGGACAACA 
2 pC3p17_rev GTCTGTCTCAATGCCACAGTCTGTCTCAATGCCACAGTCCAGT 
3 pC3_C163A_fwd CAAACTTTTCATTATTCAGGCCGCACGTGGTACAGAACTGGACTG 
4 pC3_C163A_rev CAGTCCAGTTCTGTACCACGTGCGGCCTGAATAATGAAAAGTTTG 
 
 All steps were performed at 4°C unless otherwise noted. The resulting supernatant was 
then run through a pre-equilibrated (with buffer A) Ni-nitrilo-triacetic acid-agarose column 
according to the manufacturer’s instructions (Qiagen). Unspecifically bound contaminating 
proteins were washed off using buffer B (50 mM NaH2PO4  pH 8.0, 300 mM NaCl, 2 mM β-
mercapto-ethanol and 50 mM imidazole). The ∆proC3 was eluted with buffer-C (50 mM 
NaH2PO4 pH 8.0, 300 mM NaCl, 2 mM β-mercapto-ethanol and 250 mM imidazole). The 
fractions were analyzed by SDS-PAGE. The fractions containing the pure protein were pooled, 
concentrated (YM10 membrane), and dialyzed first against buffer D (50 mM Tris-HCl, pH 8.0, 
50 mM NaCl, 1 mM EDTA and 5 mM β-mercapto-ethanol). The ∆proC3 was further purified 
by size exclusion chromatography on an analytical Superdex S200 column (Amersham 
Biosciences) with buffer E (20 mM Tris pH 8.0, 50 mM NaCl and 10 mM DTT).  The final 
yield was about 30 mg/litre culture.  
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A.3 Biophysical experiments of ∆proC3 
A.3.1 Size exclusion chromatography 
 During the course of the purification of ∆proC3, it was unusual to observe that the 
protein eluted at about 14.5 mL which is typical for a protein of an approximate size of 30 kDa, 
but in contrast, it has been previously established that ∆proC3 exists in solution as a dimer with 
an apparent mass of 59.4 kDa [10]. As we could observe from the size exclusion 
chromatogram, the elution profile reveals the presence of a single peak with no aggregation. 
For comparison, the size exclusion chromatography was performed under identical 
experimental condition for the active caspase-3 and caspase-8. Overlaying the elution profiles, 
we could clearly observe that ∆proC3 is a more compared in shape to active caspases (Fig.2).  
The elution volumes of the three proteins analyzed here are given under table 2. 
 
Table-2: Elution volume for ∆proC3, active caspase-3 and active caspase-8 
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Figure 2: Size exclusion chromatographic profiles for ∆proC3, active caspase-3 and active caspase-8.  
The instrument was pre-calibrated with BSA as a standard protein. Its elution profile is included for 
reference. Table 4 lists the weight-average molecular mass of the proteins obtained from static light 
scattering.  
 
 
Protein Elution volume 
(monomer mL) 
Elution volume 
(dimer mL) 
∆proC3 - 14.6 
Caspase-3 - 13.8 
Caspase-8 14.6 13.6 
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Size exclusion chromatography coupled to static light scattering and refractive  index 
detector 
 To further analyze the oligomerization state, ∆proC3 was subjected to a size exclusion 
chromatographic column (Analytical Superdex S200, Amersham Pharmacia) coupled to static 
light scattering (Mini-Dawn, Wyatt Technologies) and refractive index detectors (Fig.3). 
 
 
Figure 3: Size exclusion chromatography coupled to a static light scattering and refractive index detectors. Solid 
lines indicate the absorbance at 280 nm while the fitting (symbols) for the calculated weight-average molecular 
mass was done based on the scattering of the particles in solution.  
 
Table-3: Calculated weight-average molecular mass of the ∆proC3, active caspase-3 and -8  
Mw 
(kDa) Protein 
Monomer dimer 
∆proC3 - 63 
Caspase-3 - 62 
Caspase-8 31 59 
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A.3.2 Circular dichroism spectroscopy 
 The folding behaviour and thermal stability of ∆proC3 were analysed (Fig.5) at a 
concentration of 20 µM in a buffer containing 20 mM Tris-HCl pH 8.0, 50 mM NaCl and 10 
mM DTT by monitoring both spectrum and thermal denaturation by CD spectroscopy. The 
measurements were performed on a Jasco-715 spectropolarimeter equipped with a computer-
controlled water bath, using thermostated cuvettes with a 1 mm or 10 mm path length. The far-
UV CD spectrum was measured continuously from 250 to 200 nm. The buffer scan was 
subtracted from the protein scan. Thermal unfolding curves were measured by continuously 
recording the ellipticity at 222 nm and with data collection every 20 s.   
 Analysis of heat-induced unfolding curves describing a two-state transition between the 
folded and the unfolded state. The unfolding constant is defined as: 
KU = fU / (1-fU)     (1) 
where fU is the fraction of unfolded peptide. At each temperature, the observed molar ellipticity 
per residue of the folded and the unfolded state is 
 
[θ] = fU[θU] + (1- fU)[θF]    (2) 
 
where [θU] and [θF] are the molar ellipticity per residue of the unfolded and folded protein, 
respectively. [θU] and [θF] were assumed to be linear functions of temperature of the general 
form [θi] = [θi,0] + iT or [θi] = [θi,0] + i[denaturant], with i indicating the U or F state.  
 
Combining 1 and 2,  
[θ] = (KU / (1−KU) ([θU] − [θF]) + [θF]    (3) 
 
 The slope F of the pre-transition baseline was obtained from a fit according to equation 
3. The slope U of the post-transition baseline of the thermal unfolding curves was very small 
and was fixed at zero. Using the above equation, the midpoint of protein denaturation was 
calculated to be 69.5 °C.  
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Figure 5.  Left panel. Far-UV CD spectrum of ∆proC3 (red) and buffer (black). The spectrum of the 
protein shows a typical α/β secondary structure. Right panel. Thermal melting experimental trace of 
∆proC3. The calculated Tm is 69.5 °C according to equation 3.   
 
The CD spectrum resembles a typical spectrum for a globular protein of the α/β fold and 
thermal denaturation curves showed that ∆proC3 is thermally stable with a melting temperature 
of 69.5°C. 
A.3.3   Isothermal titration calorimetry  
 Synthetic peptides containing the arginine–glycine–aspartate (RGD) motif have been 
used extensively as inhibitors of integrin–ligand interactions in studies of cell adhesion, 
migration, growth and differentiation [11, 12], because the RGD motif is an integrin-
recognition motif found in many ligands. A recent report has revealed that RGD-containing 
peptides are able to directly induce apoptosis without any requirement for integrin-mediated 
cell clustering or signalling[13]. Additionally RGD-containing peptides enter cells and directly 
induce auto-processing and enzymatic activity of procaspase-3. Using the breast carcinoma cell 
line MCF-7, which has a functional deletion of the caspase-3 gene, the study confirmed that 
caspase-3 is required for RGD-mediated cell death. In addition to an RGD motif, pro-caspase-3 
also contains a potential RGD-binding motif, aspartate–aspartate–methionine (DDM), near the 
site of processing to produce the p12 and p17 subunits. On the basis of the ability of RGD–
DDX interactions to trigger integrin activation [14], the study concluded that RGD peptides 
induce apoptosis by triggering conformational changes that promote procaspase-3 
autoprocessing and activation. These findings provided an alternative molecular explanation 
for the potent pro-apoptotic properties of RGD peptides in models of angiogenesis, 
inflammation and cancer metastasis[15]. Another recent report suggested that the recombinant 
caspase-8 and 9 also bind to RGDS peptide [16]. 
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 The binding of "RGDS" peptide to ∆proC3 was assessed by isothermal titration 
calorimetry (ITC). ITC is the most quantitative means available for measuring the 
thermodynamic properties of a protein-ligand interaction. ITC measures the binding 
equilibrium directly by determining the heat evolved or absorbed, on association of a ligand 
with its binding partner. In a single experiment, the values of the binding constant (Ka), the 
stoichiometry (n), and the enthalpy of binding (∆Hb) can be determined. The free energy and 
entropy of binding are determined from the association constant. In combination with structural 
information, the energetics of binding can provide a complete dissection of the interaction and 
aid in identifying the most important regions of the interface and the energetic contributions. 
 The measurements were performed on a VP-ITC instrument (MicroCal Inc., 
Northampton, MA). The calorimeter was calibrated according to the manufacturer's 
description. Samples of protein and peptide were thoroughly dialyzed in a buffer containing 20 
mM Tris-HCl pH 8.0, 50 mM NaCl and 10 mM β-mercapto-ethanol to minimize artifacts due 
to minor differences in buffer composition. Concentration was determined after dialysis. The 
sample cell (1.36 mL) was loaded with 206 µM of ∆proC3 and the peptide solution (4 mM) 
was used as a titrant. A titration experiment typically consisted of 25-27 injections, each of 8 or 
10 µL volume and 10 or 12 s duration, with a 5 min interval between additions (stirring rate 
300 rpm). No detectable ∆H of binding was observed indicating either there is no specific 
binding or if there is binding it is not accompanied by heat change (Fig.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Isothermal titration calorimetric profile of ∆proC3 on titration against "RGDS" peptide.  Plot 
of the differential power (µcal/sec) against the injection time (min). 
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A.4 Crystallization trials 
 Attempts to screen for the crystallization condition for ∆proC3 were performed with the 
help of the high-throughput nano-drop crystallization facility (Department of Biochemistry, 
University of Zurich, Switzerland). The purity of ∆proC3, as judged by Reversed Phase-HPLC 
and SDS-PAGE, used for the purpose of crystallization was greater than 98%. The protein was 
dialyzed against a buffer containing 20 mM Tris-HCl pH 8.0 and 10mM DTT and concentrated 
to a final protein concentration of 20mg/mL. Several standard screens were used for the 
screening of ∆proC3 alone or in complex with "RGD" binding peptides like "RGDS" and 
"cyclic GRGDSP". No promising crystals were identified. 
A.5 Discussion and future perspectives 
 The crystal structure of a procaspase-3 would establish the structural determinants for 
the above discussed unique feature of procaspase-3 activation involving a change in pH or by 
the addition of "RGD" peptides. With an aim to determine the structure of procaspase-3, it was 
successfully cloned and characterized biochemically and biophysically. Procaspase-3 is a dimer 
in solution as evidenced from the size exclusion chromatography and it seems to be a compact 
species. The results from the CD experiments demonstrated that the protein is well folded and 
thermally stable. Unfortunately ITC experiments were unsuccessful under these experimental 
conditions. Nevertheless, the binding characteristic of RGDS peptide can be analysed in the 
future at a lower temperature (4°C) or using a different peptide like GRGDNP or RGD. Future 
experiments could include intrinsic fluorescence and surface plasma resonance experiments.  
 The close proximity of the C-terminal loop of the large subunit and the N-terminal loop 
of the small subunit strongly favours for the X-linked (or the interdigitated) model rather than 
the associative model of procaspase-3 activation. In particular, the conformation of the N-
terminal loop which emerged from the current thesis work favors the interdigitated model. In 
contrast, the crystal structures of the procaspase-7, the closest homolog of procaspase-3, has 
established that the dimer procaspase-7 is associative in nature [4, 5]. But there were some 
limitations to the interpretation of the structural study, especially the inter-subunit linker under 
debate is disordered in one molecule and in the other molecule, the linker occupies the dimer 
interface. The structures were resolved at nominal resolution (2.7-2.9Å) and B-factor values for 
the model as a whole and the inter-subunit linker in particular were quite high of the order of 
65 and 110 respectively. Even though caspase-3 and -7 share striking similarity in the amino 
acid sequence and in the three-dimensional structure, they have distinct and non-redundant 
functional roles [17]. So there might be a remote chance for a different activation model. 
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Appendix B Cloning, expression, purification and crystallization trials 
   for caspase-5 
 
B.1 Introduction  
 Caspase-5 is a member of the caspase-1 sub-family consisting of caspase-1, -4 and -5, 
which are cytokine activators. It shares about 52% and 77% sequence similarity with caspase-
1 and -4 respectively. Caspase-5 is expressed at a much lower level than caspase-1 and -4 [1, 
2] and it has similar substrate specificity as caspase-1 and -4 and it prefers to cleave the 
substrates containing a (W/L)EHD motif. It exists as an inactive zymogen like all other 
caspases and in the zymogen form it contains a CARD (caspase activation and recruitment) 
domain in the prodomain apart from the protease domain. Limited information is available 
concerning the precise sites at which procaspase-5 is processed to produce active caspase-5. 
Maturation of caspase-1 results from cleavage after the aspartate residues at positions 119, 
297 and 316, with the latter two residues being conserved in caspase-4 (Asp-270 and Asp-
289) and caspase-5 (Asp-311 and Asp-330); by analogy, this probably represents the removal 
of a linker peptide.  
 To date the mechanism of caspase-5 activation and its role in cytokine activation are 
poorly understood. Based on its expression pattern and sequence homology, caspase-5 was 
proposed to be the human ortholog of mouse caspase-11 [3]. Like caspase-11, protein levels 
of caspase-5 are increased by LPS (lipopolysaccharide) [3]. Moreover, caspase-5 is involved 
in IL-1β processing and can interact with caspase-1 [4]. Caspase-1 and caspase-5 are 
constituents of the NALP1 inflammasome, a complex that can trigger cleavage of proIL1-β. It 
is likely that caspase-4 and caspase-5 arose from the gene duplication of a caspase-11-like 
ancestral gene. Frameshift mutations of caspase-5 are frequently found in endometrial 
carcinoma [5]. Moreover, caspase-5 cleaves Max, a central component of the Myc/Max/Mad 
network of transcription factors that is frequently deregulated in tumors [6], suggesting a 
regulatory role of caspase-5 in tumorgenesis. Two specific cleavage sites for caspases in Max 
were identified, one at IEVE10 S and one at SAFD135 G, which are cleaved in vitro by 
caspase-5 and caspase-7. Mutational analysis indicates that both sites are also used in vivo. 
Thus Max represents the first caspase-5 substrate.  
 The unusual cleavage after a glutamic acid residue is observed only with the full-
length, DNA-binding competent Max protein but not with corresponding peptides, suggesting 
that structural determinants might be important for this activity. Furthermore, cleavage by 
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caspase-5 is inhibited by the protein kinase CK2 (casein kinase II) mediated phosphorylation 
of Max at Ser-11, a previously mapped phosphorylation site in vivo. 
 
B.2 Cloning, expression and purification 
 The active recombinant caspase-5 was cloned, expressed and purified as described 
previously [7]. A PCR based strategy was adopted for cloning of active caspase-5 using the 
primers listed under table 1. Briefly, the cloned genes for the large p20 (Met-Ala135-Asp311) 
and the small p10 subunit (Met-Ala-Ser331-Asn418) were inserted in the NcoI/BamHI sites of 
pET11d plasmids (Novagen). For separate expression of both subunits, E. coli BL21-
CodonPlus (DE3)-RIL cells (Stratagene), containing one of the two plasmids were grown to a 
density of A600 = 0.5 at 37 °C in a 0.5-liter LB medium. Expression was induced by the 
addition of IPTG (1 mM), and the culture was shaken at 37 °C for 4 hours post induction. 
Cells were harvested, washed in PBS buffer and lyzed using a French press.  
 Owing to overexpression the protein was localised in the inclusion body portion. 
Refolding was achieved by rapid mixing of equimolar amounts of each subunit to a final 
concentration of about 100 µg of subunit/ml in the refolding buffer (100 mM HEPES, pH 7.5, 
10% sucrose, 1% CHAPS, 100 mM NaCl and 10 mM DTT) and was incubated overnight at 
room temperature with continuous stirring. Misfolded and aggregated protein was removed by 
centrifugation (5,000 x g, 30 min), and the supernatant was concentrated using an Amicon-
stirred cell. To reduce the salt concentration and to facilitate binding to a cation exchange 
column (MonoS 1mL, Amersham Biosciences), the protein solution was dialyzed against the 
cation exchange buffer (50mM HEPES pH 6.5, 1% CHAPS and 10mM DTT) prior to 
chromatography. The protein was eluted using a 300 mM NaCl gradient. The yield of the 
purified caspase-5 was only 0.3 mg/L.  
 Owing to pronounced autocatalytic activity and week dimer stabilization forces 
prevailing in the caspase-1 subfamily, we had to adopt a different strategy. After refolding 
and concentration the protein was subjected to for purification by size exclusion 
chromatography on an analytical superdex S200 column (Amersham Biosciences) using a 
buffer containing 50 mM Tris pH 7.5, 50 mM NaCl, 1% CHAPS and 10 mM DTT. Fractions 
containing pure and active caspase were pooled and concentrated by ultrafiltration (centricon, 
NMWL 10,000 Da) and the final yield was about 1 mg/litre culture. Thus purified caspase-5 
had reasonable purity and the crystallization experiments were set-up, but no crystals were 
obtained. 
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Table-1: List of primers used for the cloning of caspase-5. 
 
# Primer_name Oligonucleotide sequence 
1 C5_p20_fwd 5‘-GTCACCATGGCAGGTCCACCTGAGTCAGCAG-3‘ 
2 C5_p20_ rev 5‘-GCGGATCCGCTTAGTCTCTGACCCAGAG-3’ 
3 C5_p10_fwd 5‘-GTCACCATGGCTTCTGTTTGCAAGATCCAC-3‘ 
4 C5_p10_ rev 5‘-GCGGATCCGCTTAATTGCCAGGAAAGAGG-3‘  
 
B.3 Future perspective 
 The crystal structure of caspase-5 along with the functional characterization would be 
of broad interest to the research community for understanding its specific role in cytokine 
activation. In particular, it might shed light onto the very unique and unusual feature of 
caspase-5 to cleave the Max protein next to a glutamate residue. With an aim for obtaining a 
more stable and pure protein suitable for crystallization experiments, an alternate procedure, 
caspase-5 can be re-cloned, expressed and purified as a full length protein instead of the 
current strategy of separately expressing the α- and β-subunits.  
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Appendix C Mutational studies to understand the selectivity for 
   P4 Asp in caspase-8 
 
C.1 Introduction 
 Caspases demonstrate their specificity in substrate recognition at the S4 subsite 
and previous studies established the preferred substrate recognition sequences for 
each caspases [1-4]. However, caspase-8 was shown to have more plasticity in its S4 
pocket in its ability to bind both an “optimal” IETD inhibitor and a “sub-optimal” 
DEVD inhibitor [5, 6]. The other group-III caspases like caspase-6, 9 and 10 do not 
seem to possess a broader specificity as observed in caspase-8. From the crystal 
structure of caspase-8:Z-DEVD-CHO inhibitor complex it was evident that the P4 
aspartate makes hydrogen bonds with the side chains of Trp348 and Asn342 (Fig.1). 
Among the interacting partners, the residue Trp348 is conserved in all of the group 
family members, while the residue Asn342 is unique for caspase-8 (Fig.2) and might 
be a good candidate for governing specificity.  
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 A more detailed understanding of the molecular determinants of caspase-8 
specificity was sought. To pursue such studies, mutations within the active site region 
were carried out using a point mutation approach. To investigate the specificity of the 
S4 pocket in caspase-8 with respect to other Group III caspases, the three p12 point 
mutants of caspase-8 (N342D), (N342E) and (N342H) were constructed. The chosen 
Asp, Glu, and His are the equivalent residues found within caspase-9, caspase-6, and 
Figure 1: Network of polar 
interactions in the active site of the
caspase-8:Z-DEVD-CHO inhibitor 
complex. The P4 Asp in stabilised by 
hydrogen bond with Trp348 and 
Asn342. 
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caspase-10, respectively (Table 1 and Fig.2). These three caspases do not favour 
binding to a P4 Asp [1].  
 
 
  
 
 
 
 
 
 
 
 
 Enzyme kinetic studies have been performed on the mutants using Ac-DEVD-
amc as substrate. The results indicated that the mutant N342H has higher specificity 
in comparison to the wildtype caspase-8. In contrast the mutants N342D and N342E 
had drastically lower catalytic efficiency (Table 2) [7]. In an attempt to validate the 
kinetic observations on a structural level, the three mutants were purified to 
homogeneity and screened for crystallization in complex with the inhibitor Ac-
DEVD-cmk. 
 
Table 2: Kinetic parameters for caspase-8 mutants against Ac-DEVD-amc. Table adapted 
from [7]. 
Protein KM (mM) kcat (s-1) kcat/KM (M-1s-1) 
wtC8  11 ± 1  1.15 x 10-2 ± 2 x 10-4 1030 ± 17 
C8(N342H) 27 ± 4 4.8 x 10-2 ± 2 x 10-3 1820 ± 140 
C8(N342D) 96 ± 5 5.7 x 10-3 ± 1 x 10-4 59 ± 1 
C8(N342E) 169 ± 22 5.1 x 10-4 ± 2 x 10-5 3.0 ± 0.1 
Table 1: Caspase-8 S4 subsite mutants 
 Residue 342 caspase-8 mutants 
Caspase-8 N wildtype 
Caspase-10 H N342H 
Caspase-9 D N342D 
Caspase-6 E N342E 
  339    349 
C8   SYRNPAEGTWY 
C10  SFRHVEEGSWY 
C6  SHRETVNGSWY 
C9  SWRDPKSGSWY
Figure 2: Sequence alignment (selectivity loop region) of group-III caspase sub-family. 
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C.2 Experimental procedures 
Cloning of wild-type and point mutants of caspase-8 
 Wild-type caspase-8 was cloned and expressed in E. coli as previously 
described [1, 5]. Briefly, the p18 and p12 cDNA were inserted into the pET11d 
(Novagen) vector and point mutations were introduced by PCR based cloning 
strategies. The oligonucleotide primers used for the PCR are listed in Table 3. Clones 
having correct sequence directionality were identified via DNA sequencing. 
 
Table 3: Oligonucleotide primers for generating the mutants of caspase-8. Table adapted 
from [7].  
Caspase-8 p12 oligonucleotides Oligonucleotide sequence 
N342D sense TCCTACCGAGACCCTGCAGAG 
N342D antisense CTCTGCAGGGTCTCGGTAGGA 
N342E sense TCCTACCGAGAACCTGCAGAG 
N342E antisense CTCTGCAGGTTCTCGGTAGGA 
N342H sense TCCTACCGACATCCTGCAGAG 
N342H antisense CTCTGCAGGATGTCGGTAGGA 
 
Expression, purification and crystallization of caspase-8 mutants 
 Clones were expressed in and refolded from inclusion bodies [8]. The caspase-
8 mutants were purified using two step anion exchange chromatography, first step 
using a Sepharose-Q column and the second step with a Resource-Q column 
(Amersham Pharmacia) as described previously [9]. The purified caspase-8 mutants 
were subsequently inhibited with a 3-fold molar excess of the inhibitor Ac-DEVD-
cmk in a buffer containing 20 mM Tris pH 8.0 and 10 mM DTT. Co-crystals of the 
complex between the caspase-8 mutants and the inhibitor were grown from 2 µl 
hanging drops formed by mixing equal volumes of protein (20 mg/mL) and reservoir 
solution at 20°C. The reservoir solution consists of 1.2 - 1.5 M sodium citrate, 100 
mM HEPES pH 8.0.  All the three mutants yielded crystals, but the crystals were 
either multiple or fragile needles (Fig.3a-c). Despite several attempts to optimize the 
crystallization condition with respect protein concentration, crystallization 
temperature, pH and sodium citrate concentration, very few crystals of reasonable 
quality were obtained.  
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Figure 3a: Crystal of caspase-8 
N342D: Ac-DEVD-cmk 
Figure 3b: Crystals of caspase-
8 N342E: Ac-DEVD-cmk 
Figure 3c: Crystals of caspase-8 
N342H: Ac-DEVD-cmk 
 
 Prior to data collection, the crystals were isolated and frozen in the nitrogen 
stream. Diffraction data were either collected using a rotating anode generator 
(Bruker-Nonius, FR591) at 100 K or at the Swiss Light Source synchrotron (Paul 
Sherrer Institute, Villigen, Switzerland). The resolution ranges for the crystals were in 
the range of 2.9 - 3.8 Å. The diffraction data were not of a good quality and 
eventually the data processing was not possible.  
 
C.3 Discussion and future perspectives 
 In this study a classical point mutant approach was pursued in examining the 
active site specificity of caspase-8. Many studies have investigated the amino acid 
substrate preferences for caspases. The conclusions were that the P1 Asp is 
fundamental for caspase recognition and that additionally the P4 residue determines 
specificity among the family members. Very little data has been accrued about the 
exact specificity determinants for individual caspases, including caspase- 8. The X-
ray crystal structure of caspase-8 in complex with a tetrapeptidic inhibitor comprising 
a “sub-optimal” P4 Asp residue showed that an Asp in P4 is instead well tolerated. 
Based on that, the specificity of the caspase-8 S4 pocket, in relation to Group III 
caspases, was examined further by mutation and enzyme kinetics. Unfortunately, 
attempts to identify the structural determinants were unsuccessful. A future direction 
to partly accomplish the task might be to crystallize the caspase-8 mutants with the 
optimal inhibitor Ac-IETD-cmk rather than the sub-optimal Ac-DEVD-cmk. 
Additionally, future experiments could also include the profiling of other caspase 
substrates with these mutants for further kinetic characterization of their specificities. 
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